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Abstract 
The introduction of combination antiretroviral therapy (cART) has resulted in a 
dramatic improvement in the life-expectancy for people living with HIV-infection. 
Although AIDS-defining illnesses such as HIV-dementia are now rare, mild cognitive 
disorders are still prevalent in a substantial proportion of patients on effective cART 
and suppressed HIV plasma viraemia.  
Although some clinic risk factors for HIV-associated neurocognitive impairment (NCI) 
such as low nadir CD4 T-cell count and age have been described, the pathological 
processes underlying this cognitive impairment remain elusive. A major factor that 
might be contributing to the development of HIV-associated NCI is chronic activation 
of macrophages and astrocytes resident in the brain microglia. I hypothesise that in 
vivo microglial activation is both present in effectively treated HIV-infected individuals 
and is associated with disturbances in cognitive function and biomarkers of magnetic 
resonance imaging (functional, structural and chemical) and inflammation 
 
To address these hypotheses I used cerebral positron emission tomography with 
[11C] PBR28 to measure translocator protein 18kDa (TSPO), a putative marker for 
microglial activation. To examine the impact of inflammation on brain structure, 
function and chemistry, neurologically asymptomatic HIV-infected individuals stable 
on cART were evaluated using several magnetic resonance imaging methods, 
cognitive testing and measurements of inflammatory biomarker in plasma and 
cerebrospinal fluid. 
 
I identified the presence of in vivo microglial activation in several brain regions in HIV-
infected individuals compared to HIV-negative controls. Microglial activation was 
associated with disturbances in cognitive function (verbal and learning memory), brain 
activation (reduced task-related brain activation) and white matter integrity (increased 
mean diffusivity), suggesting a deleterious effect of neuroinflammation on brain 
structure and function. Microglial activation, across several anatomical locations 
correlated with increased concentrations of plasma ribosomal 16s, a marker of 
microbial translocation. This relationship between a marker of impaired integrity of the 
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gut-blood barrier, and microglial activation, suggests a communication route is 
present between peripheral inflammation and the CNS in HIV-infected individuals.  
 
In vivo detection of microglial activation, and systemic inflammatory markers could 
provide indices to guide risk assessment and treatments for HIV-associated brain 
disease. 
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1.1 Hypotheses of the thesis 
The following hypotheses will be examined in this thesis: 
 
1. Microglial activation will be greater in neuroasymptomatic HIV-infected 
individuals stable on cART compared to HIV-negative controls. 
 
2. Microglial activation in neuroasymptomatic HIV-infected individuals 
stable on cART will be associated with poorer cognitive function, 
increase biomarkers of inflammation and abnormalities of functional, 
structural, and metabolic imaging parameters on cerebral MRI. 
 
3. Microglial activation in neuroasymptomatic HIV-infected individuals 
stable on cART will be greater in subjects with low nadir CD4 counts 
compared to those with high nadir CD4 counts. 
 
1.2 Central nervous system manifestations of HIV-infection  
1.2.1 Clinical manifestations of HIV-infection in the CNS prior to the advent of 
cART 
Early in the HIV/AIDS epidemic the deleterious consequences of HIV-infection in the 
central and peripheral nervous system were described (1). They were predominantly 
attributable to either CNS opportunistic infections, due to severe immunosuppression 
and depletion of CD4 T-cell blood counts or a spectrum of HIV-associated NCI, the 
most severe form being HIV-associated dementia (HAD).  
 
HAD is a subcortical dementia that typically occurs at the later stages of HIV-infection 
when there is advanced immunosuppression (CD4 T-cell counts below 200 cells/mL). 
HAD develops in approximately 20 to 30% of HIV-infected individuals without cART. 
Clinically HAD is characterised by a group of severe cognitive (mental slowing, 
attention and memory deficits), behavioral (apathy, social withdrawal, and mood 
disturbances) and motor symptoms (loss of balance and slowness) (2). HAD in its 
more severe forms could lead to paraplegia, vegetative state and dead (3). The onset 
of HAD is associated with several risk factors including low CD4 T-cell count and 
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high plasma HIV RNA, which accounts for the strong effects of cART on reducing its 
incidence (4).  
1.2.1.1 Neuropathology prior to the advent of cART 
HIV-encephalitis is the neuropathological correlate of HAD, and it was consistently 
observed in brain tissue of HIV-infected individuals throughout the early HIV-
epidemic (5-7) 
 
The histopathology of the brains of HIV-infected individuals with encephalitis shows 
characteristic changes. Widespread microglial activation is prominent usually 
accentuated by the presence of microglial nodules (8, 9). Multinucleated giant cells, 
although not pathognomonic of HIV-encephalitis are a prominent feature in both the 
white and grey matter. Reactive astrocytosis is also commonly seen often around 
small blood vessels in the central white matter along with activated microglia (9, 10) 
(8). The white matter pathology observed in HIV-encephalitis is characterized by 
myelin damage, axonal damage, and the presence of white matter varicosities and 
axon bulbs. These changes are also known as leucoencephalopathy (11). 
 
HIV-encephalitis can be present in any area of the brain, but it has been shown to 
have a predilection for subcortical regions particularly the basal ganglia. Kure et al. 
looked at the distribution of HIV-infection in the brain of 100 individuals with AIDS 
with histological evidence of HIV-encephalitis, using immune-staining with gp-41 
antibodies. Microglial and multinucleated cells were the groups of brain cells with the 
greatest Gp-41 positivity. They were detected and most abundant in the globus 
pallidus, ventral midbrain and dentate nucleous. Gp-41 cells were rarely seen in the 
cerebral cortex, medulla or leptomeninges. These data suggest that the HIV virus 
might have a tropism for deep gray matter structures such as the basal ganglia and 
the dentate nucleous (12). 
 
Only a small number of studies have reported the neuropathology of untreated HIV-
infected individuals before the onset of AIDS. Most of these studies consisted of HIV-
infected drug users who died of drug related accidents or haemophiliacs (13-15). In 
these individuals, a low grade CD8 lymphocytic infiltrate involving the leptomeninges, 
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and the perivascular spaces of the white matter was observed, along with 
astrocytosis and microglial activation (14, 15). 
 
The presence of HIV-encephalitis correlates with the clinical severity of HAD. The 
pathological features most closely associated with the clinical signs of HAD include: 
the level of microglial activation in the brain (16), evidence of excitotoxins (17) and 
selective neuronal loss (18). HAD has been associated with neuronal apoptosis (19, 
20) with the distribution of neuronal apoptosis closely related with structural atrophy 
and microglial activation markers, especially within subcortical brain matter structures 
(21). In addition, macrophage staining for microglial activation in the basal ganglia 
has also been found to correlate with HAD (16).   
1.2.2 HIV-infection of the CNS since the advent of cART 
The effect of cART on the reduction of incidence of CNS opportunistic infections and 
HAD had been dramatic (22). However, less severe forms of cognitive deficits 
affecting HIV-infected subjects have become increasingly apparent in recent years, 
despite access to cART (23).  
 
Rates and clinical features of milder forms of NCI in a range of clinical and 
geographical settings have demonstrated consistently higher prevalence rates (15 to 
50%) of milder forms of NCI in effectively treated HIV-infected individuals compared 
to the general population (24-29). 
 
Changes in the clinical manifestations of HIV-associated NCI since the introduction of 
cART are summarised in Table 1.1. Clinically, most HIV-infected patients with these 
milder forms of NCI complain of difficulty concentrating, memory problems and 
fatigue when required to engage in demanding mental tasks. The cognitive deficits 
are frequently seen in the domains of learning, attention/working memory, speed of 
information processing and executive function (30, 31). NCI is of clinical relevance 
with consequences for reduced quality of life (32), reduced functioning on activities of 
daily living (33) and even increased mortality (34). Furthermore, HIV-associated NCI 
may undermine sustained adherence to lifelong cART, affecting both the long-term 
effectiveness of treatment for the individual and the prevention of onward HIV-
transmission.  
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Although, the CD4 T-cell count remains an important clinical risk factor for HIV-
associated NCI, it is the nadir CD4 T-cell count (the lowest recorded CD4 T-cell 
count) that is more predictive of milder forms of NCI in the post cART era (35).  With 
the loss of current CD4 T-cell count and plasma HIV RNA, as disease predictors of 
HIV-associated NCI, there is a lack of clinical laboratory or imaging indicators to 
predict milder forms of NCI in treated HIV-infected individuals.  
1.2.2.1 Neuropathology since the advent of cART 
The introduction of cART has changed the neuropathology of HIV-infection in the 
CNS. Several studies have documented the neuropathology of HIV-infected 
individuals post-cART (36-39). All have reported a decline in CNS opportunistic 
infections associated with HIV-infection. Although there has also been a decline in 
autopsy-proven HIV-encephalitis, it appears that HIV-encephalitis is still common 
with prevalence rates of up to 25% in some cohort studies (38).  Data from the 
Edinburgh cohort have shown a 50% decrease in the incidence of CMV and a 68% 
decrease in HIV-encephalitis (40).  
The type of HIV-encephalitis described in patients on cART appears to be different 
from the one observed in HAD of the pre-cART era. Gray et al. studied brain 
autopsies of cART experienced HIV-infected individuals. The study found evidence of 
HIV-encephalitis; however, the type of pathological features differed greatly from the 
ones observed in patients with HAD. Instead of multinucleated giant cells and 
microglial nodules, the predominant features identified were myelin pallor, 
astrocytosis, and microglial activation (41).  
 
Consistent with the findings described above, Antony et al. Investigated brain 
autopsies of effectively treated HIV-infected individuals who died from causes 
independent of CNS disease in Edinburgh. In this study, high levels of microglial 
activation evidenced by high expression of CD68 and MHC II in the basal ganglia 
and hippocampus were found in effectively treated HIV-infected individuals. The 
levels of microglial activation were comparable or in some cases exceeded those 
seen in cases of HIV-encephalitis associated with HAD (40).  
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The success of cART has limited the opportunities for re-evaluating 
neurophatological findings as the number of fatalities among stable patients of cART 
is low, and generally confined to subjects that have died from other conditions such 
as drug overdoses and co-infection with viral hepatitis etc. Although 
neuropathological studies in such cases revealed ongoing neuroinflammation without 
productive HIV-infection, the contribution of drug abuse, comorbidities and co-
infections requires further study to provide a better understanding of the effects of 
HIV-infection within the CNS in stable patients on cART. 
1.2.3 Simian immunodeficiency virus models of HIV-associated brain disease 
The simian immunodeficiency virus (SIV) and HIV virus are primate lentiviruses that 
have genomic, structural, and virological similarities (42). SIV viruses have been 
isolated form different genera on non-human primates, and are designated by 
subscripts indicating the type of primate from which they were originally isolated, for 
example, SIVmac for rhesus monkeys; SIVsmm from sooty mangabeys etc. SIV-
infection of macaques accurately replicates many features of HIV-infection, including 
the development of histopathological changes typical of HIV-encephalitis, such as 
astrocytosis, multinucleated giant cells and microglial proliferation (43, 44). The 
development of SIV animal models that replicate key clinical and pathological 
features of HIV-infection in the CNS could allow the study of HIV-associated brain 
disease pathogenesis, as well as the longitudinal evaluation of immune and 
inflammatory parameters in the CNS, and the evaluation of novel therapeutics. 
 
SIV-infection of rhesus and pig-tailed macaques is the most common non-human 
primate model of HIV-disease. Initiation of SIV-infection is achieved by using 
selected strains or clones. Some of these strains have been developed to be highly 
neurovirulent such as SIV17e-fr and SIVDeltaB670. Inoculation with any of these 
combinations of viruses results in rapid, acute SIV-viral replication in both the 
peripheral blood and the CNS. High plasma and CSF viral SIV RNA levels are 
detected as early as 3 days post-inoculation and peaked 7 to 10 days after 
inoculation (45). After acute infection CSF SIV RNA declines by 2 to 3 logs, however 
within 2 to 3 weeks the SIV RNA levels increase again in those animals that develop 
moderate to severe neurological disease. The continued loss of CD4 T-cells begins 
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during the acute infection stage and by day 84 post-inoculation most animals will 
have AIDS and CNS disease (45). 
 
Models of SIV using pigtailed macaques develop immunosuppression, and higher 
frequency of CNS lesions more rapidly than rhesus macaques of cynomolgus 
macaques inoculated with the same viruses (44). These accelerated models of SIV-
brain disease have been used to study several aspects of HIV-associated brain 
disease including: the mechanisms of viral and immune damage in the CNS, the 
influence of the innate immune system on the development of CNS disease, the 
identification of host genetic resistance to CNS disease and the effect of cART on 
CNS-disease (46-50).  
 
It has become clear that SIV infects the CNS very early during the disease process 
and that innate immune responses are induced acutely in response. In the 
accelerated SIV-macaque model using either SIV17e-fr or SIVDeltaB670 
neurovirulent strains greater levels of SIV RNA is present in the CSF by 4 days post-
inoculation, regardless of whether those animals ultimately develop neurological 
lesions (47). SIV replication can also be detected in CD14+ microglia, usually 
accompanied by widespread innate immune responses (47). Using CD8 depletion in 
the SIV rhesus macaque models, it has been demonstrated that perivascular 
macrophages and not resident microglia are the major cell population productively 
infected with SIV during acute infection and among macaques with encephalitis (51). 
The innate immune response triggered by SIV-infection is characterised by activation 
of microglia and astrocytes (52, 53). Microglial activation causes induction of 
cytokines/chemokines such as CCL2, IL-6, IL-10, TNF-α and INF-γ that leading to 
neuroinflammation and neuropathological changes associated with encephalitis such 
as multinucleated giant cells, astrocytosis and neurological disease (54).  
Since the CNS represent a distinct HIV compartment and most cART do not cross 
the blood brain barrier to any significant extend (55), SIV macaque models have 
been developed were animals are treated with a combination of nucleotide reverse 
transcriptase inhibitors, protease inhibitors, and integrase inhibitors (56, 57). In these 
models plasma and CSF SIV RNA declined rapidly with therapy. However, although 
brain viral SIV RNA levels were undetectable in treated animals, the levels of viral 
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DNA were not different from viral DNA levels of untreated SIV-infected macaques. 
CNS inflammation was reduced; however, levels of CD68, TNF-α and INF-γ were not 
significantly lower compared to controls, indicating continued CSN inflammation, 
despite controlled CNS SIV replication (56). 
 
Recently Fergusson et al. Described the presence of persistent neuroinflammation in 
a cynomolgus model of CNS infection using a SIVrtTA, a doxycycline (DOX) 
dependent, conditional-SIV virus, were viral replication can only occur in the 
presence of the antibiotic doxycycline. The study compared animals on daily 
doxycycline for 40 weeks with those where doxycycline was removed after acute 
infection was achieved. Chronic neuroinflammatory responses (astrocytosis and 
microgliosis) were detected by immunehistochemical analysis of brain sections in all 
SIVrtTA infected macaques, even 40 weeks after stopping viral replication (when 
doxycycline was stopped). The results of this study indicate that despite absence of 
viral replication, neuroinflammatory responses (microglial activation) persisted after 
many weeks, suggesting a legacy effect of acute SIV-infection (58) 
 
1.3 Pathogenesis of HIV-related CNS injury  
1.3.1 HIV invasion of the brain 
During primary HIV-infection, HIV enters the central nervous system (CNS) very early 
during the course of systemic HIV-infection (59, 60) through its presence in infected 
macrophages that migrate across the blood brain barrier to replace infected 
perivascular macrophages. This mechanism is known as the “Trojan horse 
hypothesis” first described by Hasse et al (61), that demonstrated how HIV-1 and 
other lentivirus enter the CNS as passengers in cells that are trafficking through the 
brain. After entry, activated monocytes, perivascular macrophages and microglia 
infected with HIV act as both the main targets of HIV-replication and source of 
neurotoxins such as neurotoxic reactive oxygen species, prostaglandin E2 and nitric 
oxide etc, that lead to further disruption of the blood brain barrier, facilitating brain 
infection (62). HIV-infection within the CNS can be detected by measurements of 
viral RNA in the CSF, and CSF HIV RNA has been correlated with brain HIV RNA 
levels (63) and the degree of cognitive dysfunction in patients with HAD (64, 65).  
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It is well established that microglia, and perivascular macrophages are the cells that 
most contribute to viral replication within the CNS and are key players in the 
neuropathogenesis of HIV-associated brain disease. Microglia and macrophages are 
the only CNS cells that have CD4 and CCR5 receptors.  The HIV virus can also 
infect astrocytes, however without CD4 receptors, astrocytes are unlikely to 
contribute to persistent viral replication in the CNS (66, 67).   
1.3.2 The role of microglia  
Macrophages in the CNS contain several subtypes including perivascular 
macrophages, meningeal macrophage, choroid plexus macrophages and microglia. 
Microglia are specialised macrophages of the CNS that constitute approximately 5 to 
20% of all glial cells in the human adult brain (68). The resident microglia originate 
from yolk sac macrophages that migrate to the CNS during early embryogenesis 
(69), and therefore the origins of these cells are different from other glial cells such 
as astrocytes and oligodendrocytes. Microglia are essential for the maintenance of 
CNS homeostasis and the defense against brain injury. They are involved in 
phagocytosis, antigen presentation, and production of biological substances that 
regulate inflammation, cell death, and regeneration processes (70).  
 
One characteristic aspect of microglia are the capacity to modify their phenotype in 
response to brain injury. Based on pathophysiological studies it is understood that, 
microglia show many states of activation, depending on the nature of the brain injury. 
Some of the described phenotypic states include: (i) resting phenotype characterised 
by the presence of ramified branches that perform surveillance of the CNS (71). (ii) 
M1-type microglial activation and (iii) M2-type microglial activation (72, 73) see 
Figure 1.1. The distinction between M1-type and M2-type activation represents an 
ideal, which is often simplistic as the range of chemokines and antigens expressed 
by activated microglia is not specific to the M1 or M2 categories. It is important to 
understand the plasticity of microglia, where in different pathological states activated 
microglia might produce a range of different cytokines/chemokines profiles (74). 
Knowledge about the precise functions of these phenotypic states is essential for the 
understanding of the pathogenic mechanisms involve in HIV-associated brain 
disease 
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M1-type microglial activation 
M1 activated macrophages are developed in response to IFN-γ and microbial 
products such as LPS. Once activated M1 macrophages produces high levels of 
proinflammatory cytokines such as IFN-γ, TNF-α, IL-1, chemokines, and nitric oxide 
that promote cell-mediated-immunity and contribute to the clearance of pathogens. In 
HIV-associated brain disease the M1 phenotype activates when microglia contacts 
HIV viral proteins such as tat (75) and toll-like receptors 3 and 4 (76). In this scenario 
prolonged and excessive M1 activation caused by HIV replication results in the 
production of proinflammatory mediators and neurotoxins by M1 activated microglia 
that in turn causes dysfunctional activation of astrocytes leading to neuronal 
dysfunction.  
 
There is evidence that in untreated HIV-infected individuals, M1 microglial activation 
plays an important role in the pathogenesis of HAD (77). Interestingly, M1 
macrophage activation has also been associated with disease states that are driven 
by low-levels of inflammation such as atherosclerosis (78).  
 
M2-type microglial activation  
M2 activated microglia tend to suppress inflammation and play a role in promoting 
tissue repair (72). M2 activated microglia produce very low levels of inflammatory 
cytokines such as TNF-α and IL-1 and high levels of anti-inflammatory cytokines 
such as interleukin-10 (IL-10), interleukin-6 (IL-6), transforming growth factor beta 
(TGF-β), and reduce expression of major histocompatibility complex (MHC) class II 
molecules (72, 79, 80).   
 
It is currently unknown whether there are different microglial phenotypes within 
specific anatomical brain regions, but work by De Hass et al. Showing that microglia 
from specific regions in the brain express different cell surface proteins suggest that 
this may be the case (81). Therefore, it is possible that in a disease process such as 
HIV-associated NCI, different microglial activation phenotypes can be present 
simultaneously in different brain regions.  
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Figure 1.1 Diagram representing a model of microglial activation phenotypes in 
response to brain injury. 
 
    
 
 
[Legend Figure1.1: M1-type activation is characterised by the production of pro-inflammatory 
cytokines/chemokines and activation of INF-γ. M2-type activation is associated with the 
release of anti-inflammatory cytokines/chemokines such as IL-10 and TGF-β. In response to 
changes in the environment is more likely that microglia with move between M1 and M2 
phenotypes, with release of a range of pro-inflammatory or anti-inflammatory mediators. 
Adapted from Gordon et al. (73)]  
 
 
  
 24 
1.3.3 The role of astrocytes 
Astrocytes are abundant within the CNS and play and important role in CNS 
homeostasis and function (82). They can be infected by HIV inducing reactive 
astrogliosis a common feature observed in HIV-encephalitis (41). As with microglia, 
astrocytes respond to any type of brain injury by rapid activation (astrocytosis) 
comprising the increase in number and size of astrocytes, and the up-regulated 
expression of cytokines, cell surface molecules, growth factors, and neurotoxic 
factors (82). Aberrant astrocyte function together with activated microglia, may 
contribute to the pathogenesis of HIV-associated brain disease. HIV-infection of 
astrocytes has been demonstrated to disrupt BBB integrity by affecting functional gap 
junctions (83), and to inhibit glutamate transporters in the astrocytes (84). The 
disruption of astrocyte glutamate transport and BBB integrity could lead to 
excitotoxicity and neuronal damage associated with HIV-associated NCI (85). 
1.3.4 Chemokines/cytokines in HIV-related CNS injury 
Following HIV-infection of the brain, and microglial infiltration, activated microglia 
within the CNS release a variety of proinflammatory and neurotoxic factors. These 
include chemokines/cytokines (86), viral proteins (gp120, tat) (17, 87, 88), excitatory 
aminoacids (glutamate, quinolinate, cysteine) (89, 90), reactive oxygen products 
(nitric oxide, superoxide anion) (91) and other substances, including platelet 
activating factor and arachidonic acid (92, 93). Notably, the combination of toxic viral 
proteins and factors release from activated microglia can act synergistically to 
promote neuroinflammation even without extensive viral invasion of the CNS (94).  
Chemokines are a large family of small proteins (8 to10 kDa) that are produced in all 
tissues including the brain. Chemokine receptors are a family of seven 
transmembrane G-protein coupled receptors and are subdivided in 4 groups: α-
chemokine receptors (CXCR2 and CXCR4); β-chemokine receptors (CCR5, CCR4, 
CCR3 and CCR2); γ-chemokine receptor (XCR1) and δ-chemokine receptors 
(CX3CR1). Monocytes and microglia are infected with HIV primarily through CCR5 or 
CCR3 but CXCR4 may also be involved (95, 96).  
 
Increased expression of several α and β-chemokines have been documented in HIV-
infected subjects with HAD (summary Table 1.2). Altered expression of α and β-
chemokines is commonly seen in HIV-encephalitis (97) and increased expression of 
 25 
their receptors have been reported in the brains of children and adults with AIDS. 
Being essential components of brain physiology, chemokines and their receptors 
may play a crucial role in the balance between neuroprotection and neurotoxicity in 
HIV-infected individuals (86, 94, 98). For instance, no neurotoxic effects of β-
chemokines have been demonstrated in vivo, while in vitro studies have found that 
chemokines such as MIP-1β and RANTES, natural ligands of CCR5 may contribute 
to protective immunity against HIV-infection (98, 99). Therefore, although there is 
evident dysfunction in the expression of chemokines and their receptors in HIV-
encephalitis and HAD, the positive or negative effect of these in milder forms of NCI 
has not been elucidated.  
1.4 Mechanisms of HIV-related CNS injury in the setting of 
cART 
Although the mechanisms of HIV-related CNS injury associated with HAD have been 
described, the pathogenesis of milder forms of HIV-associated NCI has not been 
defined.  Several pathogenic mechanisms have been proposed, and many clinical 
risk factors identified, see Table 1.3 
1.4.1 Early impact of HIV-infection in the CNS 
HIV invasion of the brain during early stages of HIV-infection is associated with CNS 
inflammation. However, whether this inflammation within the CNS causes irreversible 
damage to the brain during early stages of infection prior to initiation of cART is not 
known. Recently, Peluso et al. reported increased levels of a marker of axonal injury, 
NFL in HIV neuroasymptomatic subjects within the first year of HIV-infection (100). In 
this study, concentrations of CSF NFL correlated with increased concentrations of 
neopterin, a marker of monocyte activation and lower concentrations of cerebral 
metabolites of neuronal integrity (NAA/Cr). Early initiation of cART in patients from 
the same cohort of patients had persistently elevated concentrations of NFL and 
neopterin, suggesting a failure to control inflammation with therapy despite early 
initiation of cART (101).  Whether early initiation of cART could eventually reduce 
CNS inflammation, is not known. Similarly, it is not clear if reducing CNS 
inflammation will have a significant effect clinically, for instance reducing the rates of 
HIV-associated NCI  
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In the clinical setting most patients are diagnosed with HIV-infection during the 
chronic phase of HIV-disease, as primary HIV-infection is usually difficult to diagnose 
because patients with primary HIV-infection rarely present to healthcare settings. 
Also, most asymptomatic HIV-infected patients start cART when the CD4 T-cell 
counts are below a value of <350 cells/mL (established as a clinical threshold in the 
UK) (102).  This could mean inflammation in the CNS it is likely to have been present 
for a significant period of time before cART is initiated.   
 
It remains unclear what is the effect of commencing cART in neurologically 
asymptomatic subjects with high CD4 T-cell counts. A neurology sub-study with the 
START study (Strategic Timing of Antiretroviral Therapy; ClinicalTrials.gov Identifier 
NCT00867048) is assessing the effect of the earlier initiation of cART on cognitive 
function. In this study subjects with CD4 T-cell counts above 500 cells/uL, are 
randomised to immediate cART or deferred cART (until CD4 T cell counts falls below 
350 cells/uL) with prospective cognitive function assessed during the study period. 
Results from this study might answer the above conundrum regarding the impact of 
the earlier initiation of cART on cognitive function.  
1.4.2 Persistent CNS viral HIV replication  
Following HIV-infection of the brain, HIV RNA remains detectable in the CSF in most 
of untreated patients during the course of HIV chronic disease (65). Most patients 
commencing cART achieve plasma and CSF HIV RNA levels below the limit of 
detection of clinical assays. However, cases of viral escape in the CSF despite 
suppression of plasma HIV RNA have been reported. Concerns have been raised 
that the viral replication in the CNS can act as a reservoir for viral persistence and 
evolution of drug resistance. CSF escape has been reported in 10 to 20% of HIV-
infected individuals without neurological symptoms (55, 103). In this group of 
subjects, CSF escape, has been associated with high levels of intrathecal immune 
activation, specifically, markers of monocyte activation such as neopterin (103). The 
clinical significance of CSF HIV RNA escape is unknown, but neurological symptoms 
with CSF escape have been reported. For example, Canestri et al. described a group 
of 11 subjects on cART that experienced neurological symptoms and had a CSF HIV 
RNA of >200 copies/ mL with suppressed plasma HIV RNA (104). This group of 
patients presented with a combination of acute and sub-acute neurological symptoms 
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and 7 out of 11 had evidence of resistance-associated mutations in CSF HIV RNA 
genotypic strains. Conversely, in neuroasymptomatic HIV-infected subjects on stable 
cART, CSF escape (>50 copies/mL) is present in approximately 10% of subjects, 
suggesting that CSF escape, might at least in the short-term, be clinically silent (103) 
 
If persistence of low-level viral replication in the CNS is the main driver of intrathecal 
immuneactivation, treatment intensification could have a significant effect on CNS 
inflammation. However, to date treatment intensification has shown no significant 
reduction in levels or intrathecal immuneactivation in patients on effective cART 
(105). 
1.4.3 Ongoing CNS immuneactivation 
There is mounting evidence suggesting that microglial activation plays a crucial role 
in the pathogenesis of milder forms of NCI. First, as described in the neuropathology 
section earlier, the presence of significant microglial activation in the brains of 
treatment experienced HIV-infected individuals suggest that neuroinflammation may 
be a key process in the pathogenesis milder forms of HIV-associated NCI (40).  
Secondly, there is a consistent association across several studies investigating NCI 
in treated subjects between low nadir CD4 count (the lowest CD4 count reached by 
an HIV-infected patient) and cognitive deficit (28, 29, 106, 107). Patients with low 
nadir CD4 counts have greater levels of ongoing systemic immune activation, and 
cART does not reverse this effect completely, even after years of effective viral 
suppression (103, 108). Third, cerebrospinal-fluid (CSF) biomarker studies 
measuring concentrations of inflammatory markers produced by activated microglia 
have revealed that despite a reduction in the level of intrathecal immune activation 
observed with cART, significant on-going inflammation activity is still present (109). 
Finally, imaging modalities such as [1H]-MRS (110) have reported significant 
increases in metabolic markers of inflammation in the basal ganglia and 
hippocampus of HIV-infected subjects on effective cART with NCI when compared to 
controls. PET imaging supports these findings with evidence of increased binding of 
PET-ligands which adhere to activated microglial cells in effectively treated HIV-
infected subjects with mild forms of NCI and in those without any evidence of 
cognitive disease (111). All the above would suggest that sustained levels of immune 
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activation only partially reversed by therapy might be present for a long time, which 
could lead to NCI.  
 
An individual’s CD4 T-cell count nadir is a marker of historical HIV-disease 
progression and a well-described risk factor for the presence of cognitive impairment 
in many cohorts (29, 112-114). As HIV-disease progresses, increased peripheral and 
CNS immune activation occurs. It is possible this process may persist despite 
effective cART and be a potential explanation for the strong clinical correlation 
observed between low nadir CD4 T-cell count and cognitive function, where 
individuals with lower nadir CD4 T-cell counts are more likely to display poorer 
cognitive function, despite higher CD4 T-cell counts after effective cART. However, 
this is a risk factor described within clinical cohorts and although this may be linked to 
increased neuroinflammation and other pathogenic mechanisms associated with the 
development of cognitive impairment, cohort biases should also be taken into 
consideration. For instance, the individual phenotypes of two HIV-infected 
individuals, one with a very low nadir CD4 T-cell count and one with a high nadir CD4 
T-cell count could be quite different. The underlying reason one individual has 
developed a low nadir CD4 T-cell count may include late HIV-disease presentation, 
greater risk-taking behavior, and general poorer engagement with healthcare 
services. Therefore, this individual may inherently have poorer cognitive function 
instead of this being directly related to HIV disease and as such the earlier initiation 
of antiretroviral therapy may have little if any impact on cognitive function (115). 
 
Microglial activation is believed to be the pathological substrate of brain immune 
activation. In vitro models of CNS infection have proposed several mechanisms by 
which activated microglia can lead to neuronal injury. They involve the release of 
neurotoxic substances that induce astrocyte dysfunction, blood brain barrier 
dysfunction, and excitotoxicity, and the induction of dysfunctional chemokine and 
cytokine signalling that can tip the balance towards neurotoxicity instead of 
neuroprotection (62). The end result of these processes is dendritic damage, 
synaptic dysfunction, and apoptosis (94). However, in vitro models do not take in to 
account the effects of antiretroviral therapy and other individual patient factors 
(comorbidities, ageing, lifestyle etc) on host immune responses and 
chemokine/cytokine signaling within the CNS. The key role microglia play in the CNS 
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suggests that many of those clinical factors may still have a common pathogenic 
pathway, in the form of microglial activation, which subsequently results in NCI 
(Figure 1.2).  
 
Another important factor is the relationship between systemic immune activation, 
CNS immune activation, and NCI. Ancuta et al. found an association between 
immune activation induced by microbial translocation and dementia in patients with 
AIDS (116), suggesting a direct relationship between systemic inflammation and NCI. 
Microbial translocation caused by the breakdown of the gut mucosa and subsequent 
translocation of microbial products from the intestinal lumen into the circulation is 
considered to be the main cause of persistent chronic inflammation in HIV-disease 
(117).  
1.4.4 Reduced ART exposure or toxicity within the CNS 
Another mechanism that could be responsible for the increasing prevalence of HIV-
associated NCI relates to reduce ART exposure within the CNS. 
The brain may constitute an important reservoir of latent or replicating HIV-virus in 
treated HIV-infected individuals. One of the reasons for this may be that some 
antiretrovirals do not reach effective brain concentrations either because of the blood 
brain barrier prevents their entry or because the drugs are pumped out of the CNS by 
ATP-binding membrane transporters (118). There is evidence that poor CNS 
penetration of ART is associated with detectable CSF HIV RNA (55) However, 
evidence that better CNS penetrating drugs affect cognitive function is less clear. 
Studies evaluating the effect of CNS penetrating cART in HIV-associated NCI are 
conflicting. Some studies described improvements in HIV-associated NCI with better 
CNS penetrating cART (119, 120), conversely other studies have reported no 
improvement (121) or even deterioration of cognitive performance (122). Though 
several studies have demonstrated the beneficial effects of cART for the CNS, there 
is a concern that ART drug toxicity may contribute to the development of HIV-
associated brain disease. An in vitro study conducted by Liner et al. demonstrated a 
considerable loss of neurons on cultured rat cortical neurons challenged with several 
antiretrovirals within the range of concentrations seen in plasma and CSF with 
standard clinical dosing (123). This study suggests that several antiretroviral agents 
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in current clinical use could be associated with neuronal toxicity at concentrations 
expected in the CNS during general clinical usage. 
 Figure 1.2 Model of pathogenesis of HIV-NCI in the era of cART:  
 
          
 
 [Legend Figure 1.2: (a) Despite effective control of plasma viremia, cART could 
increase microglial activation by two mechanisms: i. Direct effect on microglial 
causing activation ii. Insufficient concentration of cART in the brain, could lead to low 
level viral replication.  (b) Low level viral replication if present will be responsible for 
persistent microglial activation and probably direct neuronal injury through the 
production of neurotoxic viral products. (c) Peripheral immuneactivation, represented 
by microbial translocation may contribute to persistent microglial activation. (d) 
Patient factors, such as cerebrovascular disease, age, confections, and recreational 
drug use are likely to contribute to the pathogenesis of HIV-NCI. (e) Low nadir CD4 
T-cell counts have been associated with an increase in peripheral immuneactivation 
and HIV-associated NCI. (f) Neuronal injury caused by persistent microglial 
activation] 
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Clinical data describing cerebral toxicities from antiretroviral therapy are sparse. 
Cerebral imaging studies suggest toxicities may be associated with the duration 
(124) or number (125) of nucleoside-reverse-transcriptase-inhibitor agents used 
within a cART regimen, which may be markers of mitochondrial toxicity. Within cohort 
studies efavirenz use has been recently associated with poorer cognitive function 
(126) and switching from this agent has been associated with improvements in CNS-
symptomatology (127).  
1.4.5 Neurodegeneration  
The longer duration of HIV-disease combined with the increasing life expectancy of 
HIV-infected patients may play a role in the development of neurodegenerative 
diseases. HIV-associated brain disease has common pathological and immunological 
features with Alzheimer’s disease and Parkinson’s disease.  
 
Several reports have described increase in amyloid plaques in the brains of older 
patients with AIDS (128). In addition, increases in β-amyloid precursor protein (a 
marker of axonal degeneration) deposition in HIV-infected individuals on cART have 
been observed (129).  Interestingly, although the data identified amyloid associated 
neuropathology, amyloid deposition does not appear to be associated with HIV-
associated NCI. This could explain why the clinical presentation of severe forms of 
HIV-associated NCI is that of subcortical dementia, rather that the cortical dementia 
pattern observed in Alzheimer disease (130) 
 
Movement disorders are not uncommon among HIV-infected individuals. Mirsattari et 
found a 5% incidence of parkinsonism in 155 HIV-infected individuals who fulfilled the 
United Kingdom Parkinson’s Disease Brain Bank criteria for the diagnosis of 
parkinsonism (131). Another prospective study found that 50% of HIV inpatients with 
movement disorders had features of parkinsonism (132). More recently, Valcour et 
al. described an increase in extrapyramidal motor signs in the era of cART (133).  
 
Increased α-synuclein deposition in the substantia nigra in HIV-Infected individuals 
on cART has been identified (134) and lewy bodies, the morphological hallmark of 
Parkinson’s disease in the substantia nigra is composed of filamentous α-synuclein 
(135). The presence of lewy bodies is considered a prodrome for Parkinson’s 
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disease and, therefore,  the presence of significant amounts of α-synuclein may 
indicate that affected individuals could be at risk of developing Parkinson’s disease,  
eventually. Indeed, a case series have described HIV-infected individual with young 
onset parkinsonism in the context of stable cART (136). Further research is needed 
to clarify the causative link between HIV-infection, cART and Parkinson’s disease. 
 
Thus, there is evidence for the existence of neurodegeneration markers in HIV-
infected individuals on stable cART. However, neurodegeneration does not appear to 
be closely linked at present to severe forms of HIV-associated NCI.  
1.4.6 Patient factors 
Many co-morbidities and lifestyle factors have been associated with higher rates of 
NCI. Co-morbidities such as cerebrovascular, cardiovascular disease and diabetes 
(137, 138) are among the strongest predictors of NCI within the SMART study 
(Strategic Management of ART), one of the largest HIV-treatment studies to date. 
Such non-communicable co-morbidities are reported to be highly prevalent in treated 
HIV-infected subjects and may potentially increase prematurely with ageing (139).  
Co-infections are also important risk factors for NCI. HIV-infected individuals co-
infected with chronic viral hepatitis-C infection have an increased risk of NCI 
compared to those infected with HIV alone (140). Similarly, poorer cognitive function 
has been described in HIV-infected individuals with higher cytomegalovirus (CMV) 
antibody concentrations and those with past history of syphilis infection (141, 142). It 
is possible that these co-infections are associated with increased neuroinflammatory 
responses and nervous system injury. 
 
Lifestyle factors such as cigarette smoking, recreational drug and alcohol use are 
also reported to be highly prevalent in HIV-infected cohorts as are diagnoses of 
depressive symptoms which may further fuel the incidence of this condition. Not only 
may these clinical risk factors themselves directly affect cognitive function (for 
instance recreational drug-use), but they may also contribute to the pathogenesis of 
other diseases leading to cognitive decline (for instance cardiovascular disease 
contributing to vascular dementia). Moreover, the presence of these conditions may 
also lead to increase peripheral inflammatory responses (143) and 
neuroinflammation (144)  
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1.4.7 Rationale for studying microglial activation 
In HIV-associated brain disease microglial activation is an important factor in the 
pathogenesis of HAD. However, it is still unclear if the milder HIV-associated NCI, 
currently seen in treated HIV-infected individuals is the result of persistent microglial 
activation. Understanding in detail the dichotomous roles of activated microglia as 
neurotoxic or neuroprotective in HIV-infected individuals and the potential impact of 
inflammation on brain function is crucial to dissect the pathogenesis of milder forms 
of NCI. Furthermore, the identification of specific protective pathways and mediators, 
could pave the way for the development of new therapies that may reverse the 
negative effects of neuroinflammation. 
1.5 Neuroimaging in HIV disease 
Neuroimaging studies evaluating changes in brain structure, metabolism, and 
function can improve our understanding of the pathophysiology of HIV-associated 
brain disease. In this section I will be discussing findings from neuroimaging studies 
using structural, functional, metabolic, and ionizing radiation neuroimaging 
techniques in HIV-infected individuals with and without HIV-associated NCI.  
1.5.1 Brain magnetic resonance spectroscopy findings in HIV-associated NCI 
[1H]-MRS is a non-invasive tool that detects changes in cerebral metabolites, which 
reflect disturbances in cerebral function in vivo. It uses hydrogen-1 [1H] isotope to 
quantify cerebral metabolites. The number of cerebral metabolites that can be 
detected depends on several technical considerations. Echo time is an important 
parameter in MRS data acquisition. Short echo times are preferred because they 
make it possible to detect all major metabolites including NAA, Cr, mI, Cho, 
glutamate (Glu), glutamine (Gln) and lactate, while long echo time allows only the 
detection of NAA, Cho and Cr (Figure 1.3). MRS can be performed in a single 
volume of interest (voxel) at the time or in a group of voxels that can cover a larger 
brain region, known as MRS imaging. While localized MRS limits spectral acquisition 
to a few voxels, it has better spectral acquisition and reproducibility than MRS 
imaging, which makes it a more robust method for the study of cerebral metabolites 
on HIV-associated brain disease.  
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Figure 1.3. Example of a cerebral proton magnetic resonance spectroscopy in 
the frontal white matter 
                   
 
[Legend Figure 1.3: Peaks representing the cerebral metabolites NAA= N-acetyl 
aspartate; Cr = creatine; Cho = Choline; mI=myo-inositol] (Imaged kindly provided by 
Lucy Garvey)] 
 
MRS can be performed in a single volume of interest (voxel) at the time or in a group 
of voxels that can cover a larger brain region, known as MRS imaging. While 
localized MRS limits spectral acquisition to a few voxels, it has better spectral 
acquisition and reproducibility than MRS imaging, which make it a more robust 
method for the study of cerebral metabolites on HIV-associated brain disease.  
 
Interpreting MRS studies is difficult because most studies employ different 
techniques and parameters to study the brains of HIV-infected individuals (145). Most 
[1H]-MRS studies have been performed using localised, short echo time MRS 
techniques evaluating between one to six brain regions. NAA, Cho, mI and Cr are the 
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most studied cerebral metabolites in HIV-disease as MRS data acquisition for these 
metabolites is easier to obtain without the need of a complex setup. 
 
NAA is located almost exclusively in neurones and is a marker of structural and 
functional neuronal integrity (146). Cho is a marker of cellular membrane turnover 
reflecting cellular proliferation and inflammation (147). mI is produced in glial cells 
and almost exclusively in astrocytes and is a marker of glial proliferation and 
inflammation (148). Finally, Cr is a marker of energetic systems and intracellular 
metabolism. Although cerebral metabolites can be expressed as absolute 
concentrations, they are often reported as ratios.  Concentrations of Cr are constant, 
for this reason Cr is used as an internal reference for calculating metabolite ratios 
(149). The rationale is that ratios self-correct for imager and localization method 
differences, regional susceptibility variations, and partial volume effects. 
 
MRS studies pre-cART consistently showed a decrease in NAA (or NAA/Cr), and 
elevated Cho (or Cho/Cr) and mI (or mI/Cr) (150-152) in patients with HAD. These 
changes were primarily observed in the frontal gray matter and basal ganglia (153, 
154). Localised MRS studies in HIV-infected subjects without NCI, have found 
decreased levels of NAA in the white matter and the thalamus with no change in Cho 
or Cho/Cr (155-157). However, Meyerhoff et al. showed a decrease in NAA and 
increased in Cho throughout the brain using MRS imaging. (158). In patients with 
milder forms of HIV-NCI, decreases in NAA/Cr, and increases in mI/Cr and Cho/Cr 
have also been reported, especially in the white matter, basal ganglia and 
hippocampus of HIV infected subjects when compared to controls (110). 
 
Partial reversal of metabolic abnormalities has been observed in several studies 
following initiation of cART (159). Chang et al. found partial reversal of Cho and mI in 
the frontal white matter and basal ganglia of HIV-infected patients before and after 
cART (160). Winston et al. described improvement in cognitive function along with 
increases in NAA/Cr ratios in the frontal white matter of HIV-infected patients after 48 
weeks of starting cART (125). 
  
The decrease NAA or NAA/Cr has commonly been interpreted as a consequence of 
neuronal loss in HIV-infected patients. Increases in Cho or Cho/Cr may be 
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associated with either an increase in cellularity, reflecting recruitment of microglia or 
an increase in cell membrane breakdown caused by HIV-infection (147). mI does not 
cross the blood brain barrier and has a role in regulating cellular osmotic environment 
as well as cell volume (148), therefore, any elevation in mI is believed to represent 
glial proliferation and activation. This is supported by the fact that mI levels increase 
with disease severity (161), as observed in patients with HAD, especially in the 
frontal white matter where glial activation has also been observed in 
neuropathological studies (162).  
1.5.2 BOLD functional magnetic resonance imaging in HIV-associated brain 
disease 
Blood oxygenation level dependent (BOLD) functional magnetic resonance imaging 
(fMRI) allows the direct observation of brain activation while subjects are performing 
a cognitive task. fMRI is based on a group of physiological processes that begin with 
neuronal firing and glycolysis. These biological events lead to increase blood flow 
and oxygenation in activated brain regions. Changes in blood oxygenation alter the 
local magnetic properties of the blood, which can then be detected with MRI 
sequences. The signals changes are small; therefore, higher magnetic fields 
obtained with 3 or 4 Tesla (or higher) MR scanners are preferred as they yield better 
contrast to noise ratio, reducing the sample size required for BOLD-MRI studies. 
BOLD-MRI is an indirect measure of brain activation that correlates with neuronal 
activity.  
 
Data from fMRI studies require sophisticated software to perform statistical analyses 
that determine which voxels are activated by stimulation. What is seen on the screen 
of a BOLD –fMRI study is not a T1 or T2 MRI intensity view, but the transformed 
intensity value into a pixel value (linear or non-linear). The fMRI visualization is in the 
form of a statistical parametric map showing the areas of brain activation resulting 
from a statistical analysis performed by the software (Figure 1.4). 
1.5.2.1 fMRI findings in HIV-NCI 
Several fMRI studies have found correlations between changes in brain activation 
and working memory, attention, and episodic memory deficits in HIV-infected 
individuals stable on cART (Table 1.4).  
 37 
Ernst et al. looked at the degree of brain activation in 10 HIV-infected individuals of 
stable cART with normal performance on a battery neurocognitive tests compared to 
match controls. Each subject was scanned while performing a set of working memory 
tasks with various degrees of difficulty. Compared to HIV-negative controls HIV-
infected subjects showed greater BOLD activation in the lateral prefrontal cortex, 
posterior parietal cortex, and the caudate suggesting working memory functional 
impairments. The fact that patients were cognitively intact also suggests that the 
increased brain activation observed in the HIV-group, might represent adaptive 
activity to maintain normal cognitive function (163).  
 
Figure 1.4 Visualization of BOLD-fMRI. 
 
[Legend Figure 1.4 Images are showing a statistical parametric map of brain 
activation of a group of individuals performing an audiovisual experiment. Red 
clusters show visual activation; Blue clusters show auditory activation (Image kindly 
provided by Garyfilididis)] 
 
Another fMRI study used a set of visual attention tasks with increasing levels of 
attentional load to evaluate efficiency of the normal attention network in 18 HIV-
infected individuals with milder cognitive impairment compared to HIV-negative 
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controls (164). In this study, HIV-infected subjects showed an altered pattern of 
activation during the task with decreased activation of the visual attention network 
and increased activation in adjacent brain regions compared to controls. Castelo et 
al. evaluated episodic memory in neuroasymptomatic HIV-infected subjects, while 
performing an episodic encoding task (complex visual scenes) repeated stimulus 
(165). The HIV-infected group showed significantly reduced signal in the right 
posterior hippocampus, right inferior gyrus and left lingual gyrus, suggesting an 
alteration in the integrity of the hippocampus.  
 
In summary, the data presented here suggest that HIV-infected individuals have a 
greater use of brain neuronal reserves to maintain normal cognitive function. BOLD-
fMRI has the potential to detect pre-symptomatic abnormalities of brain activation. 
1.5.2.2 Effects of cART on brain function evaluated with fMRI 
A few studies have investigated the effects of cART on brain activation using fMRI 
techniques. Chang et al. evaluated the effects of cART (non-nucleoside-reverse 
transcriptase-inhibitors) in brain activation of HIV-infected individuals on therapy 
compared to those ART naïve and HIV-negative controls (166). Consistent with some 
of the studies described earlier, HIV-infected individuals with or without cART, 
showed greater increase in brain activation in right frontal regions (involved with 
visual attention) compared to HIV-negative controls. Also, compared to HIV-negative 
controls HIV-infected subjects on cART showed greater brain activation in bilateral 
superior frontal regions. The increase in brain activation was load-dependent, which 
suggests that greater recruitment of neurons was needed as the visual attention task 
(tracking four balls) became more difficult. The pattern of these abnormal activations 
suggests that chronic cART might lead to deficiencies in the attentional network. 
Interestingly, abnormalities found in the frontal lobe are consistent with damage of 
fronto-striatal structures seen in patients with HAD.  
 
Finally, another fMRI study compared brain activation changes at baseline and after 
1 year of cART using a similar visual attention task (tracking balls) (167). The study 
evaluated 32 neuroasymptomatic HIV-infected patients (all on stable cART) and 31 
HIV-negative controls. After 1 year of therapy, HIV-infected subjects had no changes 
in brain activation. However, the more difficult the tasks were the more brain 
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activation was observed in the HIV-infected group compared to the negative controls. 
The brain areas involved where again those related with visual attention. This study 
concluded that after 1 year of therapy, HIV-infected individuals have decreased 
attentional network efficiency compared to the HIV-negative controls. This study also 
suggested that HIV-infected subjects might require more brain activation, to maintain 
the task performance.   
1.5.2.3 Resting fMRI findings in HIV-associated NCI 
Brain regions activated during any cognitive process are functionally connected, 
forming neuronal networks.  These functional networks can be examined using fMRI 
during active conditions (task-positive) or during rest (task-negative) (168, 169). 
Resting functional brain networks are active during passive states and de-activated 
during active processing. In a sense, the brain is always active even at rest, and 
resting networks are in charge of preparing the scene for an active process. One of 
the most studied resting network is the default mode network (DMN) that comprises 
functionally connected regions including posterior cingulate cortex, medial prefrontal 
cortex, lateral and medial temporal lobes and posterior inferior parietal lobule (170). 
There are clear associations between brain functionality, and resting functional brain 
networks such as default mode network. Disruption of the default mode network has 
been associated with other neurological conditions such as brain trauma (171), 
neuropsychiatric disorders (172) and neurodegenerative disease (173).  
 
Only a few studies have evaluated the effect of HIV-infection on resting functional 
brain networks such as default mode network. Wang et al. investigated resting 
functional connectivity in 15 HIV-infected subjects within the first year of HIV-infection 
compared to HIV-negative controls (174). The study identified changes in resting 
functional connectivity of visual networks early in HIV-infection, suggesting an early 
effect of the HIV virus within the brain. More recently Thomas et al. studied intra and 
inter-network connectivity among 5 resting functional brain networks in 58 HIV-
infected subjects (44% on stable cART) compared to 53 HIV-negative controls (175). 
The study reported that HIV subjects had disruption of the default mode network 
compared to HIV-negative negative controls. Interestingly, connectivity of resting 
functional brain networks was lower in HIV-infected subjects compared to controls, 
but decreased at the same rate as a function of age for both groups. This suggests 
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that HIV may lead to patterns of alteration in brain function similar to those 
associated with older age. 
1.5.3 Diffusion tensor imaging findings in HIV-associated NCI 
Diffusion tensor imaging is an imaging method for studying white matter integrity in 
vivo (176). DTI measures the diffusion of water molecules in white matter allowing 
the visualization and characterisation of major white matter fibre tracts (177). 
Diffusion (movement of water) can be greater along the fiber (longitudinal direction, 
anisotropic) or can go perpendicular to it, in a radial or transverse direction, see 
Figure 1.5.   
 
Figure 1.5 Fractional anisotropy DTI map of healthy HIV-negative individual.   
    
[Legend Figure 1.5: The colours represent the direction of white matter tracts: longitudinal 
direction (green), transverse (red), horizontal (blue). DTI measures the diffusion of water 
molecules in the white matter allowing the visualisation and characterisation of major white 
matter fibre tracts] 
 
DTI has been used to study the effects of HIV-infection on white matter integrity. 
Studies looking at differences between HIV-negative and HIV-infected individuals 
have reported increases in mean diffusivity and decreases in fractional anisotropy 
within the corpus callosum and centrum semiovale in HIV-infected subjects (178). 
Wu et al. found that the reduction in fractional anisotropy within the corpus callosum, 
and the mean diffusivity was associated with poorer performance in motor speed 
tasks (179).   
 41 
Gongvatana et al. looked at fractional anisotropy and mean diffusivity from 29 
cerebral white matter regions. The study found that individuals with higher CD4 T-cell 
counts had higher anisotropy in parietal lobe regions. HIV-infected individuals on 
cART had higher anisotropy in temporal regions.  In contrast, they found age and 
hepatitis-C co-infection to be associated with white matter injury (decreased 
fractional anisotropy and increased mean diffusivity) in most of brain regions (180).  
More recently, Wright et al. investigated the effects of HIV-infection and cART on 
white matter integrity in 21 naïve HIV-infected subjects, 21 HIV subjects on cART  
and 21 HIV-negative controls. The study found that HIV-infected naïve subjects had 
disturbances in white matter integrity when compared to HIV-infected subjects on 
cART and HIV-negative controls. It also found that HIV-infected subjects on cART 
had no differences in white matter integrity, and that initiation of cART was 
associated with increases in mean diffusivity (181). 
1.5.4 In vivo imaging of neuroinflammation  
1.5.4.1 Positron emission tomography (PET) imaging of the 18kDA translocator 
protein (TSPO) 
PET imaging allows in vivo quantification of neuroinflammation by measuring the 
density of the TSPO. As a mitochondrial transmembrane protein, TSPO is highly 
expressed in microglia and astrocytes (182). Following activation through host 
responses to cellular injury, microglia and astrocytes increase the expression of 
TSPO (183) so that it can serve as a proxy for microglial activation and/or peripheral 
macrophage recruitment. TSPO is widely used as a target for nuclear imaging of 
neuroinflammation and therefore is an ideal target for monitoring the course of a 
disease and the effect of treatments. 
The functions of TSPO are not known, TSPO has been associated with 
steroidogenesis (184) and mitochondrial functions. TSPO may act as a sensor for 
cellular oxygen, mediating protective effects for neurons against damage caused by 
reactive oxygen products. Also, TSPO may be involved with regulating the 
mitochondrial permeability pores in response to signals for apoptosis (185). 
Regarding steroidogenesis, TSPO may play a role in nerve regeneration. 
Specifically, TSPO may be involved with the transport of cholesterol from the cellular 
stores across the mitochondrial membrane, so it can be used to produce 
neurosteroids (186).  
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In summary, these functions of TSPO may be important in controlling neuronal 
damage and could be the reason there is increased expression of the receptor during 
microglial activation.  
1.5.4.2 Imaging of TSPO in HIV-associated NCI 
Ligands for TSPO can be used to image microglial activation in the human brain in 
vivo using PET (187). [11C] PK11195 is the prototypical TSPO radioligand that has 
been used to measure neuroinflammation in several diseases including HIV.  Studies 
investigating microglial activation using TSPO CT PET in HIV-associated brain 
disease are sparse (Table 1.5). Three studies using [11C] PK11195 in humans have 
been published to date. Hammoud et al. demonstrated greater [11C] PK11195 binding 
in HIV-infected individuals with dementia compare to HIV-negative controls, with no 
evidence of binding between HIV-infected subjects without NCI and controls (188).  
Wiley et al. found no difference in binding between HIV-infected subjects with and 
without NCI and controls (189). More recently Garvey et al. showed an increase in 
[11C] PK11195 binding in neuroasymptomatic HIV-infected subjects stable on cART 
compared to controls (111).  The reasons for these contradictory results could be 
because of methodological problems associated with acquisition and analysis of [11C] 
PK11195 data. Despite high affinity to the TSPO in vitro [11C] PK11195 has a high 
plasma protein binding and relatively poor penetration of the blood brain barrier, 
which results in low levels of tracer accumulation in the brain. It also has low specific-
to-nonspecific binding ratio (i.e., displaceable and non-displaceable) in vivo. 
Consequently, it has a poor signal to noise ratio (190) thatlimits accurate 
quantification of differences in TSPO expression. This has a direct effect on the 
sensitivity of the ligand to detect mild neuroinflammation. 
1.5.4.3 [11C] PBR28 TSPO radioligand 
[11C] PBR28 (N-(2-methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide) is a second 
generation TSPO radioligand with high affinity for TSPO and significantly better 
signal-to-noise compared with [11C] PK11195 with greater sensitivity (190). Humans 
exhibit different affinity to TSPO ligands such as [11C] PBR28. This differential affinity 
is caused by a single nucleotide polymorphism in the TSPO gene (rs6971) that leads 
to an aminoacid substitution (Ala147Thr), which is associated with in vitro affinity of 
TSPO in platelets (191, 192). Three patterns of TSPO binding phenotypes have been 
identified in humans: high affinity binders (HABs) who are those subjects without the 
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polymorphism (HH), low affinity binders (LABs) who are homozygotes (LL) and mixed 
affinity binders (MABs) who are heterozygotes (HL) expressing both low and high 
affinity binding to TSPO. HABs and LABs express a single binding site for TSPO with 
either high or low affinity, whereas mixed affinity binders express equal amounts of 
high affinity binders and low affinity binders binding sites. 
In the case of [11C] PBR28, the difference in affinity between low affinity binders and 
high affinity binders is twenty-fold, so that LABs have no discernible PET signal in the 
brain when scanned with [11C] PBR28 (193). The identification of the TSPO affinity 
phenotype is critical for the proper interpretation of TSPO PET data. Correcting in 
vitro binding data for the rs6971 genotype improves the ability of [11C] PBR28 to 
distinguish differences in TSPO density in diseased and tissue from controls (194). 
Genotype analysis in plasma is currently available to characterise TSPO affinity. 
 
Only one study to date has used [11C] PBR28 to study neuroinflammation in HIV-NCI. 
Kreisl et al. looked at inflammatory brain changes in HIV-infected individuals with 
mild NCI (195). They compared asymptomatic HIV-infected patients (n=9), with HIV-
infected subjects with mild NCI (n=7), and HIV-negative controls (n=8). The study 
found that patients with mild NCI had 37 to 53% greater binding with [11C] PBR28 
than HIV-infected patients without NCI in frontal, parietal, medial temporal, and 
cingulate cortex, as well as putamen, thalamus and pons. However, there were no 
differences in binding between HIV-negative controls and any of the HIV-infected 
groups.  
This study had an important methodological problem, which is the lack of information 
about the affinity status of the patients used in the modeling.   
 
More recently, Coughlin et al. used another second generation TSPO ligand [11C] 
DPA-713 to investigated regional brain distribution of TSPO in HIV-infected patients 
compared to HIV-negative controls (196). The study compared 23 HIV-infected 
individuals with and without HIV-associated NCI with 12 HIV-negative controls. HIV- 
infected individuals demonstrated significantly higher TSPO binding in the white 
matter, cingulate cortex, and the supramarginal gyrus. An increase in TSPO binding 
within the frontal cortex was specifically linked to individuals with HAD. 
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In summary, second generation TSPO ligands such as [11C] PBR28 and  [11C] DPA-
713 have been shown to improve specificity and signal-to-noise ratio, which should 
make them better suited to detect abnormal brain distribution or microglial activation 
in HIV-infected individuals. 
Microglial activation is likely to contribute towards the pathogenesis of HIV-
associated brain disease. In this thesis, I studied the role of microglial activation in 
neuroasymptomatic HIV-infected individuals on stable cART, by examining the 
relationship between microglial activation and immunological and imaging biomarkers 
of inflammation. 
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Table 1.1 The changing manifestations of HIV-associated NCI pre and post-
cART 
 
Characteristic Pre-cART Post-cART 
Clinical syndrome 
Subcortical dementia 
 Milder forms of cognitive 
impairment 
 Subcortical involvement 
Risk factors 
 Low CD4 T cell count,  
 High plasma/CSF HIV 
RNA viral load 
 Nadir CD4 T cell count 
 Undetectable plasma 
viral load 
 Detectable CSF RNA 
viral load 
 
Course of disease        Rapidly progressive Fluctuating 
Clinical presentation  Cognitive: attention and 
memory deficits 
 Behavioural: apathy, 
social withdrawal  
 Motor: loss of balance, 
slowness 
 Cognitive: attention, 
memory and executive 
function deficits 
 Behavioural: uncommon 
 Fine motor symptoms  
Pathological findings  HIV-encephalitis with 
multinucleated giant cells 
and microglial nodules 
 Brain atrophy 
 HIV-encephalitis without 
multinucleated giant cells 
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Table 1.2 Summary of the role of selected chemokines in HIV-brain disease 
Chemokines 
Receptor 
(Location in the brain) 
Cellular sources in the 
brain 
Physiological function Effects in the HIV+ brain 
IP-10 (197-199) CXCR3 and CCR5 
(astrocytes, microglia and 
neurones) 
Astrocytes and microglia 
and brain endothelial cells 
Chemotaxis of neutrophils, 
lymphocytes and modulation 
of angiogenesis 
Increased concentrations in 
patients with HIV-NCI 
Stimulates HIV-1 replication in 
MDM 
IL-8 (200, 201)  CXCR1 and 
CXR2(astrocytes, microglia 
and neurones) 
Astrocytes and microglia Proinflammatory chemokine, 
monocyte chemoattractant 
Stimulates HIV -1 replication in 
monocytes and lymphocytes, 
HIV-1gp120 upregulates IL-8 in 
astrocytes 
MCP-1(53, 202, 203) CCR2, CCR5 (astrocytes 
and neurones) 
Astrocytes and microglia Powerful monocyte 
chemoattractant, also 
lymphocytes and basophils 
Increased concentration in 
patients with HIV-NCI 
Eotaxin (95, 204) CCR3, CCR5 (microglia and 
astrocytes) 
Microglia Powerful eosinophil and 
monocytes chemoattractant  
  
Upregulates HIV-1 entry into 
microglia 
Fractalkine(205-207) CX3CR1 (microglia,  
astrocytes, neurones and 
endothelial cells) 
Microglia Monocyte recruitment  
  
  
Downregulated with ART, 
upregulated in brain tissue and 
CSF of patients with HIV-NCI 
SDF-1 α(208-210) CCR3, CCR5 (astrocytes, 
microglia, neurones and 
endothelial cells) 
Microglia, neurones, 
astrocytes 
Chemoattractant of 
monocytes, involved with 
astrocyte proliferation  
  
Astrocyte proliferation in 
response to HIV-infection 
MIP-β(99, 211) CCR5 
(astrocytes, microglia and 
neurones) 
Astrocytes and microglia Monocyte chemoattractant 
  
  
May decrease infection of 
macrophages and microglia 
RANTES (98, 212, 213) CCR5, CCR1 and CCR5 
(astrocytes, microglia and 
neurones) 
Astrocytes and microglia Involvement of migration of 
monocytes, microglia and 
astrocytes  
  
  
Protects neurons against 
apoptosis induced by gp120 
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Table 1.3 Factors implicated in the pathogenesis of HIV-NCI in the era of cART 
 
 
[Legend Table 1.3: ART: antiretroviral therapy, CMV: cytomegalovirus, CNS: central 
nervous system]  
Pathogenic factors Associated clinical risk factors 
Persistent immune activation 
 
Nadir CD4 count 
 
Immune-reconstitution  Nadir CD4 count 
Antiretroviral toxicity Type of antiretroviral therapy 
Inadequate exposure to ART in the CNS Type of antiretroviral therapy 
Accelerated brain aging Age 
Neurodegeneration 
 
Family history of dementia and other 
neurodegenerative diseases 
 
Co-infections 
 Hepatitis C 
 Syphilis 
 CMV 
Co-morbidities and lifestyle factors 
 
 Cardiovascular disease 
 Diabetes 
 Clinical depression 
 Drug and alcohol abuse 
 Smoking 
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Table 1.4 Summary of selected BOLD fMRI studies in HIV-infected individuals 
Author Study design HIV-infected subjects 
HIV negative 
controls 
Cognitive 
domain 
evaluated 
Task Findings in HIV-infected individuals 
Ernst et al. 
(163) 2002 
Cross-sectional, 
BOLD fMRI 
10 HIV+ asymptomatic 
(9 on cART, 1 ART naïve) 
10 controls Working memory 
N-back 
tasks with 
letters (1.5 
Tesla MRI) 
Greater activation in the lateral prefrontal cortex compared to 
controls 
Chang et al. 
(164) 2004 
 
Cross-sectional, 
BOLD fMRI 
 
 
 
18 HIV+ (2 asymptomatic 
and 16 with NCI);15 on 
cART, 3 ART naive 
 
18 controls Visual attention 
Tracking 2, 
3 and 4 balls 
(4 Tesla 
MRI) 
HIV+ less activation in normal visual attention network and 
greater activation in adjacent brain regions. HIV+ had increases 
activation in reserve network regions 
Castelo (165) 
2006 
Cross-sectional, 
BOLD fMRI 
14 HIV+ asymptomatic (10 
on cART;3 ART naïve) 
14 controls Episodic memory 
Encoding 
task (3 
Tesla MRI) 
HIV+ showed reduced activation in the right posterior 
hippocampus, right inferior gyrus and left lingual gyrus. Pattern 
similar to ageing subjects 
Chang et 
al.(166) 2008 
Cross-sectional, 
BOLD fMRI 
HIV+ asymptomatic (n=12 
on stable cART, n=12 
ART naïve) 
18 controls Visual attention 
Tracking 2, 
3 and 4 balls 
(4 Tesla 
MRI 
HIV+ showed greater activation in right frontal regions 
compared to negative controls. HIV+ on cART had greater 
activation in bilateral superior frontal regions compared to 
negative controls 
Ernst (167) 
2009 
Prospective, BOLD 
fMRI assessment at 
baseline, 6 months 
and 1 year 
32 HIV+ asymptomatic 
9all on cART) 
31 controls 
Visual attention 
with high  
attentional load, 
fMRI 
Tracking 2, 
3 and 4 balls 
(4 Tesla 
MRI) 
Declined attention network efficiency after 1 year of follow up. 
Increase activation in prefrontal and posterior parietal cortices 
for the more difficult tasks 
Wang et al. 
(174) 2011 
Cross-sectional, 
resting fMRI 
15 HIV+ within first year of 
HIV-1 infection (ART 
naïve) 
15 controls 
Resting visual 
networks 
Resting 
(eyes shut 
during 
scanning) 
Disruption of connectivity in resting visual networks 
Thomas et al. 
(175) 2013 
Cross-sectional, 
resting fMRI 
58 HIV+ (44% on cART) 53 controls 
Resting functional 
brain networks 
Resting 
(eyes shut 
during 
scanning) 
Disruption of default mode network with patterns of similar to the 
ones seen in old age 
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Table 1.5 Summary of studies evaluating TSPO in HIV-infected subjects 
 
  
Author Subjects 
TSPO 
ligand 
used 
Brain regions 
evaluated 
cART Findings in HIV-infected subjects 
 
Wiley et al. 
2006 (189) 
 
6 HIV+ with HIV-NCI 
6 HIV+ asymptomatic 
5 HIV- controls 
 
[
11
C] 
PK11195 
 
10 brain regions 
 
All on cART, 9 out 12 HIV+ 
with detectable plasma 
viremia 
 
No differences in ligand binding between HIV+ 
and controls 
Hammoud 
et al. 
2005(188) 
5 HIV+ with HIV-NCI (3 
with HAD) 
5 HIV+ asymptomatic 
5 HIV- controls 
[
11
C] 
PK11195 
8 cortical region one 
white matter 
7 HIV+ on cART, 3 cART 
naive 
Higher ligand binding in: Thalamus, putamen, 
temporal, frontal and occipital lobe 
In HIV+ with NCI, and in HIV+ individuals 
overall when compared to controls 
Garvey et 
al. 2013 
(214) 
9 HIV+ asymptomatic 
8 HIV- controls 
 
 
[
11
C] 
PK11195 
Template derived 
regions of interest 
Not described Higher ligand binding in: Corpus callosum, 
anterior, posterior cingulate, frontal and 
temporal lobe in HIV+ asymptomatic compared 
to controls 
Kreisl et al. 
2013, (195) 
7 HIV+ asymptomatic 
7 HIV+ with MIV-NCI 
6 HIV- controls 
(no genotype information 
provided) 
 
[
11
C] 
PBR28 
119 brain regions All on cART with 
undetectable plasma 
viremia 
 
Higher ligand binding in frontal, parietal and, 
medial temporal lobe, putamen, pons, 
thalamus, and cingulate cortex in HIV+ with 
HIV-NCI vs HIV-asymptomatic. 
No difference in binding between any HIV+ 
and controls 
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2.1 Clinical cohorts 
2.1.1 Subject selection 
Subjects attending the HIV outpatient department at St Mary’s Hospital, Imperial 
College NHS Healthcare were invited to participate in the clinical studies presented in 
this thesis.  
Eligibility criteria required subjects to be HIV antibody positive for at least 2 years, 
proficient in the English language of male gender between 20 to 50 years of age, 
receiving stable cART with a plasma HIV RNA viral load of <50 copies/mL at 
screening. Exclusion criteria included current use of any anti-inflammatories or 
benzodiazepines, current use of recreational drugs or alcohol abuse and low affinity 
binder affinity to TSPO on genotype testing. Patients were screened for anxiety and 
depression using the hospital anxiety and depression scale (Figure 2.1). This scale is 
unconfounded by the presence of HIV symptomatology and hence is considered a 
reliable tool to assess anxiety and depression in HIV-infected individuals (215).  
Subjects with active or past history of neurological, psychiatric disease or evidence of 
depression and anxiety were also excluded. The age range was selected because 
there is evidence (unpublished) that age may affect the TSPO ligands volume of 
distribution, and our patient demographics indicated that approximately 65% of our 
patient cohort belongs to this age range, which made recruitment easier. For the 
analysis of [11C] PBR28 data from a control group of 10 male, age-matched, HIV-
negative, healthy participants were used. These control groups were obtained from 
studies conducted at the Imanova centre for imaging sciencies, located at the 
Hammersmith campus, Imperial College London. 
2.2 Non-human primate model 
Samples from CSF and blood (plasma) from cynomolgus macaques infected with 
SIVmac251 were provided by the National Institute of Biological Standards and 
Control (Hertfordshire, UK) in collaboration with Dr Deborah Fergusson and Dr Neil 
Almond for chemokine analysis. These animals were part of several neuropathology 
and vaccine studies. Purpose bred juvenile, SRV-negative and STLV-negative 
cynomolgus macaques originally derived from Mauritius, were used in all these 
studies. Animals were group housed and maintained in accordance with Home Office 
guidelines for care and maintenance of non-human primates. Animals were sedated 
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Figure 2.1 Hospital anxiety and depression scale 
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with ketamine hydrochloride (Vetalar V, Pharmacia Animal Health Ltd, Corby, UK) 
before inoculation of virus or sampling of blood by venepuncture. On each of these 
occasions, sedated macaques were weighed and inspected for general health and 
signs of disease. At the end of the study, macaques were killed humanely by an 
overdose of anaesthetic. 
2.3 Brain imaging 
2.3.1 Positron emission tomography imaging with [11 C] PBR28 
 
Radiotracer synthesis 
[11C] PBR28 was manufactured at Imanova immediately prior to use according to 
local Standard Operating Procedures (SOPs). Quality assurance checks were 
performed prior to injection to ensure the product meet specification as laid down by 
the local product manufacture specifications. 
 
Plasma sampling  
An arterial line was placed in all subjects for the measurement of the arterial plasma 
input function. All subjects completed pre-arterial line assessment that consisted of 
an Allen’s test to evaluate collateral circulation in both hands. Following 
administration of local anaesthesia (infiltration of the skin with 1% lidocaine), a 
cannula was inserted into the radial artery to allow arterial blood sampling during the 
PET CT scan. 
 
Image generation and processing  
For the PET study, the [11C] PBR28 PET scans were acquired using a Biograph 6 
PET CT scanner (Siemens Healthcare). Each participant was injected with 
intravenous bolus of 400MBq of carbon-11 labeled PBR28 over 20 seconds at the 
start of a 90 minutes 3 dimensional mode dynamic PET acquisition.  
PET data were reconstructed using filtered back projection with corrections for 
attenuation and scatter (based on a low-dose CT acquisition). Dynamic data were 
binned into 26 frames (durations: 8x15s, 3x1min, 5x2min, 5x5min, 5x10min). Arterial 
blood data were sampled via the radial artery to enable generation of an arterial 
plasma input function. A continuous sampling system (ABSS Allogg, Mariefred, 
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Sweden) was used to measure whole blood activity each second for the first 15 
minutes of each scan. Discrete blood samples were manually withdrawn at 5, 10, 15, 
20, 25, 30, 40, 50, 60, 70, 80, and 90 minutes after scan starts to facilitate 
measurement of whole blood and plasma activity. Samples taken at 5, 10, 15, 20, 30, 
50, 70 and 90 minute time points were also analysed using HPLC to determine the 
fraction of parent radioactivity in arterial plasma. The first three discrete blood 
samples were used to calibrate the continuous blood data, and then the continuous 
and discrete data sets were used to form a whole blood activity curve covering the 
duration of the scan. Discrete plasma samples were divided by the corresponding 
whole blood samples to form plasma-over-blood (POB) data. A constant POB model 
was fitted. This POB value was then multiplied by the whole blood curve to generate 
a total plasma curve. Parent fraction data were fitted to a sigmoid model 𝑓 =
((1 −
𝑡3
𝑡3+10𝑎
)
𝑏
+ 𝑐) /(1 + 𝑐) where t is time and a, b and c are fitted parameters. The 
resulting fitted parent fraction profile was multiplied by the total plasma curve and 
then smoothed post-peak using a tri-exponential fit to derive the required parent 
plasma input function. For each scan, a time delay was fitted and applied to the input 
function to account for any temporal delay between blood sample measurement and 
the tomographic measurements of the tissue data. Free fraction in plasma (fP) was 
measured through ultrafiltration (Amicon Ultra regenerated cellulose MWCO 30kDa, 
Millex, Ireland) in triplicate using Tris buffer (0.1M, pH=7.4) to determine and enable 
correction for non-specific binding.  
2.3.2 Brain magnetic resonance imaging 
For the PET study, MRI data acquisition was performed on a Siemens MAGNETOM® 
Verio 3.0 tesla magnetic resonance (MR) scanner (Siemens, Germany). Functional 
images were obtained using a T2 weighted echo-planar-imaging (EPI) sequence with 
whole brain coverage repetition time (TR) of 2000ms, echo time (TE) of 30ms with 35 
ascending slices with thickness of 3mm; voxel size 3x3x3mm. T1 weighted whole 
brain structural images were also obtained in all subjects. 
2.3.2.1 Functional magnetic resonance imaging  
Patients had two sessions of imaging: one session consisted of resting fMRI plus 
structural brain imaging including DTI, and a second session consisted of a task 
fMRI. 
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2.3.2.1.1 Resting functional magnetic resonance imaging 
Resting fMRI was acquired for 8 minutes when patients were instructed to close their 
eyes and relax. Following this, all patients performed a task in the scanner. 
 
Imaging pre-processing  
Data pre-processing was completed using FSL (Oxford Centre for Functional 
Magnetic Resonance Imaging of the Brain Software Library www.fmrib.ox.ac.uk). 
Image preprocessing comprised, motion correction (using MCFLIRT), spatial 
smoothing (using a Gaussian kernel of FWHM 6mm), and temporal bandpass 
filtering (high-pass temporal filtering). As a final preprocessing step, each individual’s 
time series was normalized by registration to the Montreal Neurological Institute 
(MNI) template, with 4mm resolution. 
2.3.2.1.2 Task functional MRI imaging 
A simple choice reaction time (CRT) task was selected to assess sustained attention 
in HIV-infected participants. The paradigm was developed in collaboration with 
Robert Leech at the C3NL laboratory at the Hammersmith campus, Imperial College 
London.  
The paradigm was programmed using Matlab psychophysics toolbox using the 
Psychtoolbox-3 available here www.psychotoolbox.org. Stimuli were presented 
through an IFI-SA system in vivo. Responses were recorded trough a fiber optic 
response box (Nordicneurolab), interfaced with the stimulus presentation PC running 
Matlab. In the task, participants were presented with an initial fixation cross for 350 
ms followed by a response cue as an arrow pointing either to the left or the right 
lasting 1400 ms (Figure 2.2).  
Participants were instructed to press the button box with the index finger accordingly,  
as quick and as accurately as possible. Presentation was blocked, with five repeated 
blocks of 10 response trials, 10 rest trials, and four response trials at the start of the 
experiment. The total duration of the scan was 5.06 minutes. The inter-stimulus 
interval was 1750 ms.    
 
 
 
 58 
Figure 2.2: Example of rest and go trials stimulus in the choice reaction time 
task. 
                                                  
[Legend Figure 2.2: Patients were instructed to click a botton box when the arrow 
was present on the screen; rest trials: initial fixation cross before task was on. Go 
trials: stimulus presented to patients when task was on (arrows pointing either left or 
right)] 
 
Imaging pre-processing  
The first four volumes were discarded to allow for T1 equilibration effects. Imaging 
pre-processing was performed using FSL (FMRIB software library) 
(http://www.fmrib.ox.ac.uk/fsl). The following pre-processing steps were conducted: 
motion correction using MCFLIRT, high-pass temporal filtering and spatial smoothing 
using a Gaussian kernel of 5mm full-width-half-maximun (FWHM). Removal of brain 
structures from the imaging volumes was carried out using the BET tool from the FSL 
software. Linear imaging registration tool (FLIRT) (216) was used to register the fMRI 
volumes into the individual participant’s structural scan and standard MNI152 space 
images. T1 weighted were also acquired for each participant (TR: 2300ms, TE: 
2.98ms, voxel size 1x1x1 mm). 
2.3.2.2 Diffusion tensor imaging  
Diffusion-weighted volumes with gradients applied, resulting in a total of 68 directions 
The following parameters were used: 52 contiguous slices, slice thickness=2.0 mm, 
field of view (FOV) 224 mm3, voxel size=1.8x1.8x2.0 mm, b value=1000s/mm2, 
imaging runs with diffusion weighting (b=1 s/mm2). 
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2.3.2.3 Magnetic resonance imaging spectroscopy (1H-MRS) 
 
MRS data acquisition:  
[1H]-MRS data acquisition was performed on a Siemens MAGNETOM® Verio 3.0 
tesla magnetic resonance MR scanner (Siemens, Germany) as described above 
(section 2.1.1). MRS data were acquired by a single voxel examination in 2-voxel 
locations: right frontal white matter, and the right basal ganglia (Figure 2.3).  
 
Figure 2.3 MRS voxel locations selected for the study 
 
        
  
[Legend Figure 2.3 Voxel locations selected for the study in yellow (a) Frontal white matter 
(voxel size (AP) 18mm x (RL) 18mm x (HF) 10mm. (b) Basal ganglia (voxel size (AP) 18mm 
x (RL) 18mm x (HF) 18mm if no good try (AP) 10mm x (RL) 18mm x (HF) 18mm] 
 
These anatomical voxels were selected because previous imaging studies have 
described cerebral metabolite abnormality patterns in such voxels in HIV-infected 
individuals (110, 153). A double-spin-echo sequence was performed in point-
resolved spectroscopy with the following settings: TE: 30 ms, TR of 3000 ms, a 
spectral width of 2500 Hz, 2048 data points and 128 data acquisitions. Spectra from 
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the MR imaging were post-processed using the manufacturer's software for 
automated water signal suppression and water shimming. Each examination lasted 
20 min. 
2.4 Neurocognitive testing 
For the PET study only, neurocognitive testing was performed in HIV-infected 
individuals using a commercially available cognitive test battery CogState (CogState 
Ltd, Melbourne, Australia). CogState is a computarised cognitive test battery 
designed to measure cognitive performance. This tool has been validated for the 
detection of cognitive impairment in HIV-infected subjects when compared with 
formal neurocognitive assessment (107, 217) 
The battery consisted of eleven individual tasks in the form of card-games or shapes 
that were presented in a computer screen to minimise language and cultural 
differences (Table 2.1). During testing, each participant is seated in a quiet room 
were the instructions were given verbally by the test supervisor (J.V). A practice 
session was conducted during the screening visit, followed by the baseline 
assessment conducted during the scanning visit.  
2.5 Blood and CSF biomarkers 
2.5.1 Lumbar puncture 
Lumbar punctures where performed by J.V within 1 month of the scanning visit as a 
day case procedure at St Mary’s Hospital, Imperial College London. Lumbar 
punctures were performed using aseptic technique under local anaesthesia (2-10mL 
2% lignocaine) to obtain CSF. CSF was collected in universal containers. 
2.5.2 Blood samples and CSF processing 
Blood samples were collected in EDTA bottles during the screening visit and the LP 
visit. CSF samples were collected in universal containers. 3mL of CSF were sent to 
the Clinical Biochemistry and Microbiology Laboratory at St Mary’s Hospital, London 
for the analysis of CSF protein, glucose, gram stain, and microscopy. An additional 
2mL of CSF sample was sent to the Virology Laboratory at St Mary’s Hospital, 
London for the analysis of CSF HIV RNA. CSF HIV RNA was quantified using the 
real-time PCR (Qjagen probe PCR). The limit of detection was 10 copies/mL (218).  
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Blood and remaining CSF (5mL) samples were centrifuged after 10 minutes (1500g, 
3000 rpm) in a 4°C refrigerated centrifuge. Plasma and CSF samples were then 
transferred to storage tubes and store at -80 C°. 
2.5.3 Analysis of plasma and CSF biomarkers 
2.5.3.1 Chemokines 
The MSD human chemokine 9-Plex-and 7-Plex cytokine assay (ultrasensitive kit 
K15001C, Meso Scale Discovery) for human chemokines (eotaxin, MIP-1β, TARC, 
IP-10, IL-8, MCP-1, MDC, MCP-4) was used for the analysis of plasma and/or CSF. 
The arrays were pre-incubated with 25μL/well of assay diluent for 30 minutes, with 
shaking at room temperature. Following the pre-incubation, 25μL of sample or 
calibrator in duplicate was added into the corresponding wells. Thereafter the plate 
was incubated for 2 hours, with vigorous shaking (600rpm). The array was then 
washed three times with phosphate buffered saline containing 0.005% of Tween 20, 
and then 25μL of detection antibody reagent was added into each well. The plates 
were incubated in room temperature for 2 hours and the array wash three times. The 
plates were analyzed immediately after adding 2x reading buffer. Chemokine 
concentrations in blood and CSF samples were determined with MSD Discovery 
Workbench® software, using the software’s curving fit model. The lower limit of 
detection in both plasma and CSF chemokines/cytokines (pg/mL) were: eotaxin (23), 
MIP-1β (7.5), TARC (15), IP-10 (12), IL-8 (0.6), MCP-1 (8), MDC (334), MCP-4 (8.4). 
2.5.3.2 Soluble CD14 
A commercially available kit (R&D Systems: Quantikine, Human sCD14 
Immunoassay) was used to measure sCD14 in plasma samples stored at -80 
degrees. All reagents and samples were brought to room temperature. Plasma 
samples were diluted 200X into calibrator diluent. CSF samples were diluted 40x. 
Lyophilised soluble CD14 standard was reconstituted with 5mL calibrator diluent, 
giving a stock solution of 16,000 pg/mL. The stock solution was gently agitated for 15 
minutes prior to use. The resulting standard concentrations were as follows: 16,000 
pg/mL, 8,000 pg/mL, 4,000 pg/mL, 2,000 pg/mL, 1,000 pg/mL, 500 pg/mL, 250 
pg/mL, 0 pg/mL. 100ul of assay diluent was added to each of the microplate wells, 
followed by 100μL of either standard, diluted sample or control per well in duplicate. 
A spiked control of known sCD14 concentration was run on every plate. The 
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microplate was covered with an adhesive plate sealer and incubated at room 
temperature for 3 hours then aspirated and washed 4X before 200μL of sCD14 
conjugate was added to each well. The microplate was covered with a plate sealer 
and incubated at room temperature for 1 hour followed by a further wash step. 200μL 
of substrate solution was added to each well and the plate was incubated in the dark 
at room temperature for 30 minutes. The reaction was stopped with 50μL of stop 
solution and read at 450nM with a background reading at 540nM.  The standard 
curve was calculated in GraphPad Prism using a 4PL fit and any sample duplicates 
with CVs exceeding 15% were repeated. This assay was performed in collaboration 
with Dr Adriano Boasso from Chelsea and Westminster Hospital. 
2.5.3.3 CD163 
A commercially available kit (R&D Systems: Quantikine, Human CD163 
Immunoassay) was used to measure CD163 in CSF samples stored at -80 degrees. 
All reagents and samples were brought to room temperature. CSF samples were 
used neat. Lyophilised soluble CD163 standard was reconstituted with 1mL of 
distilled water, giving a stock solution of 200ng/mL. The stock solution was gently 
agitated for 15 minutes prior to using to produce a dilution series. 100uL of assay 
diluent was added to each of the microplate wells, followed by 50uL of either 
standard, sample or control per well in duplicate. A spiked control of known CD163 
concentration was run on every plate. The microplate was covered with an adhesive 
plate sealer and incubated at room temperature for 2 hours then aspirated and 
washed 4X before 200μL of CD163 conjugate was added to each well. The 
microplate was covered with a plate sealer and incubated at room temperature for 1 
hour followed by a further wash step. 200μL of substrate solution was added to each 
well and the plate was incubated in the dark at room temperature for 30 minutes. The 
reaction was stopped with 50μL of stop solution and read at 450nM with a 
background reading at 540nM.  The standard curve was calculated in Excel using a 
lin-lin fit and any sample duplicates with CVs exceeding 15% were repeated. This 
assay was performed in collaboration with Dr Adriano Boasso from Chelsea and 
Westminster Hospital 
2.5.3.4 16s Ribosomal DNA 
Bacterial DNA was measured in plasma and CSF samples stored at -80 using 
quantitative polymerase chain reaction (qPCR). DNA was extracted from 200uL 
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plasma or CSF using an EZI Advanced robot and kit (Qiagen DNA EZI, DNA EZI mini 
kit v2.0). PCR was carried out with Platinum Syber Green Supermix UDG (Invitrogen) 
with 16s primers (Eurofons MWG Operon (forward (5’-3 ’ – TGG AGC ATG TGG TTT 
AAT TCG A) reverse (5’- 3’ – TGC GGG ACT TAA CCC AAC A))) at a final 
concentration of 0.05μM. Molecular grade water controls and spiked plasma controls 
were run on each plate. A standard curve was made from purified E.coli DNA and 
ranged from 2 x 107 to 2 x 101 copies per reaction. Quantitative real time PCR was 
performed in an Applied Biosystems ABI PRISM® 7000 using the following 
conditions; activation of Taq DNA polymerase for 10 minutes at 95oC, 40 cycles of 
denaturing for 40 seconds at 94oC, annealing for 45 seconds at 60oC, and extension 
for 45 seconds at 72oC.  A PCR run was accepted if the slope of the standard fell 
between -3.6 and -3.3, representing 90-100% efficiency, and the curve fit was above 
0.985. Samples were run in triplicate and repeated if the standard deviation of the 
quantification cycle (Cq) was over 0.300. This assay was also performed in 
collaboration with Dr Adriano Boasso from Chelsea and Westminster Hospital 
2.6 Statistical analysis  
A detailed description of the specific statistical methods employed in this thesis is 
presented in each results chapter. The statistical packages used in this thesis were: 
SPSS (Version 21.0) and GraphPad Prism (Version 6.0) 
2.7 Ethical approval 
Ethical and Trust approval were obtained via the UK national research ethics service 
to conduct the following studies presented in this thesis: 
 The neuroinflammation study (chapters 3) approval granted by NRES 
(reference number 12/LO/1570) 
 Permission to administer [11C] PBR28 was granted by the administration of 
radioactive substances advisory committee (ARSAC) of the UK (reference 
number 630/3764/29163) 
 The SIV chemokine study (chapter 6) obtained ethical approval for housing 
and research of cynomolgus macaques from the Home office 
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Table 2.1 Tasks and cognitive domain assessed using CogState 
 
 
Task performed 
 
Unit of measurement 
 
Cognitive function tested 
 
Interpretation of score 
Speed and visual attention    
 
Detection (DET) 
 
Log10 milliseconds 
          Speed of processing Lower score=better performance 
 
Identification (IDN) 
 
Log10 milliseconds Attention Lower score=better performance 
Executive function    
 
Groton maze learning test (GMLT) 
 
Total errors Executive function Lower score=better performance 
 
Continuous paired learning (CPAL) 
 
Total errors Paired associated learning and 
memory 
Lower score=better performance 
Accuracy and visual learning    
 
One card memory (OCL) 
 
Arcsine proportion correct Visual learning/memory Higher score=better performance 
 
One back memory (ONB) 
 
Arcsine proportion correct Working memory  Higher score=better performance 
Memory and verbal learning    
 
International shopping list task (ISL) 
 
Number of correct 
responses 
Verbal learning/memory Higher score=better performance 
International shopping list- recall (ISLR) 
 
 
Number of correct 
responses 
Verbal learning/memory Higher score=better performance 
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3.1 Introduction 
The exact role of neuroinflammation in treated HIV-infected individuals remains 
controversial, as inflammatory brain changes associated with microglial activation 
have been reported in both effectively treated and untreated HIV-infected individuals 
(40). Despite effective control of HIV RNA in plasma and the CSF with cART, there is 
evidence that the initial inflammatory process following HIV-infection of the brain is 
likely to persist. Studying neuroinflammation in cognitively asymptomatic HIV-infected 
patients may shed light on whether microglial activation is an earlier contributor to the 
pathogenesis of HIV-associated NCI  
 
The identification of TSPO a mitochondrial transmembrane protein, highly expressed 
in activated microglia and astrocytes, has allowed the in vivo quantification of brain 
inflammation using PET. TSPO response to injury seems to be directly associated 
with the degree of damage. There is a significant increase in TSPO density with 
neuronal cell loss (219, 220), and demyelination (221, 222). What the relative 
contributions of activated microglia and activated astrocytes to the overall TSPO 
imaging signal is not known. However, Banati et al. demonstrated that microglial cells 
are the main source of increase TSPO expression when the BBB is intact (223)  
 
The inflammatory response to brain injury can be studied in vivo using TSPO ligands 
such as [11C] PBR28. [11C] PBR28 is a second-generation TSPO ligand with greater 
sensitivity and significantly better signal-to-noise ratio compared with first generation 
ligands (190). Although there is a signal of greater microglial activation in HIV-
infected subjects with severe NCI compared to controls (188), evidence for microglial 
activation in treated HIV-infected subjects with milder NCI or without evidence of 
neurological disease is not conclusive (189, 195, 214).  
 
The detection of neuroinflammation in treated HIV-infected individuals could provide 
a unique opportunity to further explore the pathogenic mechanisms of HIV-
associated brain disease and to establish whether microglial activation has a 
deleterious effect on brain function. This chapter will address the first two hypotheses 
of this thesis; first, that microglial activation will be present in neuroasymptomatic 
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HIV-infected individuals stable on cART and secondly that microglial activation will be 
associated with abnormalities in brain function parameters.   
3.2 Methods 
3.2.1 Subject selection 
Male patients attending St Mary’s Hospital, Imperial College London NHS Healthcare 
were eligible. HIV-negative control data were obtained from [11C] PBR28 PET CT 
studies conducted at Imanova.  
 
HIV-infected subjects were required to be HIV-1 antibody positive for at least 2 years, 
proficient in the English language, age between 20 to 50 years of age, receiving 
stable cART with a plasma HIV RNA of <50 copies/mL at screening. Although, 
patients with any nadir CD4 T-cell counts were eligible, I enrolled a similar number of 
participants with high (>300 cells/uL) and low (<300 cells/uL) nadir CD4 T-cell 
counts, in order to determine difference in TSPO binding associated with this HIV-
clinical parameter. Exclusion criteria included any active, or past history of 
neurological or psychiatric disease, current use of anti-inflammatories or 
benzodiazepines, current use of recreational drugs or alcohol abuse, and low affinity 
binder affinity to TSPO on genotype testing.  
3.2.1 Study procedures 
All participants provided informed consent. During the screening visit, demographic 
information was collected and included, age, current CD4 and CD8 T-cell count, 
nadir CD4 T-cell count, time since HIV diagnosis, time since starting cART, and pre-
treatment HIV RNA. Pre-treatment HIV RNA level was defined as the highest HIV 
RNA value before initiating cART.  
3.2.2 Neurocognitive testing 
Neurocognitive testing was performed only in HIV-infected subjects using the 
CogState battery as described in section 2.4. All subjects had neurocognitive testing 
before any imaging was performed. All subjects completed neurocognitive testing at 
screening (practice run) and on the scanning day (study neurocognitive testing).  
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Analysis of neurocognitive tests scores 
Scores from each task were obtained and as a measure of overall cognitive 
performance, composite scores were calculated from combining all tasks in the 
battery. To do this each score at the study cognitive examination was standarised (Z-
scores) against age-matched normative population data (n=879) provided by the 
manufacturer. Cognitive impairment was defined as the presence of either a 
cognitive task score below one standard deviation (SD) in at least two cognitive 
tasks. 
3.2.3 Brain PET scanning with [11C] PBR28  
PET CT scanning and T1-weighted cerebral MR imaging were performed as 
described in section 2.3.1.  
3.2.3.1 Imaging analysis of [11C] PBR28 CT PET results 
Dynamic PET data were corrected for motion via frame-to-frame image registration 
and aligned with the individual’s structural T1 MRI image using SPM5 (Wellcome 
Trust Center for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) with a mutual 
information cost function. 
The CIC neuroanatomical atlas (224) was nonlinearly deformed into the individual’s 
space, via T1 MRI data mapping, to obtain a personalised anatomical parcellation of 
regions of interest. Attention focused on regions of moderate and high binding based: 
brain stem, thalamus, hippocampus, global cortical regions, cerebellum and basal 
ganglia. Each region of interest was then applied to the dynamic PET data to derive 
regional time-activity curves (TACs). 
3.2.3.2 Kinetic analysis 
Two-tissue compartment model, utilising the metabolite corrected plasma input 
function, was applied to the dynamic PET data using a fixed blood volume correction 
of 5%. For each ROI examined, the total volume of distribution (VT) was estimated 
from the rate constants as described previously by Gunn et al. (225). The Logan 
graphical method (226) employing a plasma input, 5% fixed blood volume, and a 
linear start time at 35 min was also used to estimate the absolute VT of each region 
of interest and further applied at the voxel level to produce a parametric VT map for 
each subject. The main outcome measure is the total VT for each defined brain region 
and a parametric VT map for each subject. The VT for a radioligand is defined as the 
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ratio of concentration in tissue to that in plasma, and it is an alternative to the binding 
potential (density of the neuroreceptor) in the absence of a region where the 
neuroreceptor is not present (reference region). 
3.2.3.3 VT normalisation  
Besides VT, the distribution volume ratio (DVR) in each region of interest was also 
estimated by normalizing the VT to cortical grey matter in order to evaluate local 
regional differences. Normalisation can control for unknown physiological factors 
(unrelated to inflammation) that may affect radioligand brain uptake in TSPO PET 
imaging studies (227). The grey matter was selected as an area of control for 
normalisation because its relative uniform pattern of high baseline binding in healthy 
subjects. The main outcome measured is a normalized VT(DVR) for each defined brain 
region. Model fitting and parameter estimation was performed using software 
implemented in Matlab R2008b (The MathWorks Inc., Natick, MA, USA).  
3.2.4 Statistical analysis 
Differences between patients and controls were studied both on region of interest 
level using ANOVA with genetic effect as a fixed factor using SPSS (SPSS, Version 
21, IBM, USA), and on a parametric level using FSL randomize whilst accounting for 
affinity status. Partial correlation was performed to investigate the relationship 
between TSPO binding and clinical parameters. Each HIV-infected individual enrolled 
in the study was evaluated by examining the statistical parametric maps and VT from 
all brain regions in order to identify any associations between increase PBR28 
binding and HIV-clinical and cognitive parameters. 
3.3 Results 
Patient demographics and clinical parameters for HIV-infected subjects are 
presented in Table 3.1. 12 male, HIV-infected subjects (8 HABs and 4 MABs), 
median (range) ages 43.5 (26-49) years were recruited and completed all study 
procedures. 10 Male, healthy, HIV-negative controls (6 HABs and 4 MABs), median 
age 44 years (28-52), matched by age and gender were included in the analysis. 
Median (range) nadir CD4 T-cell count (cells/uL) was 196 (70-350) and the median 
(range) time elapsed since HIV diagnosis (years) was 15 (2-19). HIV-clinical 
parameters for each HIV-infected individual are presented in Table 3.2 
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3.3.1 Neurocognitive testing results 
Results from neurocognitive testing for the HIV-infected group are presented in Table 
3.3, Table 3.4 and Table 3.5. No evidence of NCI in HIV-infected subjects was 
observed when compared against age-matched normative data.  
HIV-infected patients performed well across the range of cognitive task of varying 
complexity. However in one of the tasks, continuous pair associated learning (CPAL), 
which evaluates visual and learning memory, HIV-infected subjects had significantly 
more errors compared with controls (P=0.04). In the CPAL task subjects must learn 
to remember the location of pictures presented on a screen that is hidden beneath 
different locations on the screen. For the CPAL task the lower the number of errors 
the better the performance. 
3.3.2 [11C] PBR28 volume of distribution (VT) in HIV-infected subjects compared 
to HIV-negative controls 
 
[11C] PBR28 Total VT results  
 
An increase in mean total [11C] PBR28 VT  in HIV-infected subjects compared to HIV-
negative controls in several brain regions was observed (Figure 3.1).  
When only HABs were considered, the region of interest analysis showed a 
significant increase in total VT  in the left occipital lobe (P=0.032), and a trend towards 
increase total VT  in the left basal ganglia (P=0.095), striatum (P=0.081), left caudate 
(P=0.057), globus pallidus (P=0.091) and medulla (P=0.089) in HIV-infected subjects 
compared to controls, Figure 3.2 
[11C] PBR28 VT from selected brain regions for each HIV-infected participant (high 
and mixed affinity binders) enrolled in the study is presented in Figure 3.3 and 3.4. 
HIV-infected individuals (subjects: 03, 06, 10, 11 and 13) had an increase in [11C] 
PBR28 VT binding in most brain regions examined. In contrast, subjects 05, 07 and 
12 had brain regions with increase PBR28 binding and reduce PBR28 binding 
compared to controls. The parametric [11C] PBR28 VT maps in Figure 3.5 show that 
subject 11 and subject 06 are the HIV-infected participants with the greatest levels of 
PBR28 binding when compared individually with other HIV-infected individuals and 
the HIV-negative controls; although these 2 individuals are neurologically 
asymptomatic with no evidence of cognitive impairment. 
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Figure 3.1 Parametric map for HIV-infected patients vs HIV-negative controls. 
 
                                     
   
[Legend Figure 3.1: These images represent the parametric analysis showing significant increase in [11C] PBR28 total VT in HIV-infected 
patients compared to controls, (P=0.001). The parametric analysis includes both affinity groups high mixed affinity and mixed affinity binders 
after correction for affinity phenotype.] 
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Figure 3.2 [11C] PBR28 total VT in selected brain regions investigated for HIV-infected cases and controls.  
 
 
 
Figure 3.2 [11C]PBR28 total VT in selected brain regions investigated for HIV-infected cases and controls.  
 
 [Legend Figure 3.2: HAB= high affinity binders, MAB: mixed affinity binders, GM=grey matter, ctx= Cortex, L= left, R= right] 
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Figure 3.3 [11C] PBR28 total VT in selected brain regions of each HIV-infected participant (high affinity binders) enrolled in the study. 
 
[Legend Figure 3.3: Bars represented [11C] PBR28 total VT from selected brain regions for each PBR28 high affinity binder, HIV-infected 
participant enrolled in the study. Average [11C] PBR28 total VT  for controls is presented in dark blue with a black limit line; HAB= high affinity 
binders, ctx= cortex] 
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Figure 3.4 [11C] PBR28 total VT in selected brain regions of each HIV-infected participant (mixed affinity binders) enrolled in the study 
[Legend Figure 3.4: Bars represented [11C] PBR28 total VT from selected brain regions for each PBR28 mixed affinity binder, HIV-infected 
participant enrolled in the study. Average [11C] PBR28 total VT  for controls is presented in dark  blue with a black limit line; MAB= high affinity 
binders, ctx= cortex] 
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Figure 3.5 Comparison between parametric VT maps of HIV-infected patients and healthy controls.  
 
        
 
[Legend Figure 3.5: Images represent parametric maps of [11C] PBR28 total VT of individual HIV-infected subjects with high affinity 
to PBR28 compared to the average HIV-negative controls with high affinity for PBR28]  
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[11C] PBR28 normalized VT(DVR) results 
 
HIV-infected subjects (high affinity and mixed affinity genotype) had significant 
regional increase in VT(DVR) in the parietal lobe (P=0.001), occipital lobe (P=0.046) 
and globus pallidus (P=0.035) (Figure 3.7). A significant decrease in VT(DVR) in the 
midbrain (P=0.05) and the temporal lobe (P=0.036) were observed in HIV-infected 
patients compared to controls (Figure 3.6). When only HABs were considered, aside 
from the brain regions described, the left striatum showed an increase in VT(DVR), and 
the right amygdala a decrease in VT(DVR) in HIV-infected cases compared to controls, 
see Table 3.4 
 
Figure 3.6 Lower [11C] PBR28 VT(DVR) in three brain regions in HIV-infected cases 
compared to controls. 
 
[Legend Figure 3.6: A reduction in [11C] PBR28 binding in the temporal cortex, midbrain and 
right amygdala were demonstrated in HIV-infected individuals compared to controls. This 
data suggest differences in expression of TSPO in different brain regions of HIV-infected 
individuals on cART]  
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Figure 3.7 [11C]PBR28  VT(DVR)  in selected brain regions investigated for all HIV-infected cases and controls.  
 
 
[Legend Figure 3.7: Bars represent the [11C]PBR28 VT(DVR) for all HIV-infected participants vs HIV-negative controls; HAB= high affinity binders, 
MAB: mixed affinity binders, GM= grey matter, ctx= cortex, L= left, R= right] 
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3.3.3 Associations of [11C] PBR28 VT and clinical parameters 
 
[11C] PBR28 VT and cognitive performance 
 
After adjusting for TSPO affinity genotype and education, I looked for associations 
between [11C] PBR28 VT(DVR) and performance on neurocognitive tests. HIV-infected 
patients showed significant negative associations between greater [11C] PBR28 
VT(DVR) and poorer cognitive global performance, see Table 3.7 and Table 3.8. The 
strongest correlations were between [11C] PBR28 VT(DVR) and cognitive tasks 
evaluating memory and verbal learning. Also, when high affinity binders were only 
considered, the correlations were still observed between [11C] PBR28 VT(DVR) and 
global cognitive performance, and composite memory and verbal learning Z-scores. 
Interestingly, the partial correlation analysis for the composite speed Z-scores, 
demonstrated a positive correlation between [11C] PBR28 VT(DVR)  in several brain 
regions and performance in speed processing. However, these associations were not 
present when looking at the individual speed processing tasks (DET and IDN). The 
individual evaluation of HIV-infected participants demonstrated that subjects with 
greater [11C] PBR28 VT(DVR) binding (subjects: 06 and 11) had more errors when 
performing the continuous pair associated learning (CPAL) compared to other HIV-
infected-individuals and HIV negative controls, see Table 3.4. The CPAL cognitive 
task evaluates verbal and visual memory. 
 
[11C] PBR28 VT and HIV-clinical parameters 
 
After adjusting for TSPO affinity genotype, I investigated associations between [11C] 
PBR28 VT(DVR) and HIV clinical parameters using correlation analysis. In addition, I 
examined the clinical parameters of each HIV-individual enrolled in the study to 
identify clinical characteristics associated with high PBR28 signal, see Figure 3.8  
 
In the group analysis several correlations were identified. First, greater [11C] PBR28 
VT(DVR) was correlated with lower CD4/CD8 ratio in several brain regions, see Table 
3.9. Second, pre-treatment HIV RNA was associated with greater [11C] PBR28 
VT(DVR) in the occipital lobe and parietal lobe. Interestingly, lower nadir CD4 count was 
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not significantly associated with [11C] PBR28 VT(DVR) in any brain region evaluated. 
Finally, associations between any other HIV clinical parameters and [11C] PBR28 
VT(DVR) including, type of cART and years since HIV-infection or years since starting 
cART were not observed (P=> 0.1). 
The individual evaluation of HIV-infected participants showed that HIV-infected 
individuals with greater [11C] PBR28 VT(DVR) binding (subjects: 06,11,10,13) had 
higher pre-treatment HIV-RNA compared to HIV-infected individuals with lower [11C] 
PBR28 VT binding. Associations between other HIV clinical parameters and [
11C] 
PBR28 VT were not identified. Parametric [
11C] PBR28 VT maps, clinical and cognitive 
data for each HIV-infected individual enrolled in the study are presented in Figure 
3.8,and Table 3.2 
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Figure 3.8 PBR28 statistical parametric maps, clinical and cognitive parameters for each HIV-infected participant enrolled 
in the study   
       
 
[Legend Figure 3.8: Parametric maps superimposed over a T1 MRI image form the MNI152 atlas, showing areas of increase PBR28 binding; 
for DET, IDN, CPAL and GMLT: lower scores=better performance; for OCL, ONB and ISLT: higher score=better performance; yellow indicates 
areas with greater binding] 
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01 High 39 900 0.70 350 n/a 15 2.434 2.63 106 44 1.074 1.322 30 
02 High 45 700 0.82 110 69388 13 2.588 2.754 9 51 1.009 1.393 24 
0
0
V
T 
V
T 
8 
0 
Subject 01 
8 
0 
Subject 02 
 83 
Figure 3.8 (Continued) 
  
  
[DET, IDN, CPAL and GMLT: lower scores=better performance; for OCL, ONB and ISLT: higher score=better performance] 
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treatment 
HIV RNA 
(copies/mL) 
Years 
since 
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03 High 43 350 0.74 150 151 3 2.404 2.667 78 47 1.034 1.393 28 
04 Mixed 39 730 0.75 220 57998 16 2.498 2.714 73 51 1.0 1.322 27 
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Figure 3.8 (Continued) 
  
 
[DET, IDN, CPAL and GMLT: lower scores=better performance; for OCL, ONB and ISLT: higher score=better performance] 
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Current 
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HIV RNA 
(copies/mL) 
Years 
since 
cART 
DET 
 
IDN 
 
CPAL 
 
GMLT 
 
OCL 
 
ONB 
 
ISLT 
 
05 High 49 500 0.36 228 261970 3 2.64 2.814 2 76 1.13 1.226 27 
06 High 49 720 0.72 250 1624782 19 2.429 2.675 233 40 1.101 1.322 28 
0
0
V
T
 
V
T
 
8 8 
0 0 
Subject 05 Subject 06 
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Figure 3.8 (Continued) 
  
 
 
[DET, IDN, CPAL and GMLT: lower scores=better performance; for OCL, ONB and ISLT: higher score=better performance] 
  
Study 
case  
PBR28 
affinity  
Age 
(years) 
Current 
CD4 
(cells/mL) 
CD4/CD8 
ratio 
Nadir CD4 
(cells/mL) 
Pre-
treatment 
HIV RNA 
(copies/mL) 
Years 
since 
cART 
DET 
 
IDN 
 
CPAL 
 
GMLT 
 
OCL 
 
ONB 
 
ISLT 
 
07 High 43 1240 0.72 345 35000 2 2.523 2.742 44 64 1.021 1.322 29 
09 Mixed 46 150 0.70 70 38529  3 2.426 2.703 168 58 1.034 1.269 31 
0 0
V
T 
VT 
8 8 
0 0 
Subject 07 Subject 09 
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Figure 3.8 (Continued) 
   
 
 
 
 
 
 
 
[DET, IDN, CPAL and GMLT: lower scores=better performance; for OCL, ONB and ISLT: higher score=better performance] 
  
Study 
case  
PBR28 
affinity  
Age 
(years) 
Current 
CD4 
(cells/mL) 
CD4/CD8 
ratio 
Nadir CD4 
(cells/mL) 
Pre-
treatment 
HIV RNA 
(copies/mL) 
Years 
since 
cART 
DET 
 
IDN 
 
CPAL 
 
GMLT 
 
OCL 
 
ONB 
 
ISLT 
 
10 Mixed 40 600 0.50 130 452457  16 2.407 2.578 48 61 1.009 1.393 28 
11 High 44 440 0.67 160 187890 4 2.448 2.756 268 44 1.06 1.189 25 
0
0
V
T
 VT 
8 8 
0 
0 
Subject 10 
Subject 11 
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Figure 3.8 (Continued) 
  
 
 
[DET, IDN, CPAL and GMLT: lower scores=better performance; for OCL, ONB and ISLT: higher score=better performance] 
 
Study case  
PBR28 
affinity  
Age 
(years) 
Current 
CD4 
(cells/mL) 
CD4/CD8 
ratio 
Nadir CD4 
(cells/mL) 
Pre-
treatment 
HIV RNA 
(copies/mL) 
Years 
since 
cART 
DET 
 
IDN 
 
CPAL 
 
GMLT 
 
OCL 
 
ONB 
 
ISLT 
 
12 High 49 160 0.15 100 N/A 6 2.401 2.732 5 132 0.987 1.571 23 
13 Mixed 49 690 0.40 240 500000 3 2.516 2.724 1.28 42 1.101 1.571 27 
0
0
V
T V
T
 8 
8 
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Subject 12 Subject 13 
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3.4 Discussion 
In this study using [11C] PBR28 as an in vivo biomarker of TSPO expression, I 
investigated the presence of microglial activation in individuals with chronic HIV-
infection, stable on effective cART, without cognitive or neurological symptoms. 
When compared to HIV-negative control subjects, matched for age and gender, I 
found evidence of microglial activation in HIV-infected subjects.  
 
Unlike, previous reports on TSPO expression in neuroasymptomatic HIV-infected 
individuals; I observed increases in microglial activation, in several cortical and 
subcortical structures. The strongest signal for neuroinflammation is coming from 
subcortical brain regions, particularly basal ganglia structures (globus pallidus, 
caudate and striatum). These provide a link between in vivo microglial activation and 
evidence from neuropathological and MRS imaging studies, showing involvement of 
basal ganglia structures in HIV-infected individuals with and without HIV-associated 
brain disease (12, 228).  
 
Although in HIV-infected subjects TSPO expression was increased in most brain 
regions, I identified three brain structures (temporal lobe, midbrain and the right 
amygdala) with reduced TSPO expression in HIV-infected subjects compared to 
controls. To my knowledge, this is the first time reduced TSPO expression has been 
identified in the brains of HIV-infected subjects compared to HIV-negative controls. 
Brain regions with presence of both reduced and increased microglial activation 
could indicate that microgial activation is exhibiting different responses to HIV 
infection of the brain. In vitro studies of microglia have demonstrated that microglia 
from specific brain regions express different cell surface proteins (81), suggesting 
that in response to brain injury, microglia might express distinctive activation patterns 
in different brain regions. 
One important question is whether microglial activation (which could be of a more 
M1-phenotype) is detrimental or not to cognitive function and potentially a risk factor 
for the development of NCI. I found evidence that increase microglial activation was 
associated with poorer global cognitive function, mainly because of poorer 
performance in tasks evaluating verbal learning and memory.  Subcortical-frontal 
networks have been implicated with poorer performance in verbal learning and 
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memory (229). Performance of patients with abnormalities in this network, such poor 
attention, problem-solving difficulties and general problems with retention and recall, 
have been reported in HIV-infected subjects (30, 31, 230). Although, HIV-infected 
individuals had no evidence of NCI, the association between microglial activation in 
subcortical brain regions and poorer cognitive performance is interesting, further 
longitudinal data are essential to assess whether neuroinflammation can eventually 
lead to cognitive impairment.  
 
Finally, I found a strong relationship between microglial activation in several brain 
regions and two HIV clinical parameters: low CD4/CD8 ratio and high pre-treament 
HIV RNA. Regarding CD4/CD8 ratio, in virally suppressed HIV-infected subjects 
lower CD4/CD8 ratio has shown to independently predict immune activation (231) 
and non-AIDS comorbidities such as cardiovascular disease, bone disease, and NCI 
(232, 233). The association, between lower CD4/CD8 ratio greater [11C] PBR28 
VT(DVR) in several brain regions could indicate a direct relationship between an 
imaging marker of inflammation and an immunological marker of immune activation, 
consistent with abnormally persistent microglial activation. Individual analysis of HIV-
infected individuals revealed some interesting associations. HIV-infected subjects 
with greater pre-treatment HIV viral load were associated with greater PBR28 binding 
in most brain regions.  Although, subjects with greater levels of neuroinflammation 
were neurologically asymptomatic and had normal cognitive function by the study 
definition, they had more errors in a cognitive task evaluating visual and verbal 
memory (continuous paired associated learning task). One subject in particular, not 
only had more errors on the cognitive tasked describe before, but had reduced brain 
activation on fMRI when performing a task designed to evaluate sustained attention, 
the choice reaction time task. These findings suggest a possible detrimental effect of 
neuroinflammation on brain function. 
 
Despite studying individuals with a range of both high and low nadir CD4 T cell-
counts, I did not find associations between greater [11C] PBR28 total VT or VT(DVR) and 
nadir CD4 T-cell counts in any of the brain regions studied. Similarly when comparing 
HIV-infected individuals with low and high nadir CD4 T-cell counts, no differences in 
[11C] PBR28 total VT or VT(DVR) were observed. The lack of association with low nadir 
CD4 T cell-count could be due to the small sample size. 
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Pre-treatment HIV RNA has been proposed as a surrogate measure of an 
individual’s HIV-disease activity and a predictor of non-HIV associated diseases 
(234, 235). In this study I found that increase [11C] PBR28 VT(DVR) in the occipital and 
parietal lobes, caudate and striatum were associated with greater pre-treatment HIV 
RNA. These regions are the same regions that showed an increase in microglial 
activation compared to HIV-negative controls.  HIV enters the CNS early during 
infection, after entry, activated macrophages and microglia act as both the major 
targets for HIV-infection and a source of neurotoxins that eventually disrupts the 
blood brain barrier facilitating, brain infection (61). In this context higher plasma HIV 
RNA could cause more active virus to enter the brain, leading to significantly more 
microglial activation and early brain injury. The consequence of this process is likely 
to be persistent microglial activation despite effective cART.  
 
Limitations to this chapter include the small number of subjects recruited, restricting 
the power to detect other differences and associations. However, the sample size is 
similar to other TSPO PET studies. Also, the control group was only matched by age 
and sex, but not by other factors such as ethnicity and sexual orientation. Further 
limitations include the lack of cognitive data from the controls used for the [11C] 
PBR28 study and the absence of longitudinal follow-up PET data to identify any other 
changes in [11C] PBR28 VT. Finally, the control data provided by CogState to perform 
the cognitive analysis are only matched by age. 
 
Another important aspect is the potential effect of antiretroviral therapy on TSPO 
function. It is recognised mitochondrial toxicity can be induced by nucleoside reverse 
transcriptase inhibitors (NRTIs) (236). Nucleoside analogues inhibit HIV replication 
because of their affinity for the viral enzyme reverse transcriptase (viral DNA 
polymerase); However, NRTIs can also bind to other human DNA-polymerases like 
mitochondrial DNA polymerase gamma. By inhibiting mitochondrial DNA polymerase 
gamma, NRTIs can lead to depletion of mitochondrial DNA resulting in dysfunction of 
oxidase phosphorylation processes (237). Importantly, it appears that mitochondrial 
toxicity occurs only until a specific threshold of dysfunction has been reached (238). 
The affinity for the mitochondrial DNA polymerase determines the propensity of a 
NRTI drug to induce toxicity (239).  TSPO has been implicated with several important 
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mitochondrial processes including regulation of cellular respiration, energy production 
(185, 240), regulation of reactive oxygen species, apoptosis, and uptake of 
cholesterol to the mitochondria (241). It is possible that NTRIs such as tenofovir or 
abacavir affect TSPO expression that could affect the quantification of brain TSPO 
binding. Most patients in this study were on cART that contained a NRTI medication. 
The presence of increase TSPO signal in these patients could therefore had been 
influenced positively (increasing the expression of TSPO) or negatively (decreasing 
the expression of TSPO) by NRTI containing regiments. 
 
In summary, this study shows that neuroasymptomatic HIV-infected individuals on 
stable cART have an increase in TSPO expression, mostly in the basal ganglia and 
subcortical brain regions usually affected by HIV-brain disease. In these same 
regions [11C] PBR28 was associated with poorer cognitive function and alterations of 
clinical markers of HIV-disease activity (CD4/CD8 ratio and pre-treatment HIV RNA). 
This study addresses the first two hypotheses of my thesis, providing evidence that 
microglial activation is present in neuroasymptomatic individuals with treated chronic 
HIV-infection and that microglial activation may be detrimental to cognitive function.  
 
Longitudinal studies to detect disease progression from asymptomatic 
neuroinflammation to HIV-NCI using in vivo measurement of TSPO expression would 
be crucial to define the role of microglial activation in the pathogenesis of HIV brain 
disease. 
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  Table 3.1 HIV-infected subjects demographics and clinical parameters 
 
[Legend Table 3.1: TDF=tenofovir, DRV=darunavir, r=ritonavir, LOP=lopinavir, NP=Nevirapine, EFV=efavirenz, RLP=rilpivirine, ABC=abacavir, 
3TC= lamivudine, FTC= emtricitabine] 
Demographic / clinical parameter Median (range) unless otherwise stated 
Number, n 12 
Male gender, n (%) 12 (100) 
Age, mean years (SD) 42 (6.4) 
Ethnicity, n (%) 
White 
Black 
 
10 (83.3) 
2 (16.7) 
Education years, mean (SD) 12 (2.5) 
Current CD4/CD8 ratio,  0.7 (0.2-0.9) 
Current CD4 cell count (cells/uL) 645 (350-1240) 
Nadir CD4 cell count (cells/uL) 190 (70-350) 
Baseline plasma HIV RNA level<50 copies/mL, (%) 12 (100) 
Pre-treatment HIV RNA copy years (Log 10copies/mL)  5.0 (2.1- 6.2) 
Time-elapse since HIV diagnosis (years) 15 (2-19) 
Time-elapse since starting cART (years) 4 (2-16) 
Antiretroviral therapy, n (%) 12 (100) 
PI based, n(%) 4 (33) 
DRV/r 1 
DRV/r TDF FTC 2 
LOP/r TDF FTC 1 
NNRTI based, n(%) 8 (77) 
NVP TDF FTC 4 
NVP ABC 3TC 1 
EFV TDF FTC 2 
RLP TDF FTC 1 
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Table 3.2 Clinical parameters for each HIV-infected participant enrolled in the study 
 
 
Study case  PBR28 affinity  
Age 
(years) 
Current CD4 
(cells/mL) 
CD4/CD8 ratio 
Nadir CD4 
(cells/mL) 
Pre-treatment 
HIV RNA 
(copies/mL) 
Years since 
cART 
01 High 39 900 0.70 350 Not available 15 
02 High 45 700 0.82 110 69388 13 
03 High 43 350 0.74 150 151 3 
05 High 49 500 0.36 228 261970 3 
06 High 49 720 0.72 250 1624782 19 
07 High 43 1240 0.72 345 35000 2 
11 High 44 440 0.67 160 187890 4 
12 High 49 160 0.15 100 Not available 6 
04 Mixed 39 730 0.75 220 57998 16 
09 Mixed 46 150 0.70 70 38529  3 
10 Mixed 40 600 0.50 130 452457  16 
13 Mixed 49 690 0.40 240 500000 3 
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Table 3.3 Neurocognitive testing results for HIV-infected subjects vs HIV-negative controls 
 
[Legend Table 3.3: * Independent t-test analysis between HIV and normative data from HIV-negative individuals provided by CogState (n=873), 
P<0.05 considered significant] 
 
 
 
Task performed 
 
Unit of 
measurement 
 
Cognitive function 
tested 
 
Interpretation of score 
 
HIV–infected 
Mean (SD) 
 
 
Normative data* 
Mean (SD) 
 
 
Significance  
P=value 
Speed and visual attention       
 
Detection (DET) 
 
Log10 milliseconds   Speed of processing 
Lower score=better 
performance 
 
2.49(0.08) 
  
2.49(0.09) 
 
  
0.867 
 
 
Identification (IDN) 
 
Log10 milliseconds 
Attention 
Lower score=better 
performance 
 
2.71(0.64) 
2.70(0.07) 
 
0.912 
 
Executive function       
 
Groton maze learning test 
(GMLT) 
 
Total errors Executive function 
Lower score=better 
performance 
 
52.2(13.02) 
    55.3(22.42) 
 
         0.391 
 
 
Continuous paired learning 
(CPAL) 
 
Total errors 
Paired associated 
learning and memory 
Lower score=better 
performance 
 
    73.1(81.3) 
                                               
8.78 (10.23) 
 
                                           
0.004 
 
Accuracy and visual learning       
 
One card memory (OCL) 
 
Arcsine proportion 
correct 
Visual learning/memory 
Higher score=better 
performance 
 
1.06(0.044) 
 
1.01(0.12) 
 
 
0.591 
 
 
One back memory (ONB) 
 
Arcsine proportion 
correct 
Working memory  
Higher score=better 
performance 
 
1.32(0.077) 
1.34(0.19) 
 
0.392 
 
Memory and verbal learning       
 
International shopping list task 
(ISL) 
 
Number of correct 
responses 
Verbal learning/memory 
Higher score=better 
performance 
 
27.2(2.1) 
22.79(5.4) 
 
0.812 
 
 
International shopping list- recall 
(ISLR) 
 
 
Number of correct 
responses 
Verbal learning/memory 
Higher score=better 
performance 
 
10(1.7) 8.29(3.16) 
 
0.563 
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Table 3.4. Neurocognitive testing results for each HIV-infected participant enrolled in the study 
 
 
[Legend Table 3.4: Results presented here are the scores from cognitive tasks evaluated in the study, details of each score and domains 
evaluated are presented in Table 3.3] 
 
 
Study case 
DET 
Lower 
score=better 
performance  
IDN 
Lower 
score=better 
performance  
CPAL 
Lower 
 score=better 
performance  
GMLT 
Lower 
score=better 
performance  
OCL 
Higher 
score=better 
performance  
ONB 
Higher 
score=better 
performance  
ISLT 
Higher 
score=better 
performance  
01 2.434 2.63 106 44 1.074 1.322 30 
02 2.588 2.754 9 51 1.009 1.393 24 
03 2.404 2.667 78 47 1.034 1.393 28 
05 2.64 2.814 2 76 1.13 1.226 27 
06 2.429 2.675 233 40 1.101 1.322 28 
07 2.523 2.742 44 64 1.021 1.322 29 
11 2.448 2.756 268 44 1.06 1.189 25 
12 2.401 2.732 5 132 0.987 1.571 23 
04 2.498 2.714 73 51 1.009 1.322 27 
09 2.426 2.703 168 58 1.034 1.269 31 
10 2.407 2.578 48 61 1.009 1.393 28 
13 2.516 2.724 1.28 42 1.101 1.571 27 
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Table 3.5 Composite (Z-scores) neurocognitive group results for HIV-infected individuals 
 
 
[Legend Table 3.5: Composite mean scores for the normative data equal to zero (standardized Z-scores), SD not available from CogState, 
therefore it is not possible to obtain Z-scores to perform statistical comparisons with HIV-infected cases] 
  
Composite Interpretation of score 
HIV-infected cases 
Mean (SD) 
Speed: (DET+IDN) Lower score=better performance 0.03(0.09) 
Accuracy and visual learning: (OCL+ONB) Higher score=better performance 0.2(0.5) 
Memory and verbal learning: (ISL+ISLR) Higher score=better performance 0.001(0.8) 
Executive function: (CPAL+GMLT) Lower score=better performance 0.2 (0.5) 
Global composite score: 
(DET+IDN+OCL+ONB+ISL+ISLR+CPAL+GMLT) 
Higher score=better performance -0.006(0.3) 
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 Table 3.6 Regional [11C] PBR28 VT(DVR) in HIV-infected subjects vs HIV negative controls  
 
[Legend Table 3.6: Factorial ANOVA analysis of comparing PBR28 binding between HIV-infected cases vs controls using genotype 
as a fixed factor] 
 
Brain region HIV HABs Control HABs HIV MABs Control MABs F Mean square 
Significance 
(P-value) 
 
Mean SD Mean SD Mean SD Mean SD 
   
Frontal_Lobe 0.99 0.02 1.01 0.04 0.97 0.02 0.99 0.01 1.88 0.002 0.187 
Parietal_Lobe 0.96 0.02 0.99 0.02 0.94 0.02 1.00 0.01 27.99 0.010 0.001 
Occipital_Lobe 0.97 0.03 1.03 0.04 1.05 0.04 1.04 0.03 1.75 0.002 0.203 
Cingulate_ctx 1.07 0.02 1.06 0.05 1.01 0.06 1.02 0.01 0.00 0.000 0.983 
Insular_ctx 1.08 0.04 1.08 0.05 1.03 0.13 1.06 0.08 0.35 0.002 0.562 
Temporal_Lobe 1.05 0.02 0.97 0.05 1.06 0.02 0.98 0.02 22.02 0.033 0.001 
Hippocampus 1.10 0.07 1.06 0.11 1.07 0.11 1.04 0.08 0.63 0.006 0.439 
Amygdala 1.20 0.07 1.13 0.18 1.12 0.16 1.08 0.05 0.79 0.015 0.386 
Subcortical 1.04 0.06 1.07 0.08 1.00 0.12 1.04 0.02 0.93 0.006 0.348 
Thalamus 1.20 0.07 1.21 0.11 1.08 0.15 1.15 0.03 0.96 0.010 0.341 
Basal_Ganglia 0.91 0.05 0.97 0.07 0.96 0.11 0.94 0.03 0.36 0.002 0.557 
Striatum 0.91 0.05 0.96 0.07 0.96 0.12 0.94 0.03 0.23 0.001 0.636 
Putamen 0.97 0.03 1.04 0.09 1.02 0.08 1.02 0.06 1.34 0.006 0.263 
Caudate 0.80 0.14 0.80 0.09 0.82 0.23 0.82 0.08 0.00 0.000 0.960 
Globus_Pallidus 1.04 0.09 1.24 0.20 0.95 0.06 1.04 0.04 5.22 0.102 0.035 
Cerebellum 1.01 0.03 1.02 0.05 1.03 0.03 0.96 0.04 3.67 0.006 0.071 
Brain_Stem 1.27 0.13 1.28 0.15 1.19 0.07 1.18 0.11 0.00 0.000 0.971 
Midbrain 1.38 0.09 1.29 0.11 1.35 0.14 1.24 0.10 4.78 0.055 0.042 
Pons 1.29 0.19 1.30 0.17 1.12 0.10 1.17 0.12 0.14 0.004 0.715 
Medulla 1.12 0.24 1.25 0.20 1.18 0.09 1.20 0.20 0.71 0.029 0.409 
White matter 0.95 0.03 0.95 0.05 0.99 0.03 0.94 0.02 1.80 0.003 0.196 
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Table 3.7 Correlation coefficients (r) between [11C] PBR28 VT(DVR) and neurocognitive testing,  adjusted for TSPO affinity 
status and education years 
 
[Legend Table 3.7: Results of correlation analyses between PBR28 binding and neurocognitive testing results adjusted for TSPO status.  
*P<0.05, ** P<0.1;DET: detection, IDN: identification, CPAL: Continuous paired learning, GMLT: Groton maze learning test, OCL: one card 
memory, ONB: one back memory, ISLT: international shopping list task, ISLTR: international shopping list task-recall; 88 correlation coefficients 
were calculated (11 brain regions multiplied by 8 cognitive tasks)] 
 
 
Region DET IDN CPAL GMLT OCL ONB ISLT ISLR 
Occipital lobe -0.590* -0.526** -0.115 -0.031 0.536** -0.178 0.186 -0.547** 
Hippocampus -0.141 -0.185 0.123 -0.571** -0.017 0.208 -0.659* -0.657* 
Amygdala_R 0.472 0.160 0.005 -0.660* -0.201 0.461 -0.567** -0.752* 
Thalamus_L 0.593* 0.122 0.243 -0.676* -0.357 0.282 -0.041 -0.539** 
Striatum 0.572** 0.312 -0.119 -0.311 0.152 0.268 0.176 -0.570** 
Putamen 0.783* 0.430 -0.323 -0.20 -0.30 0.332 0.076 -0.612* 
Globus pallidus 0.107 -0.146 -0.447 -0.005 0.640* -0.311 0.175 -0.146 
Midbrain 0.290 0.218 0.022 -0.534** -0.23 0.521 -0.554** -0.648* 
Medulla 0.191 0.053 0.350 -0.639* -0.219 0.392 -0.589* -0.685* 
White matter 0.477 -0.030 0.134 -0.573** -0.381 0.142 -0.493 -0.635** 
Subcortical 0.517 0.088 0.040 -0.565** -0.094 0.206 -0.029 -0.591* 
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Table 3.8 Correlation coefficients (r) between [11C] PBR28 VT(DVR)  and composite neurocognitive Z-scores adjusted for 
TSPO affinity status and education years 
 
[Legend Table 3.8: Results of correlation analyses between PBR28 binding and neurocognitive testing Z-scores results adjusted for TSPO 
status *P<0.05, ** P<0.1; 55 correlation coefficients were calculated (11 brain regions multiplied by 5 cognitive composite domains)]  
 
 
 
 
 
Region Composite Speed 
Composite accuracy 
and visual learning 
Composite memory 
and verbal learning 
Composite executive 
function 
Global cognitive 
score 
Occipital lobe 0.072 -0.602* 0.145 0.301 0.390 
Hippocampus -0.771* -0.175 -0.624* -0.156 -0.624* 
Amygdala_R -0.750* 0.403 -0.636* 0.210 -0.635* 
Thalamus -0.609* 0.250 -0.650* -0.023 -0.651* 
Parietal lobe 0.269 -0.506 0.090 -0.534* 0.244 
Putamen_L 0.075 0.658* 0.130 0.247 -0.135 
Midbrain -0.689* 0.275 -0.518 0.408 -0.528** 
Medulla -0.749* 0.133 -0.672* 0.139 -0.672* 
White matter -0.665* 0.248 -0.681* -0.200 -0.681* 
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Table 3.9 Correlation coefficients (r) between [11C] PBR28 VT(DVR)  and HIV clinical parameters adjusted for TSPO affinity 
status 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
[Legend Table 3.9: Results of correlation analyses between PBR28 binding and clinical characteristics of HIV infected individuals adjusted for 
TSPO status. *P<0.05, ** P<0.1; 48 correlation coefficients were calculated (12 brain regions multiplied by 4 HIV clinical parameters)] 
 
Region Current CD4 T-cell count 
Nadir CD4 
T-cell count 
CD4/CD8  
ratio 
Pre-treatment HIV RNA 
Occipital lobe -0.181 -0.408 0.175 0.684* 
Hippocampus    -0.533** -0.572** -0.596* -0.003 
Parietal lobe -0.146 0.483 0.100 0.662* 
Temporal lobe -0.177 0.500 -0.553** 0.284 
Amygdala_L -0.599* -0.529** -0.759* 0.259 
Thalamus_L 0.285 -0.24 -0.525* -0.214 
Caudate_R 0.059 0.507 -0.308  0.600** 
Basal ganglia 0.230 0.315 -0.555** -0.080 
Striatum -0.137 0.221 0.333    0.604** 
Putamen -0.084 0.453 0.562 0.040 
Globus pallidus -0.243 0.315 0.059 0.115 
Midbrain 0.040 -0.068 -0.732* -0.062 
Medulla -0.633* 0.089 -0.740* 0.263 
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4.1 Introduction 
Neuroimaging techniques that allow the evaluation of brain function, brain 
metabolism and white matter integrity can improve our understanding of cognitive 
deficits in HIV-infected individuals with HIV-associated brain disease. 
 
Several advanced MRI techniques have been developed that can noninvasively 
evaluate brain function, chemistry and structure. fMRI allows the mapping of 
activated brain regions when subjects are either at rest or performing a particular 
cognitive task. DTI evaluates white matter integrity in vivo, while MRS detects 
changes in cerebral chemical concentrations. All these techniques have been used 
independently to study HIV-associated brain disease in both treated and untreated 
HIV-infected individuals (Chapter 1, section 1.5). However, the correlations between 
microglial activation measured by TSPO PET CT imaging and MRI biomarkers of 
function, chemistry, and structure have not been evaluated to date. 
 
To study the second hypothesis of this thesis, this study aimed to investigate whether 
microglial activation measured by [11C] PBR28 PET CT is associated with 
abnormalities of structural, metabolic and functional imaging parameters on MRI in 
neuroasymptomatic HIV-infected individuals on effective cART. 
 
4.2 Methods 
12 HIV-infected subjects that participated in the [11C] PBR28 PET CT study 
presented in Chapter 3, underwent brain MRI scans at Imanova. All subjects 
completed one MRI imaging assessment including: [1H]-MRS, fMRI and DTI. Data 
acquisition parameters for the MRI methods employed in this study are described in 
detail in section 2.3.2. All subjects completed the MRI scans before the PET CT was 
performed 
4.2.1 Functional magnetic resonance imaging 
4.2.1.1 Resting magnetic resonance imaging  
Analysis were carried out using Tensorial Independent Component Analysis (ICA) 
(242) as implemented in MELODIC (Multivariate Exploratory Linear Decomposition 
into Independent Components) Version 3.13, part of FSL (FMRIB's Software Library, 
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www.fmrib.ox.ac.uk/fsl). The following data pre-processing was applied to the input 
data: masking of non-brain voxels; voxel-wise de-meaning of the data and 
normalisation of the voxel-wise variance.  
 
Temporal concatenation ICA was performed across all functional datasets from each 
subject using automatic dimensionality estimation. Pre-processed data were 
whitened and projected into a 15-dimensional subspace using Principal Component 
Analysis.   The whitened observations were decomposed into sets of vectors which 
describe signal variation across the temporal domain (time-courses), the 
session/subject domain and across the maps by optimising for non-Gaussian spatial 
source distributions using a fixed-point iteration technique (243). Estimated 
component maps were divided by the standard deviation of the residual noise and 
thresholded by fitting a mixture model to the histogram of intensity values P<0.05 
(244). The default mode network was identified by visual inspection and compared to 
previously published data (169). Individual Z-values of the independent component 
representing the default mode network were tested for correlations with [11C] PBR28 
total VT and VT(DVR) values from brain regions that demonstrated increase and 
decrease [11C] PBR28 VT(DVR) binding in the PET study presented in Chapter 3. 
Partial correlation analysis was performed adjusting for TSPO affinity status. 
4.2.1.2 Task functional MRI  
Two different analyses were performed: First, I employed a model-based fMRI data 
analysis using the FEAT (FMRI Expert Analysis Tool), which is part of the FSL 
software. FEAT is based on a general linear modeling (GLM) otherwise known as 
multiple regression analysis. Higher-level analyses such as mean group effect, and 
the effect of clinical and other imaging covariates were conducted using FLAME 
(FMRIB’S Local Analysis of Mixed Effects) (242). Final statistical images were 
thresholded (Gaussian random field-based cluster) using clusters determined by 
Z≥2.3 and a cluster significance threshold of P<0.005 corrected for multiple 
comparisons. This resulted in two statistical maps of voxels, one map of voxels 
significantly activated by the choice reaction time task and a separate map of voxels 
showing relative deactivation on the same task. 
For the second analysis, I used FSL tool (Featqueary) to extract the time series 
within selected ROI having pre-processed and performed the group analysis of the 
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raw fMRI data from each participant. The region of interest selected for this analysis 
where regions with significant increase and decrease in [11C] PBR28 VT in HIV-
infected subjects. Using the extracted time series, linear correlation analysis was 
performed between the time series values in each ROI and clinical parameters and 
other quantifiable imaging measurements. 
4.2.2 Diffusion tensor imaging  
Diffusion-weighted images were registered to the b=0 image by affine 
transformations to minimise distortion due to motion and eddy currents, and then 
brain-extracted using the Brain Extraction Tool (BET), part of the FSL image 
processing toolbox (216, 245). DTI parameter maps were generated using FMRIBs 
Diffusion Toolbox (FDT) in FSL for FA (fractional anisotropy) and MD (mean 
diffusivity). The FA and MD output images were used as input for tract-base spatial 
statistics, a voxelwise approach for analysis of FA and MD data (246). A mean FA 
and MD image were created and thinned to create a mean FA and MD skeleton that 
represents the centers of all tracts common to the group. Each subject's aligned FA 
data was then projected onto this skeleton. Next the individual subject was registered 
and projected onto the group mean FA and MD skeleton. Mean FA and MD in major 
white matter tracts for the HIV-infected subjects were calculated by projecting each 
individual skeleton through masks for the major white matter tracts contained within 
the JHU white-matter tractography atlas, alongside additional cortico-thalamic and 
trans-collosal tracts defined by tractography (247, 248).  
 
FA and MD data from the HIV-infected group were compared with data from 10 
aged-matched, HIV-negative controls available from Imanova. HIV-negative controls 
employed the same MRI scanner, and imaging acquisition data used in my study. 
Independent t-test was used to compare both study groups. P=<0.05 were 
considered significant at a 95% confidence interval.  
4.2.3 Cerebral protron spectroscopy ([1H]-MRS) 
Details of data acquisition are described in section 2.3.2. All spectra were analyzed 
and quantified by a single observer (J.V.). The data were processed and ﬁtted with 
TARQUIN (version 4.1.1) software (249, 250). The ﬁtting was performed with the 
standard metabolite library provided by TARQUIN, which consisted on 16 different 
metabolites and nine lipids and macromolecular components (Figure 4.1). A 
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simulated negative singlet at 3.94 parts per million (ppm) (-CrCh2) was included to 
account for attenuation of the CH2 peak of Cr. 
 
Figure 4.1. An example fit plot of a HIV-infected individual frontal white matter 
spectra, using TARQUIN. 
           
 
[Legend Figure 4.1. Tarquin performs the fitting of cerebral metabolite peaks, 
allowing the calculation of the cerebral metabolites. Tope line is the residual obtained 
after the fitting process  [ppm=part per million; a.u= arbitrary units] 
 
The quantitation of metabolites was performed using the spectrum acquired without 
water suppression as reference. Two quality control criteria were taken into account 
in order to include the samples in the analysis: (1) A quality ﬁt (Q) lower or equal to 2, 
where Q is supplied by TARQUIN and defined as the standard deviation of the 
frequency domain residual between 0.2 and 4.0 ppm divided by the standard 
deviation of the spectral noise (249, 251); and (2) a signal-to-noise ratio (SNR) of the 
spectra greater than 5. The following metabolites were investigated: NAA, Cr, Cho 
and mI. All metabolites were expressed as ratios with respect to cerebral Cr. 
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4.2.4 Statistical analysis 
Associations between MRI imaging parameters and [11C] PBR28 VT and HIV-related 
clinical parameters were performed using partial correlation analysis adjusted for 
TSPO affinity status. Multiple comparisons were corrected by bootstrapping (252). P 
values below 0.05 were considered statistically significant. 
4.3 Results 
4.3.1 Functional MRI 
4.3.1.1 Resting functional MRI  
After decomposition of the functional data by means of ICA 15 independent 
components were obtained. The DMN was identified by visual inspection as the 
network comprising the anterior cingulate cortex, posterior cingulate cortex, the 
precuneus and lateral parietal inferior gyri (Figure 4.2). 
 
Figure 4.2 Spatial map of the default mode network (DMN) of HIV-infected 
individuals. 
 
 
 
[Legend Figure 4.2: Hot colours represent brain activation in the brain areas associated with 
the default mode network: posterior cingulate cortex, retrosplenial cortex, ventromedial 
prefrontal cortex, medial temporal lobe and ventral precuneous. The DMN are active when 
the individual is in a wakeful rest. In this study participants were instructed to close their eyes 
during scanning]  
6"1.87"
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Associations between BOLD signal in the default mode network and [11C] 
PBR28 VT(DVR)  
 
No significant correlations between [11C] PBR28 VT(DVR) in any brain region (regions 
and BOLD signal in the default mode network were observed (Table 4.1). No 
significant associations between PBR28 binding and the default mode network were 
identified in the resting fMRI data of each HIV-infected participant enrolled in the 
study  
4.3.1.2 Task functional MRI 
 
Brain activation in HIV-infected individuals following a choice reaction time 
task 
A pattern of activation within bilateral motor and sensory regions, including superior 
parietal, frontal, occipital regions and the thalamus were observed in the whole brain 
event-related analysis (task-on). This pattern of activation is similar to the one 
reported in HIV-negative individuals performing an almost identical CRT task (253). 
In HIV-infected individuals task-related activation was also present in the basal 
ganglia (Figure 4.3). As expected, task-related deactivation (task-off), showed 
deactivation within sensory-motor areas. 
 
Brain activation on each HIV-infected participant enrolled in the study 
following a choice reaction time task 
 
When looking at the pattern of brain activation of each HIV-infected subject, there 
were no differences among subjects with motor and sensory regions being activated 
during the task. However, subject 06 showed a clear pattern of reduced brain 
activation during the choice reaction task (Figure 4.4). This HIV-infected participant is 
had the greatest degree of PBR28 binding in the PET study presented in Chapter 3 
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Figure 4.3 Statistical maps of task-induced brain activation in HIV-infected 
individuals 
 
                   
 
        
 
[Legend Figure 4.3: Statistical maps of task-induced brain activation in HIV-infected 
individuals. Task induced brain activation for HIV-infected individuals (a) voxels showing 
significant brain activation during the choice reaction task versus ‘rest’; (b) Brain activation 
observed in thalamus and the basal ganglia (MNI coordinates Z=40). A standard Z-statistic 
threshold of 2.3 was used combined with a corrected cluster significance threshold 
probability of P<0.005. Results are shown superimposed on sagittal and axial slices of the 
MNI 152 T1 1-mm brain template 
.
(a) 
(b) 
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Figure 4.4. Statistical maps of task-induced brain activation of study case 06  
      
 
 
 
  
[Legend Figure 4.4:(a)Task induced brain activation for subject 06 (a) voxels showing reduced brain activation during the choice reaction task 
versus rest];(b). HIV-clinical parameters for subject 06.This subject had the highest degree of PBR28 binding on CT PET imaging]  
Study case  PBR28 affinity  
Age 
(years) 
Current CD4 
(cells/mL) 
CD4/CD8 ratio 
Nadir CD4 
(cells/mL) 
Pre-treatment 
HIV RNA 
(copies/mL) 
Years since 
cART 
06 High 49 720 0.72 250 1624782 19 
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Associations between task-related brain activation and cognitive function  
 
A significant correlation between greater activation in the left frontal and left parietal 
lobes, and cognitive performance in tasks evaluating speed of processing information 
(detection and identification) was observed in the voxelwise analysis (Figure 4.5). No 
significant associations between task-related activation and cognitive function were 
identified in the individual analysis of HIV-infected participants. 
  
Figure 4.5 Statistical maps of correlations between task-related brain activation 
and tasks evaluating speed of processing information. 
 
[Legend Figure 4.5: (a) Voxels showing significant correlation between brain activation in the 
left frontal and parietal lobes and performance on IDN task. (b) voxels showing significant 
correlation between brain activation in the left parietal lobe and performance on DET task. 
MNI coordinates for brain slices are shown. IDN=identification, DET=detection. Statistic 
images were thresholded using clusters determined by Z>2.3 and a (corrected) cluster 
significance threshold of P=0.05] 
 
DE
T 
Z=4
9 
(b
) 
ID
N 
Z=4
5 
(a
) 
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Associations between [11C] PBR28 VT(DVR)  and task-related brain activation  
 
Associations between [11C] PBR28 VT(DVR) and task-related brain activation overall 
were not observed in the group voxelwise analysis. However, the ROI analysis 
showed a significant correlation between increase [11C] PBR28 VT(DVR) in the globus 
pallidus, hippocampus, caudate and reduced task-related brain activation in basal 
ganglia structures, see Table 4.2.  No significant associations between task-related 
activation and PBR28 binding were identified in the individual analysis of HIV-
infected participants. 
 
Associations between task-related brain activation and HIV clinical parameters 
 
No significant associations between task-related brain activation and HIV-clinical 
parameters including nadir CD4 count, current CD4 count, CD4/CD8 ratio, pre-
treatment HIV RNA, years since HIV diagnosis and years since cART were observed 
in both the group voxelwise and ROI analysis (P=>0.1, for all observations). No 
significant associations between task-related activation and HIV-clinical parameters 
were identified in the individual analysis of HIV-infected participants. 
4.3.2 Diffusion tensor imaging  
 
FA and MD values for HIV-infected subjects and HIV-negative controls are presented 
in Table 4.3 and Table 4.4 
A trend towards reduced FA in the HIV-infected group compared with HIV-negative 
controls was observed across all the evaluated white matter tracts after correcting for 
multiple comparisons, with significant reduced FA in the splenium of the corpus 
callosum (P=0.04) and the right superior temporal fasciculus (P=0.05).  A trend 
towards increase MD was also observed in several white matter tracts in HIV-
infected individuals when compared to HIV-negative controls (Table 4.4).  
 
Associations between DTI parameters and [11C] PBR28 VT(DVR) for HIV-infected 
patients: 
I investigated associations between brain regions that in the PET analysis showed 
significantly greater [11C] PBR28 VT(DVR) when compared to controls (basal ganglia, 
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globus pallidus, amygdala, midbrain, and occipital, parietal, and temporal lobes) and 
DTI parameters.  
 
A significant correlation between increase [11C] PBR28 VT(DVR) in the amygdala and 
reduced FA in the cingulum cingulate (r=-0.525, P=0.001) and inferior longitudinal 
fasciculum (r=-0.537, P=0.001) white matter tracks was observed. When 
investigating associations between the brain regions of interest described above and 
MD, significant positive correlations between increase [11C] PBR28 VT(DVR)  in these 
regions and greater MD across several white matter tracks were observed (Table 
4.5).  No significant associations between DTI parameters and PBR28 binding were 
identified in the individual analysis of HIV-infected participants. 
 
Associations between DTI parameters and clinical parameters for HIV-infected 
patients 
Among clinical parameters for HIV-infected patients only CD4/CD8 ratio had 
significant correlations with DTI parameters. An increase in FA in several white 
matter tracts correlated with an increase in the CD4/CD8 ratio; left corticospinal 
(r=0.670, P=0.048), left superior longitudinal fasciculus (r=0.703, P=0.035), left 
uscinate fasciculus (r=0.661, P=0.052) and body of the corpus callosum (r=0.822, 
P=0.007). No other associations between HIV-clinical parameters and DTI 
parameters were observed in the group and individual analysis of HIV-infected 
participants enrolled in the study 
 
Associations between DTI parameters cognitive performance for HIV-infected 
patients 
 
A significant correlation between increase MD in white matter tracts and a cognitive 
task evaluating executive function/spatial problem learning, was observed.  
Reduced scores in the groton mask learning test (GMLT) (indicating poorer 
performance) was significantly associated with increase MD in the body of the corpus 
callosum (r= -0.532, P=0.092), left uscinate fasciculus (r=-0.578, P=0.063), left 
superior longitudinal fasciculus (r=-0.692, P=0.018), left superior longitudinal 
temporal fasciculus (r=-0.714, P=0.014) and left inferior fronto-occipital tract (r=-
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0.619, P=0.042). No significant associations between DTI parameters and cognitive 
function were identified in the individual analysis of HIV-infected participants 
4.3.3 Cerebral proton spectroscopy  
Results of baseline CMRs in the FWM and RBG for HIV-infected subjects are shown 
in Table 4.6. 
 
Associations between [11C] PBR28 VT(DVR)  and cerebral metabolite ratios in HIV-
infected patients 
 
A significant correlation between greater [11C] PBR28 VT(DVR)  in several brain regions 
and reduced mI/Cr and Cho/Cr in the RBG were observed, see Table 4.7. 
Interestingly, reduced NAA/Cr in the RBG correlated with greater [11C] PBR28 VT(DVR)  
in the putamen. There were no significant correlations between concentrations of any 
cerebral metabolites in the FWM and [11C] PBR28 VT(DVR); (P=>0.1), see Table 4.8 
4.7 Discussion 
In this study I investigated the relationship between microglial activation as measured 
by [11C] PBR28 and cerebral MRI biomarkers. This is the first study to describe the 
effects of microglial activation in vivo on brain activation, brain network connectivity, 
white matter structure, and cerebral metabolism in HIV-infected individuals stable on 
cART. 
 
I have made several interesting observations. First, I studied the effects of microglial 
activation on brain function using fMRI. Initially I investigated the effects of microglial 
activation on resting fMRI brain networks affected in HIV-infected individuals such as 
the default mode network (175). In this study, I found no associations between 
microglial activation and disruption of resting brain connectivity networks. However, 
in HIV-infected patients performing a cognitive task that evaluates sustained 
attention, a significant association between reduced brain activation in the basal 
ganglia and increased microglial activation in the globus pallidus and the caudate 
was observed. Traditionally, the basal ganglia has been associated with motor 
control (254). Although, basal ganglia structures play a critical role on motor 
execution and motor learning recent data suggest that they are also involved in 
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memory, attention, and learning that is not directly tied to motor functioning (255, 
256).  For instance, the caudate has been associated with instrumental learning 
where it is involved with integration of information about performance and cognitive 
control demands (257).   
 
Interestingly, a positive correlation between [11C] PBR28 VT(DVR) in the hippocampus 
and brain activation in the basal ganglia was observed. These results suggest that 
some brain regions are more susceptible to the effects of inflammation than others. 
This finding strengthens the observation from the PET study, that brain regions in 
HIV-infected individuals showed different degrees of microglial activation when 
compared to HIV-negative controls.  
 
I also examined the relationship between task-related brain activation and cognitive 
function using a voxelwise analysis. I observed an association between increase 
brain activation and performance on cognitive tests evaluating speed of processing 
information. Although all the HIV-infected individuals in this study were cognitively 
intact, a greater use of their brain capacity to maintain the task performance is 
suggested. These findings are consistent with those of other task-related fMRI 
studies and in HIV-infected individuals (163, 166) 
 
The second interesting observation was the relationship between microglial activation 
and white matter injury. First, I observed a trend towards a decrease in FA and 
increased MD in HIV-infected individuals compared to HIV-negative controls. White 
matter integrity was affected in temporal, parietal, occipital white matter regions 
including the corpus callosum.  These findings are consistent with previous reports 
demonstrating white matter injury in HIV-infected individuals despite effective cART 
(180). Most, notably in brain regions with an increase in microglial activation I 
observed a significant correlation between greater [11C] PBR28 VT and increased MD 
in most white matter regions examined.  
 
The observed deleterious effect of microglial activation on white matter is particularly 
noteworthy, as it suggests a direct effect of inflammation on white matter integrity in 
the brain of HIV-infected individuals on effective cART. The microstructural changes 
responsible for the abnormal diffusivity and anisotropy in HIV-infected patients are 
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unclear.  Inflammation has been demonstrated to increase tissue water affecting 
water diffusivity in animal models of brain inflammation (258) and disturbances in 
water diffusivity are known to reduce anisotropy and to increase mean diffusivity 
(259).   
 
I also explored the effects of abnormal white matter integrity on cognitive function 
and found a correlation between poorer performance on task evaluating executive 
function and increase MD in frontal, temporal and occipital white matter regions, 
including the corpus callosum. These results indicate that microglial activation affects 
white matter integrity, which could potentially lead to cognitive decline.  
 
Finally, I studied the relationship between microglial activation and cerebral 
metabolites as measured by cerebral proton spectroscopy. Surprisingly I found an 
increase in microglial activation to be associated with reduce cerebral metabolite 
markers of glial activation in the RBG. These results were unexpected as mI and Cho 
are cerebral metabolites known to be associated with neuroinflammation. A 
explanation for these results could be that the area investigated was not affected by 
microglial activation, especially because the voxel in the RBG was placed in the right 
thalamus, an area that did not show evidence of microglial activation compared to 
HIV-negative controls in the PET study. Alternatively, the degree of inflammation 
might not be sufficient to increase the concentrations of mI. 
 
The study described in this chapter has several limitations, and therefore data must 
be interpreted with caution. First, the small sample size limits the power to detect 
relationships. Second, I did not have control data from HIV-negative individuals for 
the fMRI and cerebral proton spectroscopy analyses; therefore, interpretation of the 
data is limited. However, as a proof of principle this study demonstrates the potential 
effect of microglial activation on cerebral function, structure and metabolism of HIV-
infected individuals on cART.  
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Table 4.1 Correlation coefficients (r) between [11C] PBR28 VT(DVR) and BOLD 
signal in the default mode network adjusted for TSPO affinity status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Legend Table 4.1: Correlation results between PBR28 binding in anatomical brain 
regions related to the default mode network and BOLD fMRI from the default mode 
network. P>0.1 for all regions investigated] 
Region 
Correlation coefficients  
(r) 
Occipital lobe 0.264 
Temporal lobe 0.259 
Parietal lobe 0.213 
Frontal lobe 0.255 
Anterior cingulate 0.246 
Posterior cingulate 0.264 
Basal ganglia 0.243 
Globus pallidus 0.212 
Midbrain 0.259 
Medulla 0.221 
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Table 4.2 Correlation coefficients (r) between [11C] PBR28 VT(DVR) and task-related brain activation adjusted for TSPO 
affinity status  
    
 
[Legend Table 4.2: Results of correlation analyses between PBR28 binging in selected brain regions and task-related brain activation results 
obtained using the FEAT tool from the FSL software; *P<0.05, ** P<0.1; 88 correlation coefficients were calculated ([11 C] PBR28(DVR) values 
from 11 brain regions multiplied by values from task related activation from 8 brain regions)] 
 
 
 
 
 
 
 
 
 
Brain region 
 
Subcortical 
 
Thalamus Striatum 
Globus 
pallidus 
Putamen Caudate Cingulate 
Basal 
ganglia 
Globus 
pallidus VT(DVR) 
-0.667** -0.712* -0.721* -0.546** -0.613* -0.800* -0.662** -0.650** 
Caudate  
VT(DVR) 
-0.125 -0.184 -0.233 -0.157 -0.131 -0.606* -0.395 -0.342 
Hippocampus  
VT(DVR) 
0.480 0.526 0.429 0.431 0.429 0.644* 0.545** 0.404 
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 Table 4.3 Fractional anisotropy (FA) results from independent t-test between HIV-infected subjects and HIV-negative 
controls 
 
 HIV-infected HIV-negative controls     
White matter tract Mean SD Mean SD 
Mean 
difference 
P= value CI (95%) 
Anterior thalamic left 0.49 0.02 0.50 0.02 -0.01 0.13 -0.03 -  0.00 
Cingulum cingulate left 0.53 0.02 0.55 0.03 -0.02 0.18 -0.04 - 0.01 
Cingulum hippocampus left 0.47 0.01 0.46 0.04 0.01 0.62 -0.02 - 0.03 
Corticospinal left 0.57 0.02 0.58 0.02 -0.01 0.29 -0.02 - 0.01 
Inferior fronto-occipital left 0.48 0.02 0.50 0.03 -0.02 0.07 -0.04 - 0.00 
Inferior longitudinal fasciculus left 0.47 0.02 0.49 0.03 -0.02 0.06 -0.04 - 0.00 
Superior longitudinal fasciculus left 0.48 0.02 0.49 0.03 -0.02 0.11 -0.04 - 0.00 
Superior fasciculus temporal left 0.49 0.02 0.50 0.03 -0.02 0.12 -0.04 - 0.01 
Uscinate fasciculus left 0.45 0.02 0.46 0.03 -0.01 0.23 -0.04 - 0.01 
Corpus callosum body 0.66 0.03 0.68 0.03 -0.02 0.17 -0.04 - 0.01 
Corpus callosum genu 0.60 0.02 0.61 0.03 0.00 0.64 -0.03 - 0.02 
Cospus callosum splenium 0.70 0.02 0.72 0.02 -0.02 0.04 -0.03 - 0.00 
Forceps major 0.57 0.05 0.57 0.02 0.00 0.88 -0.04 - 0.03 
Forceps minor 0.53 0.02 0.54 0.03 -0.01 0.32 -0.03 - 0.01 
Anterior thalamic right 0.49 0.02 0.46 0.03 -0.02 0.10 -0.04 - 0.00 
Cingulum cingulate right 0.52 0.02 0.50 0.03 -0.01 0.31 -0.04 - 0.01 
Cingulum hippocampus right 0.51 0.02 0.48 0.03 -0.01 0.20 -0.04 - 0.01 
Corticospinal right 0.57 0.02 0.49 0.02 -0.01 0.29 -0.03 - 0.01 
Inferior fronto-occipital right 0.49 0.02 0.51 0.03 -0.02 0.14 -0.04 -  0.01 
Inferior longitudinal fasciculus right 0.47 0.02 0.57 0.02 -0.01 0.49 -0.03 - 0.01 
Superior longitudinal fasciculus right 0.47 0.02 0.52 0.02 0.00 0.82 -0.02 - 0.02 
Superior fasciculus temporal right 0.48 0.02 0.55 0.03 -0.03 0.05 -0.05 - 0.00 
Uscinate fasciculus right 0.49 0.02 0.50 0.02 -0.01 0.33      -0.03 - 0.01 
 
[Legend Table 4.3 and 4.4: FA= fractional anisotropy; MD= mean diffusivity; SD=standard deviation; CI: coefficient interval]
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Table 4.4 Mean Diffusivity (MD) results from independent t-test between HIV-infected subjects and HIV-negative controls 
 HIV-infected HIV-negative controls     
White matter tract Mean (10
3
) SD Mean (10
3
) SD Mean difference P= value CI (95%) 
Anterior thalamic left 1.374 0.001 1.306 0.001 -0.0001 0.19 -0.0002 0.00 
Cingulum cingulate left 1.158 0.001 1.138 0.001 -0.0001 0.68 -0.0002 0.00 
Cingulum hippocampus left 1.913 0.001 1.668 0.002 0.0000 0.00 -0.0001 0.0001 
Corticospinal left 1.223 0.001 1.098 0.001 0.0000 0.00 -0.0001 0.0001 
Inferior fronto-occipital left 1.176 0.001 1.148 0.001 -0.0002 0.52 -0.0004 -0.0001 
Inferior longitudinal fasciculus left 1.247 0.001 1.188 0.001 -0.0002 0.20 -0.0004 -0.0001 
Superior longitudinal fasciculus left 1.089 0.001 1.067 0.001 -0.0001 0.62 -0.0002 0.00 
Superior fasciculus temporal left 1.072 0.001 1.043 0.001 -0.0001 0.47 -0.0002 0.00 
Uscinate fasciculus left 1.080 0.001 1.090 0.001 0.00 0.76 -0.0001 0.0001 
Corpus callosum body 1.763 0.001 1.604 0.002 0.00 0.02 -0.0001 0.0001 
Corpus callosum genu 1.407 0.002 1.392 0.002 -0.0001 0.85 -0.0002 0.00 
Cospus callosum splenium 1.875 0.001 1.683 0.001 -0.0001 0.01 -0.0002 0.00 
Forceps major 1.393 0.001 1.292 0.001 0.00 0.02 -0.0001 0.0001 
Forceps minor 1.214 0.002 1.221 0.001 0.00 0.90 -0.0001 0.0001 
Anterior thalamic right 1.393 0.001 1.287 0.001 0.00 0.04 -0.0001 0.0001 
Cingulum cingulate right 1.057 0.001 1.036 0.001 0.00 0.48 -0.0001 0.0001 
Cingulum hippocampus right 1.752 0.001 1.509 0.001 0.00 0.01 -0.0001 0.0001 
Corticospinal right 1.236 0.001 1.104 0.001 0.00 0.01 -0.0001 0.0001 
Inferior fronto-occipital right 1.185 0.001 1.132 0.001 -0.0002 0.14 -0.0003 0.00 
Inferior longitudinal fasciculus right 1.294 0.001 1.221 0.001 -0.0002 0.07 -0.0003 0.00 
Superior longitudinal fasciculus right 1.088 0.001 1.051 0.001 0.00 0.40 -0.0002 0.0002 
Superior fasciculus temporal right 1.035 0.001 9.945 0.001 0.00 0.30 -0.0002 0.0002 
Uscinate fasciculus right 1.123 0.001 1.086 0.001 -0.0002 0.33 -0.0003 -0.0001 
[Legend Table 4.4: *P<0.05, ** P<0.1; 22 correlation coefficients were calculated per brain region ([11 C] PBR28(DVR) values from one brain 
region multiplied by parameters from 22 MD white matter tracts) 11 brain regions were investigated)]
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Table 4.5 Correlation coefficients (r) between [11C] PBR28 VT(DVR)  and mean diffusivity parameters from white matter tracts, 
adjusted for TSPO affinity status 
 
[Legend Table 4.5: Results of correlation analyses between PBR28 binding and mean diffusivity in selected white matter tracts. *P<0.05, ** 
P<0.1; 22 correlation coefficients were calculated per brain region ([11 C] PBR28(DVR) values from one brain region multiplied by parameters from 
22 MD white matter tracts) 11 brain regions were investigated)] 
 
Brain regions 
with increase 
[
11
C] PBR28 
VT(DVR) 
Anterior 
thalamic 
left 
Cingulum 
hippocamp
us left 
Corticospin
al left 
Superior 
L_fasciculus 
left 
Superior 
L_fasciculus 
temporal left 
Uscinate 
fasciculus 
left 
Corpus 
callosum 
body 
Cospus 
callosum 
splenium 
Anterior 
thalamic 
right 
Cingulum 
cingulate 
right 
Cingulum 
hippocampu
s right 
Corticospinal 
right 
Inferior 
fronto-
occipital 
right 
Basal ganglia 0.606* 0.528** 0.741* 0.662* 0.630* 0.578** 0.687* 0.614* 0.639* 0.736* 0.762* 0.790* 0.706* 
Amygdala 0.572** 0.375 0.581** 0.606* 0.577** 0.612* 0.615* 0.489 0.575** 0.640* 0.603* 0.574** 0.549** 
Globus 
pallidus 
0.671* 0.600* 0.777* 0.716* 0.695* 0.637* 0.700* 0.658* 0.711 0.807* 0.803* 0.834* 0.773* 
Midbrain 0.563** 0.430 0.642* 0.573** 0.536** 0.577* 0.664* 0.526** 0.595* 0.620* 0.646* 0.666* 0.594* 
Temporal lobe 0.573** 0.486 0.706* 0.565** 0.522** 0.565** 0.608* 0.553** 0.621* 0.630* 0.704* 0.630* 0.654* 
Occipital lobe 0.575** 0.516 0.715* 0.612* 0.575* 0.572** 0.686* 0.539** 0.607* 0.661* 0.696* 0.750* 0.657* 
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Table 4.6 Results of cerebral [1H]-MRS in HIV-infected individuals 
 
[Legend Table 4.6: Mean results of cerebral metabolites for the frontal white matter and right 
basal ganglia of HIV-infected individuals. SD=standard deviation, NAA= N-acetylaspartate, 
Cho=Choline, mI=myoinositol, Cr=Creatine] 
 
Cerebral metabolite ratios 
HIV-infected cases 
Mean (SD) 
Frontal white matter  
NAA/Cr 1.76 (0.31) 
Cho/Cr 0.73 (0.32) 
mI/Cr 0.85 (0.34) 
Right basal ganglia  
NAA/Cr 1.73 (0.32) 
Cho/Cr 0.11 (0.08) 
mI/Cr 0.84 (0.5) 
124 
Table 4.7 Correlation coefficients (r) between [11C] PBR28 VT(DVR)  and [
1H]-MRS  in the right basal ganglia adjusted for 
TSPO affinity status  
[Legend Table 4.7: Results of correlation analysis between PBR28 binding in corresponding brain regions and right basal ganglia cerebral 
metabolites. *P<0.05, ** P<0.1, NAA= N-acetylaspartate, Cho=Choline, MI=myoinositol, Cr=Creatine; 33 correlation coefficients were calculated 
([11 C] PBR28(DVR) values from 11 brain regions multiplied by values from 3 CMRs in the RBG)] 
 Right basal ganglia 
Brain region NAA/Cr mI/Cr Cho/Cr 
Basal ganglia -0.504 -0.804* -0.773* 
Subcortical  -0.401 -0.691* -0.757* 
Thalamus -0.254 -0.630* -0.656 
Striatum -0.585** -0.795* -0.747* 
Putamen -0.694* -0.768* -0.798* 
Caudate -0.144 -0.442 -0.630** 
Globus pallidus -0.671 -0.769* -0.797* 
Anterior cingulate -0.595** -0.474 -0.520 
Hippocampus 0.687** 0.059 -0.208 
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Table 4.8 Correlation coefficients (r) between [11C] PBR28 VT(DVR)  and [
1H]-MRS  in the frontal white matter adjusted for 
TSPO affinity status  
 
 
 
 
 
 
 
 
 
 
 
 
 
[Legend Table 4.8: Results of correlation analysis between PBR28 binding in corresponding brain regions and frontal white matter cerebral 
metabolites. *P<0.05, ** P<0.1, NAA= N-acetylaspartate, Cho=Choline, MI=myoinositol, Cr=Creatine; 33 correlation coefficients were calculated 
([11 C] PBR28(DVR) values from 11 brain regions multiplied by values from 3 CMRs in the FWM)
 Frontal White Matter 
Brain region NAA/Cr mI/Cr Cho/Cr 
Basal ganglia -0.488 -0.159 0.273 
Subcortical  -0.438 -0.251 0.281 
Thalamus -0.566 -0.254 0.255 
Striatum -0.505 -0.193 0.261 
Putamen -0.532 -0.250 0.294 
Caudate -0.039 0.171 -0.172 
Globus pallidus -0.468 -0.117 0.462 
Anterior cingulate -0.583 -0.382 0.350 
Hippocampus -0.246 -0.022 0.101 
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5.1 Introduction 
Chronic immune activation is the hallmark of progressive HIV-disease, and it is likely 
to play a pivotal role in the pathogenesis of HIV-associated NCI (117). Plasma and 
CSF biomarkers of monocyte activation and microbial translocation can provide 
important information about the relationships between chronic inflammation, gut 
disease and NCI in HIV-infected individuals on cART. Although, there are no specific 
immune activation biomarkers of HIV-associated NCI in treated HIV-infected 
individuals, several candidates linked to monocyte activation and microbial 
translocation have been proposed as biomarkers for the assessment of milder and 
severe forms of HIV-associated NCI.  
 
Plasma soluble sCD163, a product of the hemoglobin scavenger receptor CD163 
that is expressed exclusively by monocytes and macrophages of the M2 phenotype 
(260, 261) has been suggested as novel marker of monocyte activation in HIV-
disease. sCD163 is produced by the shedding of CD163 following monocyte 
activation. Increase levels of sCD163 in plasma have been found to correlate with 
HIV RNA prior to and after cART in both individuals with early and chronic HIV-
infection (262). Sustained elevation of plasma sCD13 compared with HIV-negative 
controls has been associated with NCI in virologically suppressed HIV-infected 
individuals (262), and higher plasma sCD163 was specifically associated with 
impairments in the domains of executive function and learning, two of the most 
common and consistent areas of cognitive impairment in the era of cART (263).  
 
Soluble CD14 (sCD14) is another monocyte activation marker that is produced by the 
shedding CD14, a glycoprotein expressed on the surface of monocytes and 
macrophages. Monocyte activation leads to increase release of sCD14 from 
monocytes, particularly after stimulation of circulation products of microbial 
translocation such as bacterial lipopolysaccharide (LPS) (264). Elevated levels of 
sCD14 correlate with HIV-related chronic immune activation and disease progression 
(265, 266). sCD14 has been associated with NCI in HIV-infected individuals with 
advanced disease and detectable HIV RNA on cART (267).  
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Microbial translocation is characterised by the translocation of microbial products 
derived from the gastrointestinal tract of HIV-infected individuals to the bloodstream. 
Circulating microbial products have been found to contribute to HIV-related systemic 
immune activation (117). Concentrations of plasma LPS, a biomarker of microbial 
translocation has been associated with HIV-infection, immune activation and HAD 
(116, 117). The relationship between LPS-induced systemic inflammation and 
microglial activation has been evaluated in an animal model were baboons were 
scanned with  [11C] PBR28 PET CT before and after intravenous administration of 
LPS. LPS administration increased [11C] PBR28 binding, and this effect was 
mediated by an increase in inflammatory chemokines such as IL-6 and IL-1β (268).  
 
LPS is only present on a proportion of enteric bacterial microbiota (gram-negative 
bacteria) (117) and for this reason quantification of bacterial DNA encoding the 
ribosomal 16s rRNA gene has been proposed as a more sensitive biomarker of 
microbial translocation than LPS (269). Plasma levels of bacterial 16S rDNA 
individuals have been found to be significantly higher in HIV-infected individuals, and 
they correlated with plasma LPS levels (270). In HIV-infected individuals, higher 
levels of plasma ribosomal 16S rDNA are also associated with increase T-cell 
activation (270).  
 
Brain chemokines and their receptors play an important role in many physiological 
and inflammatory processes and altered expression of α and β chemokines have 
been documented in HIV-infected individuals with HIV-associated NCI (summary 
Table 1.2, Chapter 1).  
 
Studies of biomarkers for HIV-associated brain disease have focused on 
investigating relationships between immune activation markers and cognitive testing 
parameters. Few studies have examined the associations between immune 
activation biomarkers and cerebral imaging parameters of structural metabolic or 
functional disease (271, 272). 
 
To investigate the second hypothesis of this thesis, this study aimed to examine the 
relationship between in vivo microglial activation parameters as measured by [11C] 
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PBR28 PET CT and biomarkers of monocyte and microbial translocation in CSF and 
blood of neuroasymptomatic HIV-infected individuals on effective cART. 
5.2 Methods 
Blood and CSF biomarker analyses were performed as described in section 2.5. 
5.2.1 Statistical analysis 
Associations between plasma/CSF biomarker concentrations and [11C] PBR28 VT 
and HIV-related clinical parameters were performed using partial correlation analysis 
adjusted for TSPO affinity status. Multiple comparisons were corrected by 
bootstrapping (252). P values below 0.05 were considered statistically significant.  
 
Each HIV-infected participant was examined separately to examine the clinical 
characteristics and biomarker profile of HIV-infected individuals with greater PBR28 
binding. 
5.3 Results 
10 HIV-infected individuals agreed to have a lumbar puncture. All HIV-infected 
participants consented for blood sampling (n=12). Descriptive statistics for the 
plasma and CSF biomarkers evaluated are presented in Table 5.1.  
Biomarker concentrations for each HIV-infected case enrolled in the study are 
presented in Table 5.2 
5.3.1 Soluble CD14 
No association between plasma or CSF sCD14 levels and [11C] PBR28 VT(DVR) was 
observed in any brain region. Similarly no associations between plasma or CSF 
sCD14 levels and any HIV-related clinical parameters were found (P=>1). 
5.3.2 Soluble CSF CD163 
No association between CSF sCD163 levels and [11C] PBR28 VT(DVR)  was observed 
in any brain region. No associations between sCD163 in the CSF and other imaging 
biomarkers or HIV-related clinical parameters were observed (P=>1) 
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5.3.3 Ribosomal 16s 
A significant association between greater concentration of ribosomal 16s in plasma 
and increase [11C] PBR28 VT(DVR) was observed in brain regions with significant 
microglial activation including the basal ganglia and the globus pallidus, Figure 5.2 
and Table 5.2. Plasma ribosomal 16s was also correlated with an increase in mI/Cr 
(r=0.682; P=0.01) in the RBG and greater mean diffusivity in the forceps major 
(r=0.532; P=0.07), right inferior longitudinal fasciculus (r=0.601; P=0.03) and right 
inferior fronto-occipital fasciculus (r=0.509; P=0.09) on DTI, see Figure 5.3 
 
Figure 5.2. Scatter plot of correlation between basal ganglia and globus 
pallidus [11C] PBR28 VT(DVR) and concentration of plasma ribosomal 16S DNA in 
HIV-infected individuals stable on cART 
 
       
 
[Legend Figure 5.2. Scatter plot shows the correlation between concentration of 
ribosomal 16s DNA and PBR28 binding in two brain regions of HIV-infected subjects] 
 
No correlations between ribosomal 16s in CSF and [11C] PBR28 VT(DVR) in any brain 
region were observed. Similarly, no associations between ribosomal 16s in CSF and 
other imaging biomarkers and HIV-related clinical parameter were observed (P=>1). 
5.3.4 Plasma and CSF chemokines 
Three (Eotaxin-3, MIP-β, IL-8) out of nine chemokines measured in plasma and CSF 
were within the detection range of the assay and therefore available for correlation 
analyses.   
Ribosomal 16s (copies/mL)
B
a
s
a
l G
a
n
g
lia
 P
B
R
2
8
 V
t(
D
V
R
)
0 10 20 30 40 50
0
2
4
6
8
10
Ribosomal 16s (copies/mL)
G
lo
b
u
s
 P
a
lli
d
u
s
 P
B
R
2
8
 V
t 
(D
V
R
)
0 10 20 30 40 50
0
5
10
15
 133 
Figure 5.3 DTI map showing the MD of brain regions that correlated positively 
with plasma ribosomal 16s  
 
 
 
[Legend Figure 5.3. This figure represents the mean diffusivity (MD) map of three brain 
regions that correlated positively with plasma concentrations of ribosomal 16s; red 
corresponds to the forceps major, green is the right inferior longitudinal fasciculus and blue is 
the right inferior fronto-occipital fasciculus: a. coronal view, b. sagittal view, c. axial view, d. 
three dimensional view]  
 
Concentrations of IL-8, eotaxin-3, and MIP-β in both the CSF and plasma are 
presented in Table 5.1. No significant correlations between levels of individual 
chemokines in plasma and CSF were identified.  Significant associations between 
increase concentrations of eotaxin-3, MIP-β, IL-8 in the CSF, and [11C] PBR28 VT(DVR) 
in brain regions with increased microglial activation in the PET study were observed 
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(Table 5.2). Increase concentrations of IL-8 and MIP-β in the CSF were also 
associated with greater levels of mI/ Cr in the RBG (IL-8; r=0.610; P=0.06), (MIP-β; 
r= 0.639; P=0.04) 
 
Interestingly, there was a significant positive correlation between concentrations of 
plasma ribosomal 16s l, a marker of microbial translocation and concentrations of the 
proinflammatory chemokine IL-8 in the CSF (r=0.599; P=0.024, CI=0.152 to 0.956) 
No associations between plasma or CSF chemokines and other imaging biomarkers 
and HIV-related clinical parameters were observed (P=>1). 
5.3.5 Assessment of plasma and CSF biomarkers of individual HIV-infected 
participants enrolled in the study 
When evaluating plasma and CSF biomarkers data from each HIV-infected individual 
involved in the study, subjects 06 and 11 had increase concentrations of CSF IL-8 
and plasma ribosomal 16s compared to other HIV-infected participants. Subject 06 
also had the highest concentration of eotaxin-3, MIP-β and sCD163 in the CSF. 
Interestingly, subjects 06 and 11 had the greatest levels of PBR28 binding in the PET 
study compared to other HIV-infected participants. 
5.4 Discussion 
This study attempted to investigate the association between plasma and CSF 
biomarkers of inflammation and microbial activation using [11C] PBR28 CT PET. A 
significant correlation between increase plasma ribosomal 16s, a marker of microbial 
translocation and greater microglial activation in most brain regions was observed 
suggesting an effect of gut microbial translocation on cerebral immune activation. 
This finding became more significant after observing a positive correlation between 
plasma ribosomal 16s and MD in several white matter tracts on DTI. 
Hannestad et al. observed an increase in levels of TSPO detected with [11C] PBR28 
PET after intravenous administration of E.coli lipopolysaccharide (LPS), a marker of 
microbial translocation using a nonhuman primate brain model. The study 
demonstrated that systemic inflammation is associated with microglial activation in 
the brain of nonhuman primates. The increase in microglial activation after LPS 
correlated with increase inflammatory cytokine levels, suggesting that microglial 
activation was mediated by LPS-induced inflammatory cytokines such as IL-6 and IL-
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1β (268). In the study presented in this chapter, I found a significant correlation 
between plasma ribosomal 16s and levels of the inflammatory chemokine IL-8, which 
are in agreement with the findings by Hannestad et al. where microglial activation 
was induced by bacterial byproducts through mediation of inflammatory chemokines.  
 
This evidence suggests that translocation of bacterial byproducts in the systemic 
circulation through the damaged gastrointestinal barrier may contribute to immune 
activation in chronic HIV-infection, and high levels of microbial translocation markers 
such as LPS have been associated with HAD independently of plasma viral load and 
CD4 counts (116). Interestingly, the association between plasma levels of 
ribosomal16s and increase MD in white matter tracts further suggests a potential 
effect of inflammation on white matter integrity. 
 
Although, I did not observe any correlation between sCD14 and CSF sCD163 and 
microglial activation, increased concentrations of IL-8, eotaxin-3 and MIP-β in the 
CSF were significantly associated with brain regions where microglial activation was 
identified.  
 
This study supports my second hypothesis, that microglial activation is associated 
with biomarkers of inflammation. Furthermore, this pilot study has shown an 
association between systemic inflammation, microglial activation, and markers of 
injury.  This suggests a model whereby microglial activation is driven by systemic 
inflammation, which in HIV-infected individuals is maintained by the translocation of 
microbial products from an impaired gut-blood barrier.  
 
The model is consistent with immune activation mediated injury via non-specific 
activation (273) rather than HIV infection in the privileged CNS compartment.  Perry 
et al. described the molecular and cellular components that mediate the 
communication between peripheral inflammation and the brain, all which lead to the 
production of cytokines/chemokines and inflammatory mediators, which are 
associated with neuronal injury (74). Systemic inflammatory markers could provide 
indices to guide risk-assessment and treatment of HIV-associated brain disease 
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Table 5.1 Descriptive statistics of plasma and CSF biomarkers for HIV-infected individuals 
 
[Legend Table 5.1: Mean results for biomarkers measured in both plasma and CSF in HIV-infected individuals] 
 
  
Biomarker  
(units) 
CSF 
Mean  (SD) 
Plasma 
Mean (SD) 
sCD14 (ng/mL) 120 (0.03) 1480(0.29) 
sCD163 (ng/mL) 34.1 (12) N/A 
Ribosomal 16s (copies/mL) 4.7(2.8) 10.9(14.2) 
IL-8 (ng/mL) 0.028 (4.6) 0.0031 (1.3) 
Eotaxin-3 (ng/mL) 0.1295 (11.7) 0.112 (51) 
MIP-β (ng/mL) 14.622 (18) 57.621(26) 
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Table 5.2 Correlation coefficients (r) between [11C] PBR28 VT(DVR)  and plasma /CSF biomarkers adjusted for TSPO affinity 
status 
 
 
Biomarker 
Basal 
ganglia 
Globus 
pallidus 
Temporal 
lobe 
Parietal 
lobe 
Occipital 
lobe 
Caudate Striatum Medulla Midbrain 
Ribosomal 
16s (plasma) 
0.881* 0.928* 0.818* 0.832* 0.861* 0.877* 0.871* 0.645* 0.811* 
IL-8 (CSF) 0.727* 0.801* 0.766* 0.722* 0.761* 0.847* 0.692* 0.734* 0.736* 
MIP-B (CSF) 0.688* 0.696* 0.749* 0.728* 0.731 0.682** 0.444 0.653* 0.730** 
Eotaxin (CSF) 0.668** 0.622** 0.603** 0.650** 0.641** 0.499** 0.586** 0.661** 0.691** 
 
 
[Legend Table 5.2: Results of correlations between PBR28 binding and biomarkers in the CSF and plasma in HIV-infected individuals. *P<0.05, 
** P<0.1; 22 correlation coefficients calculated per biomarker with the exception of sCD163 (each biomarker in plasma and CSF multiplied by 
[11C] PBR28 VT(DVR)  values from 11 brain regions)] 
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Table 5.3 Plasma and CSF biomarkers results for each HIV-infected participant enrolled in the study 
 
 
[Legend Table 5.3: Subjects with higher PBR28 binding such as subjects 06 and 11 had increased concentration of IL-8-CSF and blood 
ribosomal 16s] 
Study case 
CD4/CD8 
ratio 
Pre-
treatment 
HIV RNA 
(copies/mL) 
sCD14 CSF 
(ng/mL) 
sCD14 blood 
(ng/mL) 
sCD163 CSF 
(ng/mL) 
Ribosomal 
16s blood 
(copies/mL) 
IL-8-CSF 
(ng/mL) 
Eotaxin-3-
CSF 
(ng/mL) 
MIP-β-CSF 
(ng/mL) 
  
01 0.70 n/a 0.1 1.27 26.78 3.6 0.023 0.148 11.03 
02 0.82 69388 0.13 1.29 34.32 0 0.034 0.142 12.52 
03 0.74 151 0.06 1.5 18.24 4.1 0.025 0.124 15.51 
04 0.75 57998 0.12 1.44 44.02 3.8 0.026 0.032 8.89 
05 0.36 261970 0.11 2.3 30.48 7.2 0.057 0.174 13.01 
06 0.72 1624782 0.18 1.26 59.71 41.7 0.065 0.180 23.53 
07 0.72 35000 0.09 1.64 27.34 5.1 0.034 0.165 9.71 
09 0.70 38529  0.09 1.23 37.99 0 0.029 0.026 15.81 
10 0.50 422457  n/a 1.45 n/a 4.1 0.03 n/a n/a 
11 0.67 187890 0.08 1.34 22.14 33.4 0.053 0.237 12.93 
12 0.15 n/a n/a 1.45 n/a 3.8 n/a n/a n/a 
13 0.40 500000 0.06 1.65 40.13 2.2 0.07 0.039 19.69 
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6.1 Introduction 
SIV-infection of non-human primates can be used as models of systemic and 
neurological manifestations of HIV-disease in humans (274). The most frequently 
utilised models to investigate brain pathology associated with HIV-infection in 
humans induce rapid development of disease and neuropathology through infection 
of pig tail macaques (Macaca nemestrina) with either a SIV-infection in combination 
with CD8 T-cell depletion or co-inoculation of the immunosuppressive SIVdeltaB670 
with the neurovirulent SIVmac17E-Fr (45, 275, 276). However, since the advent of 
cART, the rapid development of severe neurological disease is not representative of 
the current HIV-associated neurological phenotype characterized by mild cognitive 
impairment in HIV-infected individuals on effective cART. Therefore, a model 
displaying a more gradual disease development may be more suitable to study the 
pathogenesis of HIV-associated brain disease in the modern antiretroviral era.   
 
Unlike the rhesus (Macaca mulatta) and pig tale macaque models of neuropathology 
using single strain SIV-infection of cynomolgus macaques (Macaca fascicularis), 
without immunosuppression, results in a more slowly developing neuropathology. A 
recent study by Clarke et al. demonstrated that non-accelerated infections of 
cynomolgus macaques with SIV-strains (including non-neurotropic strains) can 
induce pathological changes in the brain despite limited peripheral viral replication or 
evidence of disease progression (50). In addition, the viral replication kinetics of this 
model are characterised by a low peripheral viral set point (when SIV RNA levels 
reach a plateau after the acute phase) following the initial replicative burst (maximum 
SIV RNA levels measured within the first 2 months after inoculation) (276) with low 
CSF viral loads (50, 277). The observed neuropathology in cynomolgus macaques 
infected with both neurotropic and non-neurotropic SIV-strains is that of (277) 
absence of multinucleated giant cell formation, similar to the neuropathology 
observed in HIV-brain disease in HIV-infected patients on cART. 
 
Very little is known about blood and CSF chemokine responses in cynomolgus 
macaques infected with SIV. Microglial activation is associated with the release of 
inflammatory chemokines and other immune mediators. Chemokines and chemokine 
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receptors play an important role in orchestrating the immune responses following 
brain infection with HIV. The longitudinal evaluation of chemokines in blood and CSF 
in this model of SIV-infection could provide important information about the immune 
responses associated with microglial activation following early HIV-infection of the 
brain.  
The aim of this study was to test the second hypothesis of this thesis, that microglial 
activation is associated with disturbances in biomarkers of inflammation.  To test this 
hypothesis, I examined the concentrations of inflammatory chemokines in CSF and 
blood from a cynomolgus model of SIV-infection 
6.2 Methods 
This study consisted of two different study groups. Study group 1:  plasma samples 
at baseline (before inoculation of SIVmac251), during acute infection (between 
weeks 4 and 8 post detectable infection) and at termination (chronic infection, 23 
weeks post-infection) were examined. Study group 2: CSF samples from the study 
group 1 were collected 23 weeks after infection (at termination, during necropsy) and 
compared with samples of CSF from a different group of SIV-naïve animals (n=16), 
see Figure 6.1. 
 
Infection of animals was undertaken at the National Institute of Biological Standards 
and Control (Hertfordshire, UK) by Dr Deborah Fergusson. Following a SIV-gag 
based intra dermal immunisation protocol, where 20 animals received a single 
atraumatic low dose intra-rectal inoculation of SIVmac251 (150TCD50) on a weekly 
basis for up to 10 weeks. Blood samples were monitored weekly for presence of virus 
via quantitative real-time reverse transcriptase PCR, as described previously (276) 
and following a positive result the animal removed from the inoculation schedule. SIV 
replication was detected in brain tissue by in situ hybridisation in all animals 
challenged with SIVmac251. 
 
I performed the chemokine analysis at Imperial College London, St Mary’s Campus. 
Chemokines (IL-8, eotaxin, IP 10, MCP-1, MCP-4, and MDC) were analysed using 
human ELISA ultrasensitive Multiplex platform (MSD Meso Scale, USA) as described 
in section 2.5.3. IL-8, eotaxin, IP-10, MCP-1 and MDC were selected because they 
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have been associated with regulation of HIV-disease and cognitive impairment in 
HIV-infected individuals (45, 278-281) 
 
 
Figure 6.1 Study design 
 
 
 
6.2.1 Statistical analysis 
Wilcoxon matched pairs rank test was used to determine differences in chemokine 
concentrations in plasma at baseline, acute and chronic stages of SIV-infection. To 
determine differences between CSF chemokines in SIV-infected and uninfected 
macaques a Mann Whitney U-test was employed. Associations between plasma and 
CSF concentrations and relationship to SIV-RNA levels were evaluated using 
Pearson’s correlation analysis. P values below 0.05 were considered statistically 
significant. 
6.3 Results 
All vaccinated animals became infected with SIVmac251 during the 10-week 
challenge period. All measured chemokines were within the detectable range in the 
Figure 6.1 Study design 
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plasma and CSF specimens at all-time points (Table 6.1). Median plasma SIV-RNA 
(copies per mL) during acute infection was 1.87x105 (range: 3.25x102 to 4.25x107) 
and at termination was 6.2x103, (range: 0 to 3.04x105). CSF SIV-RNA measurements 
were not available for analysis. 
6.3.1 Plasma chemokine changes following SIVmac251 infection 
Significant changes in plasma concentrations of IL-8, MCP-1, MCP-4 and eotaxin 
were observed in cynomolgus macaques following SIV infection (Figure 6.2). Greater 
concentrations of eotaxin and MCP-4 and lower levels of MCP-1 and IL-8 were seen 
at termination compared with baseline. No changes in plasma concentrations of IP-
10 or MDC were observed between baseline and acute or chronic stages of SIV-
infection (Table 6.2)  
6.3.2 CSF chemokine changes between SIV-infected and naïve macaques 
There were significant differences in concentrations of all chemokines between SIV-
infected and naïve macaques. Greater concentrations of IL-8 and lower 
concentrations of eotaxin, MCP-4, MDC, MCP-1 and IP-10 were observed in SIV-
infected animals compared to controls (Figure 6.3).  
 
6.3.3 Correlation between plasma chemokines and CSF chemokines during 
acute and chronic SIV-infection 
Greater concentrations of plasma eotaxin and IP-10 at termination were associated 
with high concentrations in the CSF (eotaxin, r=0.492, P=0.033); (IP-10: r=0.568, 
P=0.009). No other associations between plasma and blood chemokine 
concentrations were observed (P=>1) 
6.3.4 Correlation between plasma SIV-RNA viral load and plasma/CSF 
chemokines during acute and chronic SIV-infection 
During acute SIV-infection, there was a significant correlation between plasma SIV-
RNA viral load and plasma concentration of IP-10, IL-8 and MCP-1 with higher SIV-
RNA viral load associated with higher concentration of IP -10 (r=0.492, P=0.033), IL-
8 (r=0.551, P=0.012) and MCP-1 (r=0.404, P=0.077). During chronic SIV infection 
there was a significant positive correlation between plasma SIV-RNA viral load and 
plasma concentration of IP-10 (r=0.590, P=0.006) at termination. Finally, no 
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associations between plasma SIV RNA viral load at termination and other CSF 
chemokines were observed. 
Figure 6.2 Plasma chemokines in Cynomolgus macaques infected with SIVmac251.  
 
[Legend Figure 6.2: Plasma levels of chemokines were determined before and after infection 
(acute and chronic/termination). P value was calculated by the Wilcoxon matched-pairs test 
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Figure 6.3 CSF chemokine concentrations in Cynomolgus macaques.  
          
   
             
 
                 
 
[Legend Figure 6.3: CSF levels of chemokines were determined in infected and uninfected 
individuals. P values were calculated by the Mann Whitney U-test]  
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6.4 Discussion 
In order to investigate the second hypothesis of this thesis, this cross-sectional study 
explored changes to plasma and CSF inflammatory chemokines associated with 
microglial activation in cynomolgus macaques infected with SIVmac251 during 
different stages of SIV-infection. This is the first study investigating changes in 
biomarkers of microglial activation in the SIV/cynomolgus macaque model of CNS 
infection. Overall, lower levels of inflammatory chemokines in CSF and plasma 
(eotaxin, IP-10, MCP-1, MCP-10 and MDC) were observed in SIV-infected 
cynomolgus macaques compared with uninfected controls.  
 
There are several possible explanations for these results. First, as explained in the 
introduction section of this chapter, this CNS model is characterised by mild CNS 
disease (171), thus, it is possible that although these animals were systemically 
infected with SIV, and SIV replication was detected in brain tissue by in situ 
hybridisation in all animals challenged with the SIVmac251, microglial activation was 
not present. However, microglial activation in the brains of cynomolgus macaques 
infected with SIVmac251 has been demonstrated in other studies (171, 282); 
therefore, it is likely that in this model some degree of microglial activation was 
present  
The other possibility is that the microglia of these macaques are exhibiting an 
antinflammatory, neuroprotective phenotype as microglia can display different 
activation phenotypes in response to brain injury. The presence of an 
antinflammatory phenotype chemokine profile in this cohort of SIV-infected 
macaques is evidenced by the low concentrations of CSF inflammatory chemokines 
associated with monocyte activation (eotaxin, IP-10, MCP-1) and the increase 
concentrations of anti-inflammatory mediators such as IL-8. In SIV-disease increases 
of IL-8 and eotaxin have been associated with resistance to SIV-infection (283). Also 
there is evidence that inflammatory chemokines can modulate each other. Eotaxin is 
a natural ligand of the CCR3 receptor and an antagonist for the CCR5 and CCR2 
receptors (284). CCR2 is a major proinflammatory chemokine receptor expressed by 
macrophages, including microglia. Eotaxin has been shown to block monocytes 
responses to MCP-1 a major ligand for CCR2, and to interfere with HIV-entry into 
microglia (285). In this context, it is possible that eotaxin may have a modulatory role 
in inflammation through CCR2, controlling the expression of MCP-1 and MCP-4 as it 
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was seen in the plasma of infected animals following SIV-infection. Finally, greater 
concentrations of plasma IP-10 correlated well with CSF IP-10 and SIV-RNA during 
acute and chronic stages of SIV-infection, suggesting the potential of this chemokine 
as a biomarker of monocyte activation.   
 
Finally, it is also possible that chronic immunosuppression and the breakdown of the 
gut-blood barrier are needed to reproduce the finding in humans. Future work should 
include the measurement of markers of microbial translocation such as ribosomal 
16s in NHP models of CNS infection. 
 
This study has several limitations. First, CSF-SIV RNA measurements were not 
available; therefore, it was not possible to evaluate the association between CSF 
chemokines and CSF-SIV viral load. Secondly, some of these animals took part in 
studies evaluating novel HIV vaccines that could have altered the immune responses 
to SIV within the brain. It is important to state that all the vaccine candidates tested 
on these animals were unsuccessful in effectively controlling plasma SIV RNA and as 
a result the effect that they could have in the brains of the macaques is likely to be 
minimal. Third, although the neuropathology of this animal model is similar to the one 
found in treated HIV-infected patients, it is not reflective of the clinical situation 
observed in patients on cART as most patients on treatment have undetectable HIV 
RNA during chronic infection.  
 
In summary, in this cynomolgus SIV-model, I observed significant differences in CSF 
and plasma proinflammatory chemokines. The chemokine pattern described here, 
suggests a degree of disease control by the host, possibly limiting CNS injury. 
Immunologic or genetic variations that affect chemokine levels might also affect the 
susceptibility of the brain to HIV-infection and the rate of progression once the 
infection is established. This could explain why most of the inflammatory chemokines 
were not upregulated in infected primates.  
 
These findings have given me an insight into the mechanisms involved in the fine-
tuning modulation of CNS monocyte chemokine expression and activation in the 
presence of SIV-infection. Also, this study supports my second hypothesis, that 
microglial activation is associated with changes to CNS biomarkers of inflammation. 
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The cynomolgus macaques animal model described in this chapter displays 
inflammatory changes, and gradual neuropathology similar from those reported in 
patients on cART following infection with attenuated SIV-strains. The development of 
novel attenuated molecular clones derived from SIV-strains that are dependent upon 
the presence of an antibiotic switch to replicate, could potentially be used to 
investigate associations between viral replication and microglial activation (286) in a 
NHP model that reflects both the neuropathological and neuroinflammatory changes 
of patients with HIV-associated brain disease. 
 
Future work is currently undergoing to examine the expression of TSPO 18kda in 
brain tissue of the cynomolgus macaques involved in this study. This can be done 
either by autoradiography or immunoblotting using anti-TSPO antibodies (287). In 
this study, animal samples were fixed with formaline, which makes brain tissue 
unsuitable for autoradiography analyses. However, immunoblotting with anti-TSPO is 
possible with fixed brain samples. These experiments will provide important 
information about the degree of expression of TSPO in cynomolgus macaques and 
the relationships between plasma/CSF chemokine concentrations and expression of 
TSPO. 
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Table 6.1. Descriptive statistics of CSF chemokine data  
 
 [Legend Table 6.1: Median (Pg/mL), IQR (interquartile range)] 
  
Chemokines SIV-infected Control 
 
Median (IQR) % Detectable Median (IQR) % Detectable 
Eotaxin 24  (1.8-260) 90% 3.17 (1.2-20) 70% 
IP-10 0.317 (0.1-52) 75% 299 (70-1730) 75% 
IL-8 329 (2.2-694) 100% 0.2 (0.1-6.304) 75% 
MCP-1 125 (6.7-390.5) 80% 303(145-994) 90% 
MCP-4 6.67 (1.5-20) 90% 18.5 (2.8-59.7) 75% 
MDC 7.04 (1.5-390) 90% 128 (36-713) 70% 
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Table 6.2 Chemokine profiles of cynomolgus macaques following SIVmac251 
infection 
 
Chemokine 
assessed 
Acute SIV infection  
(plasma) 
Chronic SIV infection 
(plasma at termination) 
1
CSF 
(at termination) 
Eotaxin    
MCP-1    
IP-10                   -                -  
MDC                   -                -  
MCP-4                   -   
IL-8                   -   
 
[Legend Table 6.2: Chemokine profiles during acute and chronic infection when compared 
with chemokine concentrations from the same macaques before infection with SIVmac251.  
1 CSF: chemokine profile in the CSF when compared to cchemokine concentrations from 
HIV-negative macaques] 
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7.1 Conclusions 
It has been proposed that microglial activation is the main pathogenic mechanism for 
the development of HIV-associated brain disease in HIV-infected individuals on 
stable cART. This thesis sought to examine the following three hypotheses: 
 
1. Microglial activation will be greater in neuroasymptomatic HIV-infected 
individuals stable on cART compared to HIV-negative controls 
 
2. Microglial activation in neuroasymptomatic HIV-infected individuals 
stable on cART will be associated with poorer cognitive function, 
increase biomarkers of inflammation and abnormalities of functional, 
structural and metabolic imaging parameters on cerebral MRI 
 
3. Microglial activation in neuroasymptomatic HIV-infected individuals 
stable on cART will be greater in subjects with low nadir CD4 counts 
compared to those with high nadir CD4 counts 
 
7.2 First Hypothesis 
Microglial activation will be greater in neuroasymptomatic HIV-infected 
individuals stable on cART compared to HIV-negative controls 
 
This hypothesis was tested in a clinical study assessing in vivo microglial activation in 
HIV-infected individuals stable on cART compared to HIV-negative controls. In 
Chapter 3, in vivo microglial activation was evaluated using cerebral PET imaging 
with [11C] PBR28. This study found evidence of microglial activation in individuals 
with chronic HIV-infection stable on cART without cognitive or neurological 
symptoms, proving the first hypothesis. The signal for microglial activation was global 
involving both cortical and subcortical brain regions; however, the strongest signal 
was observed in subcortical brain regions such as the basal ganglia. Interestingly, 
this study also revealed another finding regarding expression of TSPO in HIV-
infected individuals stable on cART. Although, overall there was greater microglial 
activation in the brain of HIV-infected individuals, I identified brain regions with lower 
microglial activation (temporal lobe, midbrain, and the right amygdala) compared to 
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HIV-negative individuals. This to my knowledge is the first time that a reduction of 
TSPO expression has been identified in the CNS of HIV-infected individuals stable 
on cART. Evidence of brain regions with both increased and reduced microglial 
activation suggests several possibilities. First, in response to HIV-infection, microglial 
activation expresses distinctive activation patterns (protective vs inflammatory) in 
different brain regions. Second, that HIV-infection may have a preference for specific 
brain regions such as the basal ganglia. The latter has been observed in 
neuropathological and imaging studies of HIV-infected individuals with HIV-
associated brain disease (12, 228). Future work to assess the evolution of microglial 
activation in longitudinal studies involving both neurosymptomatic and asymptomatic 
HIV-infected individuals on cART are needed, as well as studies that can determine 
the type of microglial activation phenotype present in HIV-infected individuals with 
and without cART. 
 
7.3 Second Hypothesis 
Microglial activation in neuroasymptomatic HIV-infected individuals stable on 
cART will be associated with poorer cognitive function, increased biomarkers 
of inflammation and abnormalities of functional, structural and metabolic 
imaging parameters on cerebral MRI 
 
To examine the second hypothesis a series of cross sectional studies were 
performed to evaluate the relationship between microglial activation measured by 
cerebral [11C] PBR28 PET CT and functional, structural, metabolic, and 
immunological cerebral parameters in individuals with chronic HIV-infection stable on 
cART.  
 
In Chapter 3, HIV-infected individuals participating in the  [11C] PBR28 PET CT study 
had neurocognitive testing to detect the presence of NCI. Although, HIV-infected 
individuals had no evidence of NCI, I found an association between poorer 
performance in cognitive tasks assessing verbal learning and memory and increased 
microglial activation in several brain regions including the hippocampus, amygdala, 
putamen and occipital lobe.  Poor performance in tasks evaluating verbal learning 
and memory has been associated with abnormalities in subcortical brain networks 
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(288), and has been reported in HIV-infected subjects (31). The association between 
microglial activation in subcortical brain regions and poorer cognitive performance 
supports my second hypothesis and suggests that microglial activation could be 
detrimental to cognitive function and potentially lead to NCI. 
 
Chapter 4, sought to further examine the second hypothesis evaluating the 
associations between microglial activation and structural, functional, and metabolic 
cerebral MRI parameters in stable HIV-infected individuals. HIV-infected subjects 
who participated in the [11C] PBR28 PET CT study were investigated with a series of   
MRI imaging modalities including fMRI, DTI and MRS. The results of this study did 
provide evidence to support the second hypothesis as overall, greater microglial 
activation was associated with disturbances in brain activation, white matter integrity, 
and cerebral metabolism. Although, brain regions with an increase in microglial 
activation were not associated with disruption of resting brain connectivity networks, 
reduce brain activation in the basal ganglia was associated with increase microglial 
activation in the globus pallidus and the caudate.  
 
Interestingly, this study also demonstrated a strong correlation between regions with 
greater microglial activation and increased mean diffusivity in all white matter tracts 
examined. Inflammation has been demonstrated to increase tissue water, directly 
affecting water diffusivity in animal models of brain inflammation (258). Water 
diffusivity disruption increases mean diffusivity and reduces fractional anisotropy 
(259) on DTI, and this pattern of white matter injury is consistent with the one 
observed in the study presented in chapter 4, and the pattern reported in DTI studies 
of HIV-infected individuals of stable cART (180). 
Also in Chapter 4, MRS was used to assess the relationship between microglial 
activation and cerebral metabolites. Remarkably, increased microglial activation was 
associated with reduced mI/Cr ratio in the right basal ganglia. These results were 
unexpected as increases in mI/Cr are suggestive of cerebral inflammation. This result 
could be explained by the fact that the voxel investigated was placed in the right 
thalamus, which was a brain region that did not show evidence of greater microglial 
activation compared to controls. Similarly, it could indicate that microglial activation 
does not affect brain regions equally, with some brain regions more susceptible to 
the effects of inflammation than others. 
 159 
 
Importantly, the results presented in Chapter 3 have several limitations. First, control 
data for fMRI and MRS analysis were not available; therefore, I could not determine if 
brain activation and cerebral metabolite concentrations in HIV-infected individuals 
were different from HIV-negative subjects. Second, multiple comparisons during 
correlation analyses can lead to errors of inference. To limit this effect I tried to adjust 
for multiple comparisons when appropriated. All these limitations must be considered 
when interpreting the data. 
 
In Chapter 5 and 6 associations between microglial activation and biomarkers of 
inflammation were assessed in order to address the second hypothesis. In Chapter 
5, blood and CSF biomarker analyses were performed in HIV-infected individuals 
who participated in the [11C] PBR28 PET CT study. Interestingly, although no 
correlations between increase microglial activation and two markers of 
immuneactivation, sCD14 and sCD163 in plasma or CSF were observed, significant 
associations between plasma ribosomal 16s, a marker of microbial translocation and 
increased microglial activation were found. This is the first study to describe a direct 
association between in vivo microglial activation and microbial translocation in 
neuroasymptomatic HIV-infected individuals stable on cART. Microbial translocation 
from the gastrointestinal tract has been strongly associated with persistent 
immuneactivation in HIV-infected individuals (117) and HAD (116). I found that 
increase concentration of IL-8 in the CSF correlated positively with plasma ribosomal 
16s. Thus, It is feasible that the effects of microbial translocation on microglial 
activation are mediated by circulating inflammatory chemokines.  
 
Evidence from several studies supports the notion that systemic inflammation can 
lead to microglial activation. For instance, peripheral challenge with microbial 
products such as LPS has been found to induce microglial activation in animals and 
humans (268, 289). Several routes of communication between peripheral 
inflammation and the brain have been proposed. First, inflammatory markers such as 
cytokines or chemokines synthesised at the site of inflammation, enter the blood, and 
communicate with perivascular macrophages in areas that lack the BBB. The signals 
communicated can activate the microglia and spread through the CNS parenchyma 
(290). Second, inflammatory chemokines/cytokines or the microbial products 
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themselves can cross the blood brain barrier and activate directly the microglia (291). 
Finally, there are evidence that inflammatory events in the abdominal cavity can 
trigger signals from the vagal-nerve sensory system to the CNS, which can activate 
resident macrophages and astrocytes (292). Immuneactivation cause by the 
continuous release of microbial products from a disrupted gut-blood barrier could 
lead to persistent microbial translocation, neuronal injury, and eventually the 
development of HIV-associated NCI. 
 
In chapter 6, a non human animal model was used to explore changes to plasma and 
CSF inflammatory chemokines associated with microglial activation in cynomolgus 
macaques infected with SIVmac251 during different stages of SIV-infection. In this 
study, I observed significant differences in CSF and plasma proinflammatory 
chemokine concentrations in SIV-infected animals compared to controls. 
Unexpectedly, I found lower concentration on inflammatory chemokines in SIV-
infected animals compared with SIV-negative controls. This may be owed to the host 
exhibiting a degree of disease control, limiting neuronal injury, possibly with microglia 
expressing a neuroprotective instead of an inflammatory phenotype. It is also 
possible that there might not have been enough time for microglial activation to occur 
within the brain.  
The studies presented in Chapters 5 and 6 paves the way to design future studies 
using imaging, and systemic inflammatory biomarkers to examine in detail the effects 
of microglial activation on brain function, and to develop new strategies to guide risk 
assessment and novel therapies for the management of HIV-associated brain 
disease in the cART era.   
7.4 Third Hypothesis 
Microglial activation in neuroasymptomatic HIV-infected individuals stable on 
cART will be greater in subjects with low nadir CD4 counts compared to those 
with high nadir CD4 counts 
 
This hypothesis was tested in the clinical study presented in Chapter 3. Here, 
individuals with chronic HIV-infection without cognitive or neurological symptoms 
stable of cART undertook imaging with [11C] PBR28 PET CT. HIV-infected subjects 
for this study were recruited with a range of nadir CD4 counts to be able to prove the 
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hypothesis. This study found no evidence to support the third hypothesis of the 
thesis. Nadir CD4 count was not associated with microglial activation in any of the 
brain regions examined. On the converse, microglial activation in several brain 
regions was correlated with lower CD4/CD8 ratio and greater pre-treatment HIV 
RNA. Lower CD4/CD8 indicates persistence of high circulating CD8 T cells, which 
can remain even after effective cART. In HIV-negative populations this immune risk 
profile is characteristic of immunosenescence (293, 294). In HIV-infected individuals 
a lower CD4/CD8 ratio is considered a strong predictor of disease progression (295), 
non-AIDS comorbidities (232) and persistent immuneactivation (231). Thus, it is 
possible that the strong correlation between microglial activation and lower CD4/CD8 
ratios indicates an effect of systemic inflammation within the CNS. Measuring pre-
treatment HIV RNA has been proposed as an indicator of HIV disease activity and a 
predictor of non-AIDS comorbidities (234, 235). In this study, I found an association 
between brain regions with increasing microglial activation and greater pre-treatment 
HIV RNA. This observation has not been described previously, and it is important as 
it might suggest a legacy effect, where high HIV RNA before treatment is established 
potentially leading to both persistent microglial activation and early brain injury. 
Although I found not evidence to support my third hypothesis, I have made 
interesting observations that have potential clinical implications for therapeutic 
strategies.  
7.5 Summary 
Mild forms of cerebral impairment affecting HIV-infected individuals on stable cART 
have become increasingly apparent in recent years and the reasons for its 
development are unclear. Microglial activation has been proposed as the main 
pathogenic mechanism associated with HIV-associated brain disease. In this thesis, I 
demonstrated that in vivo microglial activation is present in individuals with chronic 
HIV-infection on effective cART, without any cognitive or neurological deficit, and that 
microglial activation is associated with disturbances on cerebral function including, 
brain activation, white matter integrity, cerebral metabolites and cognitive 
performance. I also identified a correlation between biomarkers of microbial 
translocation and microglial activation. This association could be mediated by the 
expression of inflammatory chemokines, suggesting a link between peripheral 
inflammation and microglial activation in treated HIV-infected individuals. Individual 
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analyses of HIV-infected individuals revealed differences in the degree of PBR28 
binding across subjects. Subjects with the greatest PBR28 binding were associated 
with increase levels of microbial translocation and CSF/plasma biomarkers of 
inflammation.  
Although this thesis did not demonstrate a relationship between nadir CD4 T-cell 
counts and microglial activation, it showed a significant association with other 
markers of disease activity and progression such as pre-treatment HIV RNA and 
CD4/CD8 ratio.  
 
It is possible that greater HIV viraemia both in the periphery, and the CNS 
compartment leads to an exaggerated microglial response, and this process is likely 
to occur early during the disease process. The microglia becomes primed by the 
systemic inflammation generated by HIV infection despite effective control of the HIV 
virus with cART. Persistent systemic inflammation in the presence of cART is a well 
recognised process in HIV disease (296), which is driven by many factors including 
the translocation of microbial products from the gut (297) 
 
In this context, the exaggerated response of primed microglia to persistent systemic 
inflammation, might lead to disturbances in neuronal function, which contributes to 
the pathogenesis and progression of HIV-associated brain disease. Uncovering the 
mechanisms by which microglial activation affects the CNS of treated HIV-infected 
individuals is critical, as this could allow the identification of novel biomarkers for the 
early detection of patients at risk of HIV-associated NCI, and to develop therapeutics 
for the management of patients with established HIV-associate brain disease.  
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